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Abstract 
 
Ajoene, a garlic-derived natural product and its structural analogues are strongly 
cytotoxic to cancer cells. These compounds are however known to exhibit low blood 
stability and erythrocyte toxicity. This thesis reports on the synthesis of eight ajoene 
analogues designed to probe structure-activity relations into cancer cell cytotoxicity and 
blood stability. Structural variations included introduction of different solubility 
enhancing terminal groups (amide and phenol) as well as variations in the sulfoxide / 
vinyl-disulfide core. 
 
The phenol ajoene analogues were found to be more cytotoxic against WHCO1 
oesophageal cancer cell proliferation than the corresponding amides. The structure-
activity data support a thiolysis mechanism where ajoene forms a mixed disulfide with a 
reactive cysteine residue on a protein target which leads to both its cytotoxicity and blood 
instability. This in turn is mediated by the reactivity of the disulfide pharmacophore 
which is enhanced by the vinyl group. The sulfoxide functional group is perceived as 
modulating disulphide reactivity by an inductive electron-withdrawal through the 
aliphatic σ-framework. The dihydroajoenes emerged as attractive candidates for further 
cancer therapeutic development with improved blood stability with a half-life around 
120 minutes and good cancer cell cytotoxicity (IC50 of approximately 20 µM). A 
spectrophotometric and proteomic binding study demonstrated S-thiolation between 
ajoene and the cysteine 93 residue in the -subunit of haemoglobin which may explain 
the observed blood instability. 
 
A biotinylated ajoene analogue was designed and synthesised to identify ajoene’s protein 
targets within the cancer cell. This was achieved using a convergent “Click”-strategy, 
involving azidated ajoene and biotin-alkyne. Both the biotin-ajoene and the azide-ajoene 
showed strong cytotoxicity against WHCO1 cancer cells. An immunoblotting experiment 
showed the successful biotinylation of haemoglobin, as a model protein by both whole 
probe and an in situ “Click”-reaction. This biotinylated probe can be used in future work 
to identify the ajoene protein targets in cancer cells.  
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Chapter One: Literature Review 
 
“Sith Garlic then hath powers to save from death, 
Bear with it though it make unsavory breath: 
And scorn not Garlic, like to some that think 
It only makes men wink, and drink, and stink.” 
-The Englishmans Doctor by Sir John Harrington 1608 
1.1 Historical use and medicinal significance of garlic 
Garlic (lat. Allium sativum) is a popular seasoning and medicinal plant. The word garlic is 
derived from the Anglo Saxon word gar-leac meaning “spear plant”,1 and is thought to 
have originated in Central Asia after which it was taken to North Africa and Europe. In 
many cultures it has gained the medicinal reputation as a “cure-all” because the plant can 
strengthen the body’s immune system to fight off disease, as well as acting directly on 
pathogens and cancer cells. In 1858, Louis Pasteur was the first to experimentally confirm 
garlic’s antibacterial activity, which underpinned its common use during World War I and 
II in situations where antibiotics were scarce. This led to it being coined “Russian 
penicillin".2,3 In light of the traditional use of garlic, it has been vastly researched in 
modern medicine, with over two hundred and fifty thousand scientific articles and books, 
making it one of the most researched medicinal plants. The scope of bioactivity spans 
several areas to include anti-microbial,4 anti-parasitic,5 anti-fungal,6 anti-tumour,7 and 
immunomodulatory activities,8–11 which have been attributed to the plant’s ability to 
form over twenty organo-sulfur compounds (OSC’s) as part of its allelochemical defence 
repertoire. 
 
1.2 Overview of the chemistry and biology of allicin 
Within an intact garlic clove an analogue of the thiol-bearing amino acid cysteine, called 
S-allyl cysteine S-oxide, participates in a self-defence mechanism against pathogens and 
certain herbivores.12 This defensive substrate, commonly known as alliin,13 is 
compartmentalised in a mesophyll vacuole of the garlic clove, while its enzymatic 
counterpart, alliinase, is found within the cell wall. Upon crushing or damaging of the 
clove, alliin is enzymatically converted to 2-propensulfenic acid and 2-aminoacrylic acid 
by the S-C lyase, alliinase. The subsequent condensation of two 2-propenesulfenic acid 
molecules gives the pungent smelling allicin (see Figure 1). 
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Figure 1: Biosynthesis of allicin 
 
The structure of garlic’s primary metabolite, allicin, was first elucidated in seminal work 
by Cavallito and Bailey in 1944.14 Three years later in 1947, they demonstrated that the 
chemical oxidation of diallyl disulfide (DADS) with peracetic acid produces allicin 
synthetically (see Figure 2).  
 
 
 
Figure 2: Selective oxidation of DADS using peracetic acid 
 
Early studies on garlic were aimed at validating its traditional use as a natural antibiotic, 
and focused on its anti-microbial activity. Thus far, studies on allicin have demonstrated 
a wide range of anti-microbial activities against acid-fast (mycobacterium tuberculosis), 
gram-negative (Escherichia coli and shigella dysentriae) and gram-positive 
(staphylococcus) strains of bacteria.15,16 Jalali et al. demonstrated in vivo anti-microbial 
effects of allicin on male rabbits with burn wounds by topically applying ethanolic garlic 
extracts. The treated rabbits showed significantly lowered bacterial contamination as 
well as a visible reduction in wound size.17 It was stated that additional tissue 
regenerative and angiogenic effects were not linked to allicin, but to the secondary 
compounds that form from its degradation.18 The poor chemical stability of allicin has 
made it an unreliable compound for medical research, and emphasis has thus been placed 
on investigating its more stable degradation products, which themselves, synergistically 
or individually, are toxic to pathogens and cancer cells.19,20 Figure 3 shows four distinct 
degradation pathways of allicin that were first described by Block in 1986.14 The labile 
thiosulfinate functional group of allicin can undergo a Cope-type rearrangement to give 
2-propenesulfenic acid and thioacrolein, via route i). Route ii) involves hydrolysis to 
produce 2-propenesulfinic acid and allylmercaptan (SAM). The latter, in route iii), can 
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undergo a substitution reaction with allicin to give DADS and 2-propenesulfenic acid. 
Lastly, shown in route iv), the thioallylation of allicin with 2-propenesulfenic acid affords 
a sulfonium ion intermediate which forms the basis for the generation of multiple higher 
order OSC’s. 
 
 
 
Figure 3: Decomposition pathways of allicin 
 
Allicin and its degradation products, called first- and second-generation OSC’s 
respectively, form the core of the plant’s self-defence mechanism, and contribute to the 
wide scope of garlic’s beneficial health effects. Shared commonalities in the mode of 
action and resulting bioactivity of these OSC’s has led to their classification into distinct 
chemotype sub-sets according to structural features. The following section will provide a 
background on the sulfur chemistry that involves their formation and governs their 
biological activity. 
 
1.3 Garlic organo-sulfur chemotypes 
Allicin is a first-generation OSC and the plant’s key chemical defence. It is the 
predominant thiosulfinate found in crushed garlic, while its propyl- and methyl-
derivatives are present in much lesser amounts. For this reason, the majority of the 
second-generation garlic OSC’s fall into the allicin-derived allyl-family. These allyl-sulfur 
compounds can be separated into water-soluble constituents such as S-allylcysteine 
(SAC) and S-allymercaptocysteine (SAMC), and lipid-soluble constituents, which include 
diallyl sulfide (DAS), diallyl di-, tri- and tetra-sulfides (DADS, DATS, DAS4), dithiins and 
E/Z-ajoene.21,22 Figure 4 shows the two principle cysteine-containing water-soluble 
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OSC’s together with the general structure of the three principle lipid-soluble chemotypes 
that are produced from allicin’s (thiosulfinate) chemical transformation.  
 
 
 
Figure 4: Classification of first- and second-generation garlic OSC’s 
 
The generation of allicin metabolites depends on the garlic preparation, the extraction 
method (i.e. choice of solvent, temperature and time) and the garlic cultivar.19,23–25 For 
example, essential oil of garlic is rich in allicin, but a mere twenty hours at room 
temperature already sees its full conversion into second-generation products such as 
DAS, DADS and higher polysulfanes (where S(n) = 3-6).26 Steam-distillates of crushed 
garlic contain DADS and DATS as the main products, whereas preparations that incubate 
crushed garlic in vegetable oil promote the conversion of allicin to E- and Z-ajoene and 
dithiins.27,28 The culinary-savoured fermented or baked whole garlic cloves (at high 
temperatures of approximately 200 °C) is, in effect, devoid of any first or second-
generation OSC’s, as the allicin-forming enzyme (alliinase) is denatured, and the volatile 
OSC’s escape. This results in the clove having a sweet flavour lacking the characteristic 
pungent odour and taste. Aged garlic extracts are traditionally prepared as part of 
Tibetan and Ayurvedic medicinal practices. Here macerated garlic is soaked in 20% 
ethanol in water at room temperature for twenty months. A lengthy storage such as this 
transforms the lipophilic OSC’s into the more stable water-soluble SAMC, SAC and S-
methylcysteine (SMC).29  
 
The complicated rearrangement chemistry of garlic products and the difficulty in 
isolating single compounds from garlic preparations has highlighted the need for 
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synthetic access to these compounds in order to discriminate the specific bioactivities of 
individual OSC’s. The sulfide or polysulfide backbone is a structural similarity and likely 
represents the pharmacophore that is shared in all OSC’s found in garlic. The focus of this 
thesis is on ajoene, which is one of the lipophilic second-generation compounds, and thus 
the following section reviews literature on the synthesis and biology of its closest organo-
sulfur relatives. 
 
1.3.1 Dialkyl polysulfanes 
Dialkyl polysulfanes (R1-S(n)-R2 (n = 1-6), see Figure 5) constitute the largest group of 
garlic OSC’s, in which bioactivity is due to sulfur’s ability to form S-S bonds through redox 
reactions. In general, polysulfanes are similar or superior to allicin in bioactivity due to 
their enhanced stability and higher target specificity.30 Diallyl disulfide (DADS) is a direct 
product of allicin degradation that is formed via an S-alkyl substitution pathway (see 
Figure 3, Reaction iii)), and represents the major dialkyl disulfane constituent found in 
crushed garlic ( >50%).26 For instance, garlic oil extracted from a particularly strong 
British garlic variety was found to contain 530 mg/g of DADS, followed by DATS (115 
mg/g), DAS (106 mg/g), DAS4 (43 mg/g), DAS5 (11 mg/g) and DAS6 (0.1 mg/g) (see 
Figure 5 for structures).31 Dialkyl disulfanes can be synthetically accessed through 
standard disulfide methodology, (e.g. via sulfenate exchange methodology, viz. R1-S- + LG-
S-R2  R1-S-S-R2 + LG- for mixed disulfides). Studies on DADS have shown it to have anti-
microbial,32 anti-thrombotic and anti-cancer activities.33 
 
 
 
 
Figure 5: General structure of dialkyl polysulfanes, and the six diallylpolysulfane constituents of 
garlic 
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Diallyl sulfide (DAS) and its analogous mono-sulfide compounds are the simplest 
members of the dialkyl polysulfane family, and are formed in garlic preparations during 
polysulfide degradation or OSC metabolism (via SAM).27 Lacking a cleavable disulfide, its 
biological activity is restricted to lipophilic membrane disruptions and ligation 
properties.30 
 
The higher dialkyl polysulfanes (R1-S(n>2)-R2) are related to DADS in that their polysulfide 
chains are able to undergo a thiol-disulfide exchange. As with DADS, a disulfide exchange 
reaction yields another disulfide (R-S-S-R’); however instead of liberating a free thiol 
(RSH), trisulfides and higher polysulfanes produce hydropersulfide (RSSH) or 
hydropolysulfide (RS(x)H), respectively.34,35 This so called perthiol or polysulfane is a 
highly reactive species that is able to illicit further activity by participating in redox-
reactions, radical chemistry, catalysis and metal binding.30 There is significant interest in 
DATS, as it exhibits excellent activity against platelet aggregation,36 as well as activity 
against colon and gastric cancer.37 Block hypothesised that the biosynthesis of DATS 
occurs through a series of additions and eliminations that can iteratively produce the 
higher polysulfane forms.18 Hence, two allicin molecules self-react via sulfinylation of the 
thiosulfinate sulfenyl sulfur to give a sulfonium ion. Water-mediated desulfenylation 
produces a homoelongated sulfinate that iteratively undergoes a further sulfinylation, 
under acidic catalysis, with the loss of 2-propenesulfenic acid. The final step involves a 
desulfinylation to give DATS (Figure 6). 
 
 
 
Figure 6: Proposed biosynthesis of diallyl trisulfide (DATS) 
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1.3.2 Dithiins 
Dithiins are synthetically exciting targets as they are cyclic vinyl-sulfides. They are 
formed during allicin degradation in non-polar solvents and were first identified by 
Brodnitz in 1971 as a product of allicin’s thermal degradation.26 Figure 7 shows Block’s 
proposed mechanism for their formation, which involves a non-regioselective hetero-
Diels Alder cycloaddition of two thioacrolein molecules to give 1,3- and 1,2-dithiins in a 
9:2 ratio.14 To date, little research has been conducted on their biological activity, but the 
disulfide 1,2-dithiin, in particular, presents an interesting lead for further work relating 
to our studies on ajoene due to its vinyl-disulfide (vide infra). 
 
 
 
Figure 7: Proposed formation of dithiins found in garlic preparations; suspected pharmacophores 
are highlighted in red 
 
1.3.3 Ajoenes 
Ajoene, from the Spanish word ajo (pronounced “aho”) for garlic, was first identified by 
Apitz-Castro et al. in 1983 whilst studying garlic’s anti-thrombotic effects.38 Two seminal 
papers by Block in 1984 and 1986, elucidated its structure as one containing a unique 
sulfoxide vinyl-disulfide backbone that is shown in red in Figure 8.14,18 He postulated that 
ajoenes emerge from a S-thiolation reaction involving two allicin molecules. The resultant 
sulfonium ion undergoes a β-elimination and desulfinylation to form a thiocarbocation 
(thionium ion) that subsequently undergoes a Michael addition with sulfenic acid to yield 
E/Z-ajoene. 
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Figure 8: Block’s proposed ajoene biosynthesis 
 
The ajoene molecule occurs naturally as a mixture of E- and Z-isomers about the vinyl-
disulfide bond. Naznin et al. demonstrated that freshly-crushed garlic does not contain 
ajoene until exposed to solvents.28 In one study, a non-polar solvent was shown to favour 
the formation of Z-ajoene whereas a more polar system was found to favour E-ajoene.39 
In another study, fresh garlic preparations in vegetable oil revealed a 1:3 mixture of E/Z 
isomers, which following heating at 30 °C for three days shifted to a 1:1 ratio due to the 
Z-isomer being less thermodynamically stable (more reactive) than the E-isomer. Naznin 
et al. reported that the heating of garlic in rice oil for four hours gave the highest yield of 
ajoene (648 µg/g of garlic) in a 1:3 ratio of E/Z isomers. Lastly, it has been shown that 
temperatures above 100 °C lead to ajoene degradation (little E- and no Z-ajoene detected 
after four hours).28 The first “total” synthesis of E/Z-ajoene was achieved by Block et al. 
in 1986 by refluxing allicin in aqueous acetone to obtain the natural product in 34% yield 
as a 4:1 mixture E/Z-isomers (Figure 9).14 The non-selectivity of the reaction and large 
number of by-products renders this an inefficient synthesis. Moreover, it can’t be used to 
access derivatives, but in spite of these limitations this low-yielding approach currently 
provides the only synthetic access to ajoene. The natural product displays broad-
spectrum bioactivities that include the suppression of platelet aggregation in vitro and in 
vivo,14 as well as activities against malaria,40 obesity,41,42 bacterial43 and fungal 
infections44–46 and cancer.47–49  
 
 
 
Figure 9: Biomimetic ajoene synthesis involving the refluxing of allicin in aqueous acetone 
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1.4 Garlic and cancer 
Cancer is one of the leading causes of mortality worldwide and consequently there is 
much interest in garlic’s cancer preventative and anti-cancer activity.50 The pathogenesis 
of cancer was popularised by Hanahan and Weinberg (in 2000 and 2011) when they 
specified eight distinct cellular features that govern its development.51,52 These include: 
self-sufficiency in growth signals, insensitivity to growth-inhibition signals, evasion of 
programmed cell death, limitless replicative potential, sustained angiogenesis, tissue 
invasion and metastasis, reprogramming of energy metabolism and evasion of immune 
destruction. The complex interplay between these cellular mechanisms implies that 
successful cancer therapies have to manipulate multiple targets in order to combat this 
adaptive and durable disease.  
 
During the past thirty years epidemiological studies have looked into the nutraceutical 
potential of garlic as a cancer preventative agent in populations spanning from China and 
Europe through to the Americas. Many of the studies have demonstrated a reciprocal 
relationship between garlic intake and cancer incidence primarily of the gastrointestinal 
tract. Multiple meta-analyses of the pooled data, however, have exposed a lack of 
uniformity in the garlic preparations, heterogeneity in test groups and other biases.7 It is 
well known that garlic OSC’s can exert direct cytotoxic effects on cancer cells by inhibiting 
proliferation and inducing apoptosis.53 Allicin54, dialkyl sulfanes55,56 and ajoene57 have all 
been shown to illicit pro-apoptotic responses by causing mitochondrial perturbations 
that lead to caspase-mediated signalling events, as well as concurrently down-regulating 
anti-apoptotic pathways involving Bcl-2.58 The anti-proliferative activity of garlic OSC’s 
may in part be related to their ability to induce G2/M cell cycle arrest.59,60 Some 
investigations on ajoene61 and DADS62 have linked the generation of reactive oxygen 
species (ROS) to both of the aforementioned intercellular stress events.63,64 Furthermore, 
studies have indicated that garlic OSC’s may primarily act as oxidative thiolating agents 
that can form mixed disulfides with low molecular weight thiols, such as cysteine65,66 and 
glutathione.64,67 In a cellular context, a disulfide exchange with a key protein target, as 
seen in Figure 10, will lead to alterations in signalling pathways which in combination 
with secondary downstream events may affect the initiation, promotion and the 
progression of tumour cells.30 
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Figure 10: Thiol-disulfide exchange between an OSC and a target protein 
 
1.5 The S-thiolation of protein targets by garlic compounds 
Seminal work conducted by Wills in the 1950’s showed that allicin rapidly S-thiolates and 
inhibits the plasma proteins papain and alcohol dehydrogenase via a mixed disulfide 
exchange reaction within the active site of the enzyme.68 Seki et al. demonstrated that 
DATS can directly oxidise cysteine residues on β-tubulin, resulting in disruption of the 
microtubule network during early mitosis.37,69 In each case the garlic compounds are 
proposed to S-thiolate a reactive cysteine residue on a protein. 
 
This mixed disulfide reaction is well known in biological systems to involve the small 
molecule thiol glutathione (GSH) in which the tripeptide GSH represents the major thiol-
disulfide redox buffer in eukaryotic and some prokaryotic cells. The glutathione-
dependent redox cycle utilises GSH in its reduced form to scavenge ROS in which it forms 
the enzymatically-reversible disulfide conjugate GSSG. In addition, both GSH and GSSG 
are able to S-thiolate redox sensitive cysteine residues on proteins to form a GSH-protein 
adduct.70 This process of S-glutathionylation, illustrated in Figure 11,71 is an important 
post-translational modification involved in cell redox signalling while concomitantly 
protecting free thiol residues from irreversible oxidative damage. 
 
 
 
Figure 11: Glutathionylation of a redox sensitive protein 
 
 11  
Although OSC’s most probably affect the GSH:GSSG redox cycle by forming oxidative S-S 
adducts with the reduced GSH thiol, the high millimolar cellular concentration of GSH 
versus the micromolar cytotoxicity of OSC’s are indicative of additional targets being 
involved other than GSH. Since OSC disulfide pharmacophores are able to S-thiolate 
proteins in an analogous manner to S-glutathionylation, there may be overlap between 
the protein targets. Table 1 lists a selection of proteins that are targets of 
glutathionylation.69,72 
 
Table 1: Proteins which are S-glutathionylated by GSH/GSSG 
 
 
HSP70-9B (mortalin-2)  
 
Stress-induced phosphoprotein 
1 
 
Tubulin 
 
Theoredoxin-1 
 
HSP60 
 
Peroxiredoxin 1 
 
Protein-disulfide isomerase 
 
Peptidylprolyl isomerase  
 
RNA-binding protein 
regulatory subunit 
 
Glutaredoxin 
 
Profilin 
 
Myosin 
 
Haemoglobin 
 
Aldolase 
 
Triosephosphate isomerase  
 
Actin 
 
Cytochrome c oxidase 
 
Vimentin 
 
Research at UCT has identified that garlic OSC’s may act as GSSG mimics to affect the 
redox state of the cell. Experiments by Pinto et. al. demonstrated that the allyl-sulfur 
compound 2-propenyl thiosulfate can spontaneously react with GSH under physiological 
conditions to form S-allyl-GSH, which itself is able to inhibit proteins with cysteine (Cys) 
in their active or allosteric site. To date, only a handful of garlic OSC-protein interactions 
have been specifically identified and these are listed in Table 2: 
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Table 2: Currently identified garlic OSC protein targets 
 
Protein target Garlic compound(s) 
-tubulin37,59,73 DATS, SAMC, Z-ajoene 
Glutathione reductase74 Ajoene 
Sulfur transferase64 2-PTS 
Rhodanase75 2-PTS 
Gastric lipase76 Ajoene 
Intergrin α4β177 Ajoene 
Phase II enzymes (GST, UGT)78,79 DATS 
 
1.6 Ajoene – a superior thiolating agent 
A paper by Gallwitz in 1999, highlighted ajoene as a potential glutathione disulfide (GSSG) 
mimic by reporting that ajoene covalently modifies the glutathione reductase enzyme by 
forming a mixed disulfide with its cysteine active site, which results in enzyme 
inhibition.80 Based on this evidence it is hypothesised that garlic OSC’s that contain a 
disulfide or polysulfide functional group, can undergo a thiolysis exchange with a suitable 
cysteine thiol. A thiol-disulfide exchange, aka. thiolysis, involves the nucleophilic attack 
of a thiolate (red in Figure 12) at the sulfur of a disulfide bond to form a trisulfide 
intermediate that shares the negative charge across all sulfur atoms. Thereafter, a 
disulfide is produced along with a thiolate leaving group (blue in Figure 12). The 
formation of the intermediate, which is governed by the nucleophilicity of the thiolate 
and the electrophilicity of the sulfur of the disulfide, is kinetically controlled, while the 
formation of the thiolate nucleophile and the expulsion of the leaving group are governed 
by thermodynamic principles.  
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Figure 12: Mechanism of a thiol-disulfide exchange reaction 
 
In Figure 12 above the cysteine thiolate represents the reactive nucleophile, and its 
formation is governed by its ionizability (pKa).81 In the laboratory, the thiolate can be 
generated by the addition of a base, whereas within a cellular setting this is achieved by 
the basicity of the protein microenvironment. Free cysteine has a pKa of 8.3-8.5, and is 
predominantly protonated at physiological pH (approximately 7), making it a poor 
nucleophile. Within a protein reactive cysteine thiol groups are influenced by adjacent 
electron-rich and charged amino acid residues. These can stabilise the thiolate anion and 
effectively lower its pKa to shift the equilibrium towards the thiolate, which is a potent 
nucleophile.82,83 In certain enzyme active sites, cysteine thiols are reported to have pKa 
values as low as 3.4.84 In spite of this, once the thiolate is formed it remains the protein’s 
only reaction contributor (incoming nucleophile) and thus the electrophilicity and steric 
accessibility of the OSC disulfide is what actually governs the rate of reaction. Most garlic 
OSC’s contain symmetrical disulfides which do not involve any regioselectivity in thiolate 
attack. In contrast, ajoene and 1,2-dithiin contain a vinyl-disulfide, which presents a 
regioselectivity question regarding the site of nucleophilic attack (See Figure 13).  
 
 
 
Figure 13: Regioselectivity of the disulfide exchange with ajoene 
 
This regioselectivity is determined by the relative electrophilicities of the two sulfur 
atoms (non-vinyl and vinyl), which in turn links with thiolate leaving ability. With ajoene, 
the favoured leaving group is the resonance-stabilised enethiolate in preference to the 
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unconjugated sulfide; hence, regioselective attack proceeds at the non-vinyl sulfur. For 
this reason ajoene is a superior thiolating agent compared to other garlic OSC’s because 
of the stabilised leaving group favouring the thermodynamics of the exchange. 
Furthermore, it is proposed that ajoene may also compete with GSSG in exchange 
reactions with site-specific redox sensitive cysteine residues in protein targets (See 
Figure 13). This aspect has a powerful bearing on the Results and Discussion section 
(Chapters Three and Four) of this thesis. 
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Chapter Two: Ajoene Research at the University of Cape Town 
 
This Chapter will review previous work carried out in the University of Cape Town (UCT) 
group that has relevance to research work described in this thesis. 
 
2.1 Synthesis of ajoene analogues  
With a particular interest in the anti-cancer activity of potential ajoene analogues, in 2008 
our laboratory at UCT published a four-step synthetic route to access end-substituted 
ajoene analogues in an overall 30% yield.66,85 The synthetic route is displayed in Figure 
14 and will be described in the following section.  
 
 
 
Figure 14: Synthesis of doubly-end substituted ajoenes 
 
2.1.1 Step one: Propargylation 
Figure 15 shows the first step involving the S-propargylation of an appropriately R1-
substituted thiolate in which the R1-group ends up on the sulfoxide end (left-hand side) 
in the final ajoene molecule. In the case of a commercially available R1-substituted thiol, 
standard propargylation conditions (KOH, propargyl bromide, MeOH) affords thioether 
A. Alternatively, it is possible to access the thiol by first preparing an isothiouronium salt 
by refluxing a suitable R1-substituted alkyl halide and thiourea in acetonitrile, as depicted 
in Figure 16. The filtered and washed salt is then hydrolysed in situ to generate the 
thiolate, which is similarly propargylated to form the desired R1-substituted thioether A. 
Yields in this step are high (> 90%). 
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Figure 15: Thiolate propargylation 
 
 
 
 
Figure 16: Isothiouronium salt preparation 
 
2.1.2 Step two: Radical addition 
The second step was inspired by a reaction pioneered by Kampmeier86 that was 
published in JACS in 1965 in which it was shown that thiolacetic acid undergoes a 
regioselective radical addition to the terminus of 1-hexyne due to the formation of the 
more stable vinyl radical intermediate (vide infra). The regioselective addition of 
thiolacetic acid to thioether A (Figure 14) was the key step of our sequence, as it 
generates a protected vinyl-sulfide relevant to the target. For the radical addition, ACCN 
(1,1′-azobis(cyclohexanecarbonitrile) is used as the radical initiator. It is a member of the 
azobis-family of radical initiators and by virtue of its labile 1,1’-azobis core undergoes 
thermal radical cleavage at 85°C to give an active -cyano radical.87 In the initiation step, 
this -cyano radical abstracts a proton from thiolacetic acid. For the propagation steps 
the resultant thiyl radical then regioselectively adds to the alkyne terminus of the 
propargylic thioether A to form a vinyl thioacetate radical. The vinyl thioacetate radical 
then abstracts a proton from thiolacetic acid to afford the desired stereoisomeric vinyl 
thioacetate B as a mixture of E:Z isomers in a ratio of approximately 1:2. The 
predominance of the Z-isomer was welcomed in view of its higher bioactivity.65 This step 
propagates the chain reaction, since it regenerates another thiyl radical. Reduction of the 
Z-thioacetate radical intermediate is sterically less demanding than that of the E- and thus 
the Z-isomer is formed faster than the E-isomer (kinetic control). Undesirable 
termination involves dimerization of two thiyl radicals to form a disulfide diacetate by-
product, B’, as shown in Figure 17. Yields for this step of the sequence vary depending 
on the substrate, but are generally around 60-70%. The preparation of the natural 
product ajoene itself is not possible via this route owing to a suspected intramolecular 
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cyclisation (5-exo-trig or 6-endo-trig) involving the allyl-substituent (R1 = allyl) during 
the radical addition step. 
 
 
 
Figure 17: Proposed mechanism of radical addition of thiol acetic acid to the terminus of alkyne A 
to form of thiolacetic acid B 
 
2.1.3 Step three: Sulfenylation 
The vinyl-disulfide formation step was inspired by work by Brandsma who demonstrated 
sulfenylation of a base-generated thiolate by an alkyl alkanethiosulfonate.88 In the ajoene 
case a -SR2 substituent is introduced into the right-hand side (disulfide end) of the ajoene 
molecule in the form of the vinyl-disulfide pharmacophore, Figure 18. This reaction 
represents the second key step in the synthetic sequence as it also influences the E:Z 
outcome of the ajoene product. From a practical perspective, thioester B is first 
hydrolysed with KOH to generate an enethiolate anion. Thereafter, the enethiolate is 
sulfenylated at its soft sulfur end with the R2-substituted p-toluenethiosulfonate 
(sulfenylating agent) to afford vinyl-disulfide C. The ratio of E:Z (1:2 in B) doesn’t change 
significantly towards favouring the E-isomer when the temperature is kept low (less than 
0 °C). However, at higher temperature isomerization can occur, presumably via the 
thioaldehyde tautomer undergoing a bond rotation about the Cα-Cβ axis to enrich the 
thermodynamically more stable E-isomeric form after enethiolate regeneration, as 
shown in Figure 19. Yields for the overall transformation to afford C were usually fairly 
acceptable in the region of >75%.  
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Figure 18: Pharmacophore generation via low temperature S-alkylation 
 
 
 
 
Figure 19: Tautomeric shift of enethiolate 
 
2.1.4 Step four: Oxidation 
The final step in the ajoene analogue synthesis involves a low-temperature 
chemoselective oxidation, as shown in Figure 20. By reacting C with a molar equivalent 
of m-CPBA at low temperature (-78°C), only its most nucleophilic (sulfide) sulfur is 
oxidised to afford the sulfoxide D. The sulfoxide is produced as a racemate, and its 
stereogenic nature is observed in the 1H-NMR spectrum of the product D in form of 
diastereotopic splitting for its α-proton signals, which allowed unambiguous assignment 
of the chemoselective site of oxidation. The E:Z ratio was retained from C within 
experimental (column chromatography) consideration. Yields for this step were 
normally around 75%.  
 
 
 
Figure 20: Chemoselective sulfide oxidation 
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2.2 Structure-activity relationships: cytotoxicity of ajoene in cancer cells 
In the 2008 study, the ajoene analogues synthesised by the UCT route were tested for 
their anti-proliferative activity against WHCO1 oesophageal cancer cells and a structure-
activity profile generated. The results revealed that activity was retained when varying 
the R1/R2 end-groups (Figure 21).  
 
 
 
Figure 21: General structure of substituted ajoenes developed at UCT 66,85 
 
This important finding revealed that the pharmacophore does not reside within the 
terminal allyl groups of ajoene. Interestingly, it was also shown that end-group 
substitutions at R1 and/or R2 were found to modulate activity, with some analogues 
showing an improved activity compared to ajoene,66,85 due to an increase in lipophilicity. 
Also, a stereochemical bias was observed, with the Z-isomers consistently showing a very 
moderate (about 1.5 fold) increase in activity over the corresponding E-isomers, 
supporting the importance of geometrically-specific protein-binding interactions in their 
bioactivity.60 In some cases, it was not possible to separate the individual E- and Z-ajoene 
isomers by chromatography, particularly in compounds containing aromatic rings, and in 
these cases, the IC50 was reflected as the activity of the E/Z-mixture.66 It is worth noting 
that these ajoene derivatives also showed an improved shelf-life stability over ajoene. 
The most active analogue was found to be a bis-paramethoxybenzyl substituted ajoene, 
called bis-PMB (R1/R2 = PMB), which displayed a twelvefold increase in activity compared 
to the natural product ajoene (Table 3). The modulatory role of the end-groups pointed 
towards the pharmacophore residing within the backbone of the ajoene molecule which 
was validated by synthesising a mini-library where each of its three functional groups, 
namely the sulfoxide, vinyl and disulfide, were varied individually. Owing to its improved 
stability and activity compared to ajoene, bis-PMB was chosen as the lead for this 
elucidation study. Table 3 shows the cytoxicities against WHCO1 cells of the synthetically 
modified analogues (Entries 6-10).66  
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Table 3: Structure activity pharmacophore analysis of bis-PMB regarding inhibition of WHCO1 
cell proliferation 
 
Entry Name/descriptor Structure WHCO1 
IC50 ± SD (µM) 
1 ajoene 
 
Z: 25.0 ± 2.8 
E: 39.0 ± 7.8 
2 propyl-allyl 
ajoene 
 
Z: 23.0 ± 4.2 
E: 37.0 ± 4.5 
3 propyl-propyl 
ajoene 
 
Z: 18.0 ± 4.1 
E: 24.0 ± 2.8 
4 PMB-allyl 
ajoene 
 
E/Z: 7.4 ± 0.7 
5 bis-PMB ajoene 
 
E/Z: 2.1 ± 0.4 
6 bis-PMB sulfide 
ajoene 
 
 
E/Z: 0.7 ± 0.3 
7 bis-PMB 
dihydroajoene 
 
16 ± 3.7 
8 bis-PMB sulfide 
dihydroajoene 
 
 
> 200 
9 bis-PMB sulfoxide 
vinyl-sulfide 
  
Z: >200 
E: >200 
10 bis-PMB sulfide 
vinyl-sulfide 
  
E/Z: > 200 
 
Entry 6, the bis-PMB analogue with the sulfoxide removed, retained anti-proliferative 
activity indicating that the sulfoxide is not the pharmacophore. Surprisingly, this 
analogue showed the highest activity of the series (including its parent bis-PMB). The 
removal of the doubled bond (bis-PMB dihydroajoene) led to a decreased activity (Entry 
7) due to less stabilization of the anion in the exchange. These results highlight that the 
sulfoxide and the double bond, on their own, play a modulatory role and are thus not 
essential for activity. The removal of both the sulfoxide and vinyl-disulfide resulted in 
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loss of activity below 200 µM which implies that there is synergism between the sulfoxide 
and the double bond that governs disulfide thiolysis. Substitution of the disulfide by a 
sulfide (Entries 9-10) resulted in a loss of activity below the highest tested concentration 
of 200 µM, proving that the disulfide is the pharmacophore.  
 
In summary, the ajoene synthesis developed in our laboratory has enabled access to 
ajoene analogues such as “bis-PMB” that are more potent in their ability to kill cancer 
cells, with cytotoxicity comparable to that of current clinical cancer therapeutics.66 The 
SAR study has laid the foundation for probing the mechanism of action of ajoene in cancer 
cells, as well as for developing further ajoene analogues with enhanced bioactivity in a 
medicinal chemistry context. 
 
2.3 Development of bis-PMB as a cancer therapeutic lead 
There are a number of studies that have previously looked into the bioavailability and 
metabolism of garlic in the context of a medicinal chemistry development. Lawson et al. 
conducted investigations on subjects who had ingested 25 g of raw garlic (~ 60 mg 
allicin). Following ingestion, no allicin was detected in either serum or urine from 1 to 24 
hours after consumption.27,89 Similarly, breath analysis of a 90 kg man who had ingested 
38 g of raw garlic showed no detectable allicin upon exhalation. Various second-
generation OCS’s, such as DADS, DATS and other dialkyl disulfanes, as well as acetone, 
have been identified as the major metabolites.90 In a study conducted by Egen-Schwind 
et al., allicin was perfused through an isolated rat liver and found to be completely 
metabolised to DADS and S-allyl mercaptan (SAM) after the first pass through the organ. 
The further breakdown products ajoenes and vinyldithiins were also recovered in the 
perfusion medium (Krebs-Henseleit buffer). Akin to the behaviour in the hepatic and 
gastrointestinal system, allicin rapidly disappears from the blood after injection.91 In 
contrast, the second-generation OSC’s showed higher half-lives in blood. Specifically, 
ajoene and DATS were recorded as 1 and 4 minutes, while 1,2-vinyldithiin, DADS and 1,3-
vinyldithiin had half-lives of 15, 60, and >120 minutes, respectively.92 These findings 
highlight that the introduction of garlic OSC’s into a biological system results in a complex 
metabolic behaviour, and that allicin, owing to its blood instability and first pass effect 
through the liver, cannot be the bioactive principle from garlic, except if the bioactivity 
occurs before the compounds reach the liver or blood (i.e. in the GI tract).91 Allicin 
contains a reactive thiosulfinate group which can be viewed as an activated disulfide, 
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implying that it is very susceptible to thiolysis in vivo. Its longer-lived in vivo metabolites 
are probably the bioactive principles of the systemic circulation.  
 
Although it has been shown that ajoene has a low half-life in blood,93 there are two 
reports in which ajoene is reported to be active at inhibiting tumour xenograft formation 
in vivo. In the first study, daily intraperitoneal injections of Z-ajoene into mice with 
hepatocarcinoma 22 (4 mg/kg) and sarcoma 180 (8 mg/kg) xenografts, over twelve days, 
showed a 42% and 32% reduction in tumour size respectively.59 In the second study, mice 
with B16/BL6 melanoma cell xenografts showed a 90% reduction in tumour size after 28 
days when E/Z-ajoene was administered intravenously (25 mg/kg of bodyweight, 
daily).94  
 
With the ajoene analogue bis-PMB showing excellent in vitro cytotoxicity against cancer 
cell lines, as well as reports on the bioactivity of ajoene in vivo, in a previous project to 
this MSc it was decided to test bis-PMB in a preclinical animal model for cancer. In this 
experiment, nude mice with WHCO1 xenografts were treated with daily intraperitoneal 
injections of bis-PMB (8 mg/kg) in 20% DMSO/intralipid for four weeks. Interestingly, no 
significant change in tumour size was observed between the control and treated groups 
of mice. This result was surprising based on the excellent in vitro activity of bis-PMB as 
well as the literature reports supporting the in vivo activity of ajoene. Therefore the 
experiment was followed up by conducting a pharmacokinetic HPLC study of bis-PMB in 
a nude mouse. Figure 22 illustrates how the blood concentration of bis-PMB was found 
to rapidly decrease following intravenous injection into a mouse, implying very poor 
metabolic stability. Furthermore, it was observed that the mice had difficulty breathing 
and that the blood samples had turned dark purple.  
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Figure 22: Concentration of intravenously administered bis-PMB versus time in pharmacokinetic 
trails on a mouse as measured by HPLC 
 
In order to further probe the interactions between bis-PMB and blood, an in vitro blood 
stability test was conducted. Here, fresh blood was collected from mice and separated 
into plasma and red blood cell (erythrocyte) fractions. These different fractions were 
incubated with bis-PMB, and the resultant stability is shown in Figure 23 as quantitated 
by LC-MS. The results revealed that bis-PMB had poor stability in the presence of 
erythrocytes but good stability in plasma.  
 
 
Figure 23: Concentration of bis-PMB in whole blood, plasma and red blood cell (RBC) fractions over 
time 
 
Hence, in the first part of this thesis the aim was to better understand the 
pharmacokinetic profile of bis-PMB and to improve its blood stability while retaining its 
strong cytotoxicity. 
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2.4 Dansyl-labelled ajoene  
In order to track the movement of ajoene in cancer cells, an ajoene probe with a 
fluorescent dansyl tag was synthesised by Cotton.95 This derivative allowed visualisation 
and tracking within the cell using confocal laser spectroscopy, which revealed strong 
activity in the ER (Endoplasmic Reticulum). Crucial to the design of the probe was 
application of our mechanistic understanding of the regioselectivity in the disulfide 
exchange, resulting in placement of the dansyl label on the more electrophilic non-vinyl 
sulfur end of the molecule, as seen in Figure 24:  
 
 
 
 
Figure 24: Dansylated ajoene probe 
 
In agreement with the previous structure-activity findings, the dansyl-ajoene (DP) was 
found to be fully active at inhibiting proliferation and inducing apoptosis in MDA-MB-231 
human breast-cancer and in WHCO1 human oesophageal-cancer cells with an IC50 similar 
to that for ajoene. The transfer of the dansyl label during protein-ajoene exchange was 
envisioned to proceed as illustrated in Figure 25: 
 
 
 
Figure 25: Transfer of dansyl tag to a protein target by S-thiolation 
 
In addition, an analysis of the cell lysate by western blot (WB) analysis allowed a cursory 
insight into the protein targets involved. As expected, lysates collected from MDA-MB-
231 cells treated with the dansyl-ajoene probe (DP) (25 µM), for 6 and 24 hours, were 
found to contain many dansyl-labelled protein targets under non-reducing conditions 
only. Figure 26 shows the presence of dansylated targets as distinct protein bands for 
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both time points when probed with an anti-dansyl antibody. The control of untreated 
cells (UT) showed no labelled protein bands. To test whether the dansyl label was 
attached to the protein through a disulfide linkage, the lysate was treated with the 
reducing agent β-mercaptoethanol, which confirmed the presence of a disulfide linkage 
since no anti-dansyl active protein bands were observed in these samples. These 
experiments thus confirmed our hypothesis by showing that DP is able to S-thiolate 
multiple protein targets, and furthermore illustrated the reversibility of S-thiolation 
under reducing conditions.  
 
 
Figure 26: Western blot showing multiple dansylated proteins in DP-treated cell lysate95 
 
These findings confirm the ajoene regioselectivity in disulfide formation with cysteine 
residues of cancer proteins. In order to identify the actual targets, this project envisions 
an alternative labelling strategy that allows for the isolation of the proteins targeted by 
ajoene. 
 
2.5 The design of the biotinylated probe 
In order to isolate and identify the ajoene labelled proteins in cancer cells we chose to use 
a more direct approach involving the synthesis of a biotinylated ajoene probe. Biotin is 
exploited in diverse biotechnological applications due to its stability, solubility in 
physiological media as well as its high affinity and specificity towards avidin.96 The probe 
design took into account our understanding of the biotin / ajoene system based on an 
Honours project (C. Pike 2013) as well as recent literature on biotin conjugation 
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chemistry.97 Based on the previously established regioselectivity of S-thiolation, the 
biotin tag was placed on the S-allyl side of the ajoene. It is proposed that the biotinylated 
protein adduct could be captured from a treated cell lysate with an appropriate avidin 
conjugate bound to a magnetic bead or in the form of immobilised streptavidin. 
Streptavidin is a tetrameric protein in which each monomer has an eight-stranded β-
barrel secondary structure. Biotin binds to the interior of the respective binding pocket 
and therefore a spacer group is recommended between biotin and the active compound,98 
see Figure 27: 
 
 
 
Figure 27: Protein S-thiolation by ajoene in cancer cells 
 
For the synthesis of the probe, in order to avoid a potential reaction between biotin and 
ajoene, it was envisioned to use a convergent strategy in which the biotin and ajoene 
fragments would be separated by a spacer and coupled in the final step using a “Click”-
strategy.98  
 
In 2001, Sharpless et al. defined “Click chemistry” as: “reactions that are high yielding, 
wide in scope, create only by-products that can be removed without chromatography, are 
stereospecific, simple to perform, and can be conducted in easily removable or benign 
solvents.”99 The copper(I)-catalysed alkyne-azide cycloaddition (CuAAC) is the most 
successful and versatile “Click”-reaction currently available. It involves a Cu(I) catalysed 
regioselective [3+2]-dipolar cycloaddition between a terminal alkyne and an azide to 
form the 1,4-regioisomer of 1,2,3-triazole, as illustrated in Figure 28. The reaction may 
be classified formally as a cycloaddition, but is not pericyclic in nature as with the original 
Huisgen thermal cycloadditions. In short, the cycle starts with the formation of a copper 
acetylide, followed by coordination of the azide reaction partner to the copper via ligand 
displacement. Thereafter, an unusual six-membered copper(III) metallacycle is formed. 
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The ring then contracts to a triazolylcopper derivative followed by protonolysis that ends 
the cycle to afford the triazole product regioselectively.100 
 
 
 
Figure 28: Mechanism of the Copper-Catalysed Azide-Alkyne Cycloaddition (CuAAC) 
 
The triazole linkage is extremely stable, as it not susceptible to hydrolysis, or facile 
oxidation or reduction, as well as surviving MS ionization. The presence of the copper(I) 
catalyst increases the rate of reaction by more than 106-fold, compared to the uncatalysed 
non-regioselective Huisgen azide-alkyne 1,3-dipolar cycloaddition. In accordance with 
other “Click”-labelling technologies, CuAAC employs bioorthogonal reactive chemistry 
with high target specificity, as the azide and alkyne reaction partners have no endogenous 
representation in biological cells or organisms. Owing to the small size of an alkyne or 
azide attachment the modified molecules can be processed by enzymes while some larger 
labels may cause functional perturbations.101,102 The copper(I) catalyst has proven 
problematic in in vivo studies due to its cytotoxicity. During in vitro trials however, the 
cells can be conveniently pre-treated with one reaction partner, then lysed and treated 
with the other “Click”-counterpart, using Cu(I) generated in situ by the sodium ascorbate 
reduction of CuSO4 (Cu(II)). This strategy enables the labelling of various biological 
targets in their native environment. In 2012, Jezowska showed that a biotin linker 
equipped with an activated triple bond donor could successfully biotinylate 
oligonucleotides and peptides via CuAAC (Shown in Figure 29).98  
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Figure 29: In situ biotinylation of azide-labelled biological molecules98 
 
We chose to incorporate this alkyne-linker-biotin idea as part of our probe design, which 
required us to synthesise a suitable azide-ajoene reaction partner, full details on which 
will be described in the chapter on Results and Discussion (Chapter Four). Figure 30 
shows a workflow describing the two approaches of biotinylation. In the first approach 
the plan was to add the probe to cancer cells, hoping to biotinylate directly via a 
regioselective disulfide exchange. In the second approach, the plan was to pre-treat 
cancer cells with the azide-bearing ajoene to promote disulfide exchange followed by 
lysis of the cells and only then addition of the alkyne partner to the lysate to bring about 
the “Click”-reaction in situ. The use of the fully assembled probe on intact cells was 
thought could potentially result in compromised activity due to its large size and possible 
solubility issues. For this reason both approaches were considered. 
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Figure 30: The two biotinylation approaches 
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2.6 Thesis hypothesis  
 
The cytotoxicity of ajoene in cancer cells and its rapid degradation by erythrocytes is due 
to thiolysis exchange with reactive cysteines on target proteins within the erythrocyte or 
cancer cell. 
 
Aim 
To investigate the structure-blood stability relations in ajoene and to synthesise a 
biotinylated ajoene probe to identify the protein targets of ajoene in the cancer cell. 
 
Objectives 
- Structure-Activity Relationships of bis-PMB Analogues: 
 Design and synthesise a library of ajoene analogues with increased water 
solubility and blood stability; 
 Biological testing of the library for in vitro cancer cell cytotoxicity and blood 
stability. 
- Synthesis of a Biotin-labelled Ajoene Probe: 
 Design and synthesise of a biotinylated ajoene probe using “Click”-chemistry; 
 Confirmation of biotin-ajoene cytotoxicity in cancer cells; 
 Demonstrate that biotin-ajoene is able to S-thiolate proteins in cancer cells 
directly or through its azide precursor  
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Chapter Three: Structure-Activity Relationships of bis-PMB Analogues  
 
3.1 Introduction 
The in vitro cancer cell anti-proliferation activity of the ajoene derivatives invited a 
number of mechanistic questions, as well as the possibility of evaluating their potential 
in drug-discovery, since the most active derivative, bis-PMB was about twelve times more 
active than the parent ajoene against an oesophageal cancer cell-line as shown in Figure 
31: 
 
 
 
Figure 31: Structure of bis-PMB 
 
Our SAR studies on ajoene derivatives identified that end-group modifications allow 
retention of in vitro bioactivity against cancer cell lines, in which there was a correlation 
between the IC50 and the substituent lipophilicity, and it was from this study that bis-PMB 
had emerged as the lead compound for further in vivo experiments, with a greatly 
enhanced activity compared to that of ajoene. We had previously shown that synthetic 
ajoene analogus have up to threefold higher cytoxicity towards tumour cells than the 
corresponding normal counterpart.60 The literature had reported that ajoene reduced 
tumour growth in mice59,94, which prompted us to explore the activity of bis-PMB. 
However, a failure in a study by us to observe a decrease in tumour size using bis-PMB-
treated mice, compared to the control group, necessitated a follow-up pharmacokinetic 
evaluation, focusing on solubility and drug half-life as likely causes of the inactivity. 
Although the lipophilic p-methoxybenzyl (PMB) substituents enhanced the in vitro 
activity their lipophilic character posed solubilisation difficulties when trying to 
solubilise the compound in a polar medium for administration in the in vivo study. A 
suitable injection mixture was developed using Chondroitin, PEG and DMSO, but 
nevertheless left the possibility that bis-PMB could have precipitated out once introduced 
into the circulatory system, rendering it “biologically unavailable” and thus undetectable. 
The second likely cause of inactivity was considered likely to be due to the lability of bis-
PMB’s disulfide pharmacophore by it reacting with cysteine thiol groups of blood 
 
 32  
proteins. Hence, an SAR study was carried out designed to address the influence of these 
two parameters on the bioavailability.  
 
3.2 Design of bis-PMB analogues 
The two likely causal factors relating to inactivity were addressed by modifying the 
pharmacophore for the reactivity issue, and one of the end groups for the polarity, as 
indicated in Figure 32: 
 
 
 
Figure 32: Ajoene modification with respect to polarity and reactivity modulation 
 
3.2.1 Solubility parameter 
For enhancing the aqueous solubility it was decided to replace the methoxy group of one 
of the bis-PMB groups with one having an improved hydrogen-bonding capability. Drastic 
changes were avoided for fear of introducing other activity issues such as conformational 
changes and lipopholicity changes. To this end, the methoxy methyl group was replaced 
by H (eg. 6, 7, 11 and 12 in Figure 33 below) and an amidomethylene moiety 
(CH2CONH2) (eg. 8, 9, 13 and 14 in Figure 33  below) that was expected to result in the 
more soluble derivative of the two. We expected the two derivatives to increase water 
solubility compared to ajoene while retaining the attractive lipophilic character due to 
the other PMB group.  
 
3.2.2 Reactivity parameter 
The reactivity parameter involved removing the double bond in order to create a 
dihydroajoene series. This was expected to reduce the reactivity of the disulfide as a 
thiolating agent in the disulfide exchange in view of reduction in stabilisation of the 
resultant thiolate versus the enethiolate (ajoene) leaving group. In this regard the 
sulfoxide functionality was considered to still provide an inductive stabilisation of the 
thiolate leaving group. Hence, the redox level at sulfur as sulfide or sulfoxide was also 
included as part of the study. The library of derivatives targeted, and ultimately 
synthesised, is shown in Figure 33: 
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Figure 33: bis-PMB-analogue library, showing reactivity modulations in red 
 
The solubility tag was most conveniently incorporated into the sulfenylating agent to be 
used in the UCT synthesis already described, rather than into the vinyl thioacetate 
segment. The dihydroajoene series was prepared using an independent sequence to the 
UCT ajoene derivative synthesis. The synthesis of compounds in the two series will now 
be independently described: 
 
3.3 Derivative Synthesis 
3.3.1 Ajoene derivatives 
The retrosynthetic plan for preparing the “water-soluble” ajoenes is shown in Figure 34. 
It envisaged synthesis of fragment 2, a para-methoxybenzyl analogue of the previously 
described (Chapter 2) vinyl thioacetate. Similarly, the ajoene vinyl disulfide 
pharmacophore would be obtained from disulfide bond formation between thioacetate 2 
and the phenolic sulfenylating agent 5, which in turn would be accessed from methyl (4-
hydroxyphenyl)acetate in three functional group interconversion steps. The disulphide 
formation would be followed by divergent modification involving alkylation of the phenol 
hydroxyl group and/or oxidation of the sulfide to the sulfoxide. 
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Figure 34: Retrosynthesis of ajoene analogues with polarity modification 
 
3.3.1.1 Synthesis of coupling fragment 2 
 
 
Figure 35: Synthesis of propargylic thioether, 1 
 
The first step towards the synthesis of coupling partner 2 involved the formation of the 
isothiouronium salt shown in Figure 35 by refluxing PMBCl with thiourea (1.2 eq) in 
acetonitrile for fourteen hours. Following cooling of the solution, the product 
precipitated, and this was filtered and washed with chilled acetonitrile. Without any 
further purification the salt was taken up in methanol, and hydrolysed with KOH (2 eq, 
for 2 hours at -20 °C) to generate the thiol in situ, which was subsequently alkylated using 
an excess of propargyl bromide (1.5 eq) at 0 °C to form the desired thioether 1 within 30 
minutes. Purification by silica gel column chromatography afforded 1 as a clear-yellow 
oil in an overall 85% yield.  
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The 1H-NMR spectrum of 1 showed propargylic methylene and terminal alkyne proton 
resonances as a doublet at 3.80 ppm (2H) and a triplet (1H) at 2.28 ppm, respectively. 
The eleven carbon atoms of 1 could be observed in the 13C-NMR spectrum as nine 
resonances due to symmetry in the benzene ring. The diagnostic quaternary alkyne 
carbon (C-8) signal appeared at 80.1 ppm.  
 
 
 
Figure 36: Synthesis of vinyl thioacetate, 2 
 
The regioselective radical addition step proceeded as normal (Page 16) when dissolving 
1 in toluene and heating the solution to 85 °C before adding the radical initiator ACCN 
(0.1 eq) followed by thiolacetic acid dropwise (Figure 36) The mixture was then refluxed 
for three hours. TLC analysis showed the formation of a more polar spot that was isolated 
by silica gel column chromatography to afford the odiferous vinyl thioacetate oil, 2, as a 
1:2 mixture of E/Z-isomers in 45% yield.  
 
The IR spectrum of 2 showed a C=O stretch at 1700 cm-1 for the thioacetate group. 
Importantly, disappearance of the propargylic system in the 1H-NMR spectrum was 
observed and the appearance of two vinylic resonances with cis (9.6 Hz) and trans (15.6 
Hz) vicinal couplings, indicating that regioselective addition of the thioacetyl group had 
taken place to the alkyne terminus (Figure 37). The complete assignment of resonances 
(eleven for each) for each isomer in the 13C-NMR spectrum could be achieved with the 
help of HSQC. Notably, the carbonyl carbon (C-10) resonated far downfield at 191.4 ppm 
(Z) and 193.1 ppm (E), while the vinyl carbon signals were observable at 130.3 (Z), 128.7 
(E) for the α-vinyl carbon C-9, and 119.7 (E), 119.5 (Z) for the β-vinyl carbon C-8. In total, 
twenty two carbon resonances could be observed for the two isomers.  
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Figure 37: 1H-NMR spectrum of PMB-vinyl thioacetate, 2 
 
3.3.1.2 Synthesis of coupling fragment 5 
 
 
 
Figure 38: Synthesis of hydroxyphenethyl thiotosylate, 5 
Synthesis of the coupling partner, 5, involved applying standard functional group 
conversion reactions (Figure 38) starting with the LiAlH4 (2.2 eq) reduction of 
commercially available methyl (4-hydroxyphenyl)acetate. This was achieved in dry THF 
at 0 °C, and the reaction was complete after two hours as monitored via TLC, with the 
formation of a single UV-active spot of higher polarity. The reaction was quenched under 
acidic conditions to liberate the product from the aluminium-alkoxide salts. A subsequent 
work-up and purification by flash chromatography yielded 3 as a colourless crystalline 
solid in 98% yield that could be recrystallised from EtOAc/Hexane. Its resulting melting 
point range of 91-93 °C corresponded sufficiently well with the literature value of 90 
°C.103  
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Formation of the primary alcohol was confirmed by the 1H-NMR spectrum of 3 which 
revealed the disappearance of the methoxycarbonylmethylene functionality (as two 
singlets). This was replaced by two triplets for the two vicinal methylene groups. 
Similarly, the 13C-NMR spectrum confirmed the presence of all six expected resonances 
in a 4:2 aromatic:aliphatic split.  
 
The next step involved an Appel reaction to convert the primary hydroxyl group of 3 into 
its iodide 4. The reaction proceeds by activation of triphenylphosphine by reaction with 
iodine to give an iodophosphonium salt. The hydroxyl group oxygen attacks phosphorus 
to generate an oxyphosphonium intermediate with loss of HI to the imidazole. This 
transforms the oxygen into a leaving group, and an SN2 displacement by iodide takes 
place to form the final alkyl iodide and triphenylphosphine oxide as a byproduct (Figure 
39). 
 
 
Figure 39: Mechanism of the Appel transformation of 3 to iodide, 4 
 
According to TLC the reaction in THF was complete within two hours at room temperature. 
Purification by silica column chromatography successfully removed the 
triphenylphosphine oxide by-product to obtain 4 as a yellow crystalline solid in 97% 
yield.  
 
The 1H-NMR spectrum of 4 showed the disappearance of the alcohol hydroxyl signal of 3 
together with an upfield shift of the methylene group bearing the heteroatom. In the 13C-
NMR spectrum the signal at 6.4 ppm represented a characteristically highly shielded 
iodo-alkyl carbon.  
 
The sulfenylating agent 5 was obtained by the SN2 reaction of 4 with an excess of 
potassium thiotosylate (2 eq) in DMF at room temperature overnight. Diluting the 
resulting reaction mixture with EtOAc and subjecting it to copious washings with H2O 
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successfully removed the DMF and any inorganic by-products. Purification by silica gel 
column chromatography afforded 5 as a clear-yellow oil in 97% yield.  
 
Its 13C-NMR spectrum displayed eleven resonances that were assigned to the fifteen 
carbon atoms in the molecule. The addition of a tosyl group showed an extra set of double 
doublets at 7.82 and 7.34 ppm and a methyl singlet at 2.45 ppm in the 1H-NMR spectrum 
(Figure 40). Lastly, the IR spectrum showed the retention of the phenolic group by virtue 
of an O-H stretch at 3436 cm-1. 
 
 
 
Figure 40: 1H-NMR spectrum of sulfenylating agent, 5 
 
3.3.1.3 Coupling of 2 and 5 to the disulfide, 6 
 
 
 
Figure 41: Fragment coupling by sulfenylation 
 
The coupling of 2 and 5 was achieved using the UCT synthesis (described in section 2.1) 
which involved treating 2 with potassium hydroxide (MeOH, -78 °C) to generate its 
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enethiolate followed by sulfenylation with 5 at the soft end of the enolate. Isolation by 
silica column chromatography gave 6 (Figure 42) in 72% yield and as a 3:5 mixture of 
E/Z isomers according to the 1H-NMR spectrum.  
 
 
 
Figure 42: Phenol-ajoene 6 
 
Support for formation of 6 was given by the appearance of characteristic signals for both 
coupling fragments in its 1H-NMR spectrum, with the exception of the thioacetyl methyl 
singlet (the IR also lacking the carbonyl stretch) as well as thiotosylate signals. Cis and 
trans isomers were detected by virtue of the appearance of two distinct geometric sets of 
doublets of triplets at 6.24 and 6.09 ppm for the Hα proton (H-9) of the Z- and E-isomers 
respectively. The triplet arose due to an allylic coupling with the allylic methylene 
hydrogens (H-7) while a vicinal coupling of 9.3 Hz could be assigned to the Z-isomer at 
6.24 ppm and a 14.6 Hz coupling for the E-isomer at 6.09 ppm. Similarly the Hβ (H-8) 
hydrogen appeared as two sets of doublet of triplets at 5.88 and 5.70 ppm, with the same 
cis and trans couplings with H-9 but a larger vicinal coupling of 7.3 Hz with H-7, as shown 
in Figure 43: 
 
 
 
Figure 43: Expansion of 1H NMR vinylic signals of 6 
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The 13C-NMR spectrum of 6 showed resonances for all 19 carbon atoms for each isomer, 
in which some carbons away from the stereogenic axis resonated at the same chemical 
shift. Two downfield signals at 158.8 and 154.3 ppm could be assigned to the deshielded 
quaternary aromatic carbons, C-2 and C-15 respectively. The remaining two quaternary 
centres, C-5 and C-12, were identified at 132.2 and 130.7 ppm. Although H-10 and H-11 
were indistinguishable in the 1H-NMR spectrum, HSQC analysis of the 13C-NMR spectrum 
revealed C-10 as having distinct E- and Z- signals (39.9 and 40.6 ppm), while the benzylic 
C-11 appeared as a single resonance at 34.8 ppm for both isomers, as seen in Figure 44: 
 
 
 
Figure 44: Expansion of HSQC for C-10/-11 of 6 
 
3.3.1.4 Final derivatisations 
The various options for final derivatisations are shown in Figure 45: 
 
 
 
Figure 45: Derivatisation sequence, depicting oxidation and alkylation steps 
 
Hence, chemoselective oxidation as previously accomplished (Page 18), of the more 
nucleophilic sulfur of 6 with m-CPBA in DCM at -78 °C afforded the ajoene-phenol 
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derivative 7. Following a basic work-up to remove the benzoic acid by-product as well as 
excess m-CPBA, isolation by chromatography produced 7 as a 1:2 mixture of E/Z-isomers 
in 60% yield.  
 
Formation of the sulfoxide as opposed to the sulfone was indicated by the presence of 
diastereotopic H-7 hydrogens due to the adjacent chiral sulfoxide centre, with a large 
geminal coupling of about 13 Hz. Figure 46 illustrates the diastereotopic splitting of the 
proton alpha to the chiral sulfoxide and highlights their corresponding coupling 
constants with each of the vinylic proton. The full 1H-NMR spectrum of 7 is presented in 
Figure 47. 
 
 
 
Figure 46: H-7 coupling patterns for 7 (J-values of multiplets are estimated) 
 
While taking overlapping signals and geometric isomerism into account, all 38 carbon 
atoms (19 per isomer) could be identified by the aid of 13C-NMR and HSQC analysis. The 
13C-NMR spectrum revealed the strong deshielding effect of the sulfoxide on adjacent 
carbon atoms, C-6 and C-7. The E- and Z-isomers of C-6 in 7 resonated higher at 56.4 and 
57.0 ppm, compared to at 34.8 and 35.6 ppm in 6. Similarly, the two isomeric signals for 
C-7 had shifted from 32.9 and 29.5 ppm (in 6) to 52.9 and 49.6 ppm, for E and Z 
respectively in 7.  
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Figure 47: 1H-NMR spectrum of phenol-ajoene, 7 
 
As shown in Figure 45 introduction of the amide functionality was required at the two 
different oxidation levels. This could be achieved by using potassium carbonate (2 eq) as 
base with 2-chloroacetamide (2 eq) and TBAI (0.1 eq) in acetonitrile for twelve hours at 
reflux. The TBAI was used to generate iodoacetamide in situ. Figure 48 summarises the 
SN2 reaction involved. For ajoene-amide 9 it was more efficient to introduce the amide 
functionality after the sulphide had already been oxidised.  
 
 
 
Figure 48: Phenol alkylation 
 
Application of this methodology afforded the sulfide-amide 8 as a 3:4 mixture of E/Z-
isomers in 40% yield, and the sulfoxide-amide, 9, in 48% and an E:Z-ratio of 3:2. 
Interestingly inversion of the ratio from 1:2 in 7 to 3:2 in 9 implies that the reaction in 
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some way enriched in the E-isomer, presumably via deprotonation of one of the acidic α-
sulfoxide protons, followed by double bond isomerisation to the more stable trans-
isomer and finally reprotonation.  
 
The 1H-NMR spectra of 8 and 9 were analogous to those of 6 and 7, namely the diagnostic 
E/Z splitting observed in the vinylic protons (order of chemical shift = Z-E-E-Z), the 
presence of two sets of aromatic signals (dd x 2) and the five methylene proton signals 
accounting for the methoxy, benzylic (x2) and alpha-sulfide (x2) (sulfoxide for 7 and 9) 
positions. However an extra methylene singlet at around 4.5 ppm in both spectra (8/9) 
for each isomer could be observed for the newly introduced amidomethylene moiety 
(Figure 49). Moreover, a pair of N-H resonances at ~6.6 and 6.0 ppm (E- and Z- 
coincidental here) could be observed for the non-equivalent amide hydrogens. Two N-H 
stretching bands in the IR at around 3200 and 3400 cm-1 as well as an amide carbonyl 
stretch at 1700 cm-1 confirmed the presence of the primary amide. The 13C-NMR 
spectrum provided further evidence as it showed two additional acetamide carbon 
signals for C-16 and C-17 at 67.5/67.4 ppm (-CH2-) and 171.2/171.1 ppm (carbonyl) for 
8/9 respectively. The HRMS data for 8 gave a molecular ion (M+H)+ at 436.1068 (M+H)+, 
in which C21H26NO3S3 requires 436.1080, thus further corroborating that successful 
amide modification of these analogues had been achieved.  
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Figure 49: 1H-NMR spectrum of amide-ajoene analogues, 8 and 9 
 
With the bis-PMB ajoene analogues in hand attention was turned towards accessing the 
analogous compounds in the dihydroajoene series, which will be described in the 
following section. 
 
3.3.2 Dihydroajoene derivatives 
The synthesis envisioned (Figure 50) proceeding via the mono-alkylation of 1,3-
propanedithiol in which it was realised that care in respect of reagent equivalents would 
need to be taken in order to avoid over-substitution to afford the dialkylated product. 
Thereafter, the remaining thiol would be sulfenylated with 5, to obtain 11. Subsequent 
chemoselective oxidation of the more nucleophilic sulfur of 11 was expected to afford the 
sulfoxide disulfide, 12. Finally, alkylation of 11 and 12 with caesium carbonate, 2-
chloroacetamide and TBAI as in the ajoene series was expected to afford the targets 13 
and 14. 
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Figure 50: Retrosynthesis of dihydroajoene analogues with polarity modification 
 
3.3.2.1 Synthesis of 11 and 12 
The following sequence summarises the two substitution and oxidation steps just 
described, Figure 51: 
 
 
 
Figure 51: Synthesis of PMB-S-propanethiol, 10 
 
Optimal conditions for the first step involved mixing an excess of 1,3-propanedithiol (1.2 
eq) with potassium hydroxide (1.4 eq) in anhydrous methanol at 0 °C and then adding 
PMBCl (1 eq) dropwise. After two hours, TLC analysis showed that PMBCl had been 
completely consumed, and the reaction was neutralised with 1M HCl. Purification by 
silica gel column chromatography afforded the desired mono-alkylated thiol 10 in 88% 
yield.  
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Two pairs of aromatic doublets at 7.23 and 6.85 ppm together with two methylene 
triplets at 2.52 and 1.84 ppm from the propanedithiol partner with an integration ratio 
of 2:2:2:2 in the 1H-NMR spectrum of 10 indicated a successful mono-alkylation. In 
addition a triplet for the thiol hydrogen was observed at 1.33 ppm.  
 
The second thioalkylation proceeded by sulfenylating 10 with 5 in MeOH at -78 °C using 
triethylamine (1.5 eq) as a base catalyst. Warming the reaction mixture to room 
temperature over one hour followed by an acidic work-up and purification gave the 
sulfide disulfide, 11, as a colourless waxy solid in 77% yield. 
 
A successful coupling could be discerned by the appearance of signals for the 
sulfenylating agent into the 1H-NMR spectrum and integrating correctly to the signals for 
the starting material 10. The IR of 11 showed the appearance of a S-S stretching band at 
550 cm-1 and the phenolic hydroxyl showed a strong O-H stretching band at 3433 cm-1. 
All 15 carbon signals could be accounted for in the 13C-NMR spectrum. Lowfield signals 
resonating at 158.8 and 154.3 ppm, respectively, represented the quaternary aromatic 
signals adjacent to the methoxy and hydroxyl groups respectively. 
 
Analogous to the ajoene synthesis, the last step in this sequence involved a regioselective 
oxidation of 11 at the benzylic sulfur with m-CPBA (1.5 eq) in DCM at -78 °C. The reaction 
proceeded over one hour and gave the sulfoxide, 12, in 70% yield. 
 
Figure 52 confirms previous observations regarding the effects of the chiral sulfoxide on 
the prochiral hydrogens, H-6 which were observed as a diastereotopic pair of AB 
doublets at 3.99 and 3.95 ppm, shifted downfield from 3.67 ppm in 11. The multiplet at 
2.77-2.58 ppm contained the H-7 hydrogens towards H-9, which in 11 were separated as 
two distinct signals at 2.51 and 2.73 ppm. This was due to the deshielding effect of the 
sulfoxide through an inductive effect. Similarly, all 15 carbon signals were accounted for 
in the 13C-NMR spectrum in which notably C-6 experienced a strong deshielding shift 
from 35.8 ppm (in 11) to 57.7 ppm in 12, as well as C-7 seen to 49.0 ppm from 29.9 ppm, 
both shifts caused by the electron-withdrawing sulfoxide. Lastly, the HRMS data 
supported formation of 12, with the molecular parent ion (M+H)+ found at 397.0966; 
C19H25O3S3 requires 397.0960. Generally, the NMR spectra in this series were much easier 
to assign than in the ajoene series because of the absence of E/Z-geometrical isomers.  
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Figure 52: 1H-NMR spectrum of phenol-dihydroajoene, 12 
 
3.3.2.2 Synthesis of 13 and 14 
The last two compounds of the dihydroajoene compounds were accessed divergently via 
their phenol parent, 11, through first alkylation followed by oxidation to 14, Figure 53: 
 
 
 
Figure 53: Synthesis of amide-dihydroajoenes, 13 and 14 
 
For 13, sulfide 11, caesium carbonate (1.5 eq), 2-chloroacetamide (1.5 eq) and TBAI (0.1 
eq) were reacted in acetonitrile at room temperature for eighteen hours. Compared to 
the alkylation of the ajoene analogues 8 and 9 the dihydroajoene compound, 13, was 
obtained in a much higher yield of 77% as a more polar spot on TLC.  
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A singlet at 4.48 ppm in its 1H-NMR spectrum for the newly introduced amidomethylene 
group together with two broad non-equivalent (due to amide resonance) amide 
hydrogen singlets at 6.53 and 5.71 ppm indicated a successful alkylation. The 13C-NMR 
spectrum of 13 showed further evidence of the new functionality in form of a strongly 
deshielded carbonyl carbon at 171.1 ppm as well as a much less deshielded methylene 
carbon neighbour resonating at 67.5 ppm. The infrared spectrum showed characteristic 
amine N-H stretches and a carbonyl C=O stretch at 3160/3380 cm-1 and 1666 cm-1, 
respectively.  
 
The amide sulfoxide sulfide, 14, was obtained via the regioselective oxidation with  
m-CPBA in 72% yield, as previously described for 12.  
 
A diagnostic diastereotopic pair of AB doublets at 3.96 and 3.93 ppm in the 1H-NMR 
spectrum for H-6 proved that oxidation had taken place at the sulfide sulfur only, Figure 
54. Seventeen distinct carbon resonances were detected and accounted for. The 
successful synthesis of 14 was lastly confirmed via its HRMS data, where its parent ion 
(M+H)+ was found at 454.1187, C21H28NO4S3 requires 454.1186. 
 
 
 
Figure 54: 1H-NMR spectrum of amide-dihydroajoene, 14 
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3.4 Biological evaluation of bis-PMB analogues 
3.4.1 Anti-proliferative activity 
The synthesised library of bis-PMB and its 8 analogues were first tested for cytotoxicity 
against WHCO1 cancer cell proliferation using the MTT cell viability assay.104 This 
colorimetric assay quantitates viable cells by detecting residual reductase enzyme 
activity in the cells after treatment. The viable enzyme is able to convert yellow MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) to purple formazan. In 
brief, WHCO1 cells were treated in 96-well plates with varying concentrations of the 
ajoene analogue for 48 hours, the treated cells were then incubated with the MTT reagent 
for four hours after which the reaction was stopped by the addition of a denaturing 
solubilizing reagent. To show that the compounds do not directly disrupt the assay, a 
control included the incubation of compound and the MTT reagent without cells present. 
The resulting colour change (yellow to purple) is colorimetrically quantified using a 
multiwall scanning spectrophotometer, from which, a dose-response curve could be 
generated and an IC50 value determined. The IC50 is a quantitative measure of the 
concentration of drug found to inhibit the growth of 50% of the cells. Table 4 shows the 
IC50 values obtained for bis-PMB and its eight structural analogues. Each IC50 
determination represents an average of between three and five independent 
determinations. It can be seen that the standard deviations are small and that the data 
obtained from these experiments is reproducible. 
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Table 4: Activity of bis-PMB and its analogues against WHCO1 cell proliferation 
 
Name/# Structure 
 
WHCO1 
IC50  SD (M) 
n 
 
bis-PMB 
 
 
2.1  0.4 60 
 
 
 
 
7 
 
 
 
 
 
2.7  0.5 
 
 
5 
 
6 
 
 
 
0.5  0.3 
 
4 
 
12 
 
 
 
4.9  0.6 
 
4 
 
11 
 
 
 
14.3  3.1 
 
3 
 
 
9 
 
 
 
 
7.4  1.7 
 
 
5 
 
 
8 
 
 
 
8.6  4.2 
 
 
3 
 
 
14 
 
 
 
13.6  0.7 
 
 
3 
 
 
13 
 
 
 
23.2  0.9 
 
 
3 
n = number of independent repeats 
 
In previous work,66 the ajoene disulfide was identified as the pharmacophore. Its vinyl 
group was shown to enhance activity by labilising the disulfide and its removal in bis-
PMB dihydroajoene demonstrated an eightfold decrease in activity. The removal of the 
sulfoxide, in the presence of the vinyl group, was found to actually enhance activity 
threefold. However, the ajoene analogue that lacked the double bond and the sulfoxide 
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(sulfide dihydroajoene) remained inactive at a concentration of 200 µM (cut-off), which 
implied some synergism between the (two functionalities) sulfoxide and vinyl-disulfide.  
 
In this study, we found that our library of ajoene analogues all had comparable activity to 
the parent, bis-PMB regardless of whether a full vinyl-disulfide or sulfoxide group was 
present, with all compounds falling into the strongly active IC50 range of 0.5 – 23 µM. All 
compounds were found to be more active against WHCO1 cancer cells than the natural 
product ajoene (allyl parent: IC50 = 39.2 µM (E) and 25.2 µM (Z)).60 The phenol analogue 
6, lacking the sulfoxide, was the most active with an IC50 in the nanomolar range of 0.48 
µM, which was in agreement with our previous findings for the methoxy analogues (bis-
PMB series) where the sulfide vinyl-disulfide was found to be more active than the 
sulfoxide.66 The amide 8 did not however reflect this trend. Although the phenol 11 and 
amide 13 dihydroajoenes were the least active in their respective series, they are still 
considered to be strongly active, with IC50’s in the 15-25 M range, and show 
substantially higher activity compared to the previously inactive bis-PMB sulfide 
dihydroajoene (<200 M). Overall, the phenol-substituted analogues were 2-3 fold more 
active than their amide counterparts and of similar activity to the bis-PMB series 
(methoxy derivatives). 
 
The removal of the double bond resulted in a twofold drop of activity, when comparing 
the ajoene with its dihydroajoene (saturated vinyl disulfide) partner in both the phenol 
and amide series (7 versus 12 and 9 versus 14) although this was found to be more 
pronounced in the bis-PMB series (eightfold decrease). In support of a thiolysis 
mechanism, the double bonds stabilises the enethiolate anion leaving group through 
resonance delocalisation, which effectively drives the disulfide exchange as 
demonstrated in our recent publication.105 The loss of the double bond in the 
dihydroajoene series, lacking disulfide activation, may therefore explain the observed 
reduced cytotoxicity. When however comparing 12 and 14 to an analogous dialkyl 
disulfide such as dipropyldisulfide, it can be seen that the dihydroajoenes are still very 
active (4.9 and 13.6 µM, respectively, versus 50000 µM).105 The ten thousand-fold 
increase in activity implies a very important role for the sulfoxide/sulfide and the 
aromatic side groups. 
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In both the dihydroajoene series (11-14) removal of the sulfoxide in 11 and 13 caused 
an increase in activity (threefold phenol and twofold amide). This is in agreement with 
our group’s previous paper where it also found that the sulfoxide restored the activity of 
the methoxy dihydroajoene (sulphide version).66 The role of the sulfoxide moiety appears 
more subtle, though, where it may produce a long range inductive withdrawing effect 
through the molecule’s sigma framework to make the sulfur distal to the sulfoxide more 
electrophilic. The increased electrophilicity of the sulfur in the disulfide would be 
expected to promote thiolysis and thus effectively lower the IC50. However it must be 
stressed that the sulfoxide overall probably plays a minor role, as the presence of the 
disulfide alone (in the sulfide dihydroajoenes 11 and 13) yields analogues which are 
strongly active, and in some cases (phenol 6 and the bis-PMB analogue from previously 
published data66) the sulfide is the more active compound. The findings that the amide 
series is overall less active than the phenol and methoxy analogues may lend some 
support to our previous observations that increased lipophilicity may contribute to 
increased activity.  
 
In summary, the sulfoxide does not appear to play much of a role in enhancing the activity 
of the vinyl-disulfide series (and in some cases it is favourable to not have it at all), 
although it does increase the activity of the sulfide dihydroajoenes. This presumably 
occurs through an increase in the electrophilicity of the disulfide due to inductive 
electron-withdrawal via the σ-framework, which in turn enhances the leaving ability of 
the thiolate. It has been previously proposed that the sulfoxide may promote hydrogen 
bonding to adjacent amino acid residues in the cysteine peptide microenvironment.74 
However, this argument does not appear to apply here for the ajoene series. Importantly, 
however, in line with our previous findings on ajoene and its analogues, this study 
supports the disulfide being the pharmacophore, in which the double bond plays an 
activating role by stabilising the leaving group anion in thiolysis.  
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3.4.2 Stability studies of ajoene analogues in blood  
The series of ajoene analogues in this thesis were designed to probe structural features 
affecting the blood stability of the ajoene pharmacophore. The previous in vivo and in 
vitro blood stability experiments of the bis-PMB parent showed that it is not bioavailable 
in a mouse as no bis-PMB was detected in the blood even after 5 minutes following 
intravenous administration. It would appear that a specific erythrocyte (red blood cell) 
interaction is involved as the rapid disappearance of bis-PMB was only observed in vitro 
in whole blood and in the erythrocyte fraction but not in plasma. Owing to the high 
cytotoxicity of bis-PMB against cancer cell lines and in view of being an efficient S-
thiolating agent, we hypothesised that it may rapidly S-thiolate erythrocyte proteins or 
glutathione (GSH) thereby leading to its in vivo instability. In the current study we aimed 
to synthetically modify the bis-PMB pharmacophore in an attempt to lengthen its half-life 
in blood and therefore increase its bioavailability. 
 
The in vitro half-life experiments were performed by Dr Carmen de Kock in the 
Department of Pharmacology, UCT. Freshly collected mouse blood was incubated with 
the compounds at 37 °C for the indicated time points. The compound remaining was then 
quantified by liquid chromatography-mass spectrometry (LC-MS) as the peak area and 
compared to a calibration curve. The obtained results are preliminary as the experiment 
was only performed twice and the conditions were not yet optimised. Nevertheless, 
obvious trends are consistenly observed and are reported in this thesis. In corroboration 
with previous observations for the bis-PMB series, the stability trends of phenol 
analogues (R = OH) in mouse blood are shown in Figure 55: 
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Figure 55: in vitro blood stability of phenol bis-PMB analogues in mouse blood at 37 °C 
 
In agreement with previous findings for bis-PMB, it was not detected at the 20 minute 
time point following in vitro incubation in whole mouse blood. Similarly, the phenol 
sulfoxide vinyl-disulfide (purple in Figure 54), displayed a very similar profile to that of 
bis-PMB. This finding was not surprising as both contain the sulfoxide vinyl-disulfide 
backbone of bis-PMB. The sulfide vinyl-disulfide (red) was found to have slightly 
improved stability with detectability up to 60 minutes fitting in with our ideas of 
thiolation (sulfoxide enhancing the reactivity of the double bond). In comparison, the two 
phenol dihydroajoenes (green and blue) showed greatly improved stability with good 
detectability at the maximum time point (120 minutes), with the sulfoxide (blue) showing 
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the greatest stability of the series. It is immediately evident that the phenol 
dihydroajoenes (green and blue) have enhanced blood stability compared to the vinyl-
disulfides (black, red and purple). 
 
Similarly the stability trends of the amide bis-PMB (R = OCH2CONH2) series are shown in 
Figure 56: 
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Figure 56: in vitro blood stability of amide bis-PMB analogues in mouse blood at 37 °C 
 
Here, comparable trends were observed. The dihydroajoenes (green and blue) were 
detectable for significantly longer time periods compared to the vinyl-disulfides (red and 
purple). Interestingly, approximately 20% of both amide vinyl-disulfides (red and 
purple) were still detectable at 20 minutes post-incubation, compared to 0% at the same 
time point for the phenol vinyl-disulfides as well as bis-PMB. As expected intuitively, 
stability and cytotoxicity were found to be inversely related, i.e. the less cytotoxic (higher 
IC50) the greater the stability. Interestingly, in the dihydroajoene series, the sulfide 
(green) was retained in blood the longest with 50% remaining after 120 minutes, 
compared to the sulfoxide (blue) – this was the reverse of the trend for the phenol series. 
 
A striking trend in the blood stability SAR data is that the four dihydroajoenes 
synthesised were found to have acceptable retention (stability) in whole blood at 40 
minutes (green and blue), whereas their respective vinyl-disulfide analogues were far 
less stable being either undetectable (phenol) or weakly detectable (amides) at 20 
minutes. These data further support that the vinyl-disulfide in ajoene enhances its 
reactivity in a biological context by causing cancer cell cytotoxicity and poor in vitro 
blood-stability.  The role of the sulfoxide in blood stability is not so clear although its 
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presence appears to enhance blood instability in most cases. It is evident though, that the 
sulfoxide does not play as much of a modulating role as the presence of the vinyl group, 
where in both series the dihydroajoenes were found to be significantly more stable than 
their respective vinyl-disulfide counterparts.  
 
The correlation between WHCO1 cytotoxicity and blood-instability fits with our ideas on 
thiolysis exchange as being the cause, in which the more activated disulfide (i.e. vinyl 
disulfide) promotes the exchange reaction. 
 
3.4.3 Ajoene metabolism within blood 
It is well established that garlic compounds are toxic to erythrocytes and furthermore we 
found that the ajoene analogue bis-PMB is only unstable in whole blood and not in plasma. 
It would therefore appear that ajoene is either S-thiolating GSH or targeting a thiol group 
on an erythrocyte protein. Owing to the darkening of the blood and the difficulty in 
breathing in the treated mice, we hypothesised that ajoene may be interacting the 
oxygen-carrying protein, haemoglobin (Hb).  
 
It is well known in the literature that garlic and onions are toxic to farm animals causing 
haemolytic anaemia.34,106 It has also been shown that allicin is able to rapidly enter 
erythrocytes to spontaneously react with GSH which decreases the cells ability to 
counteract the production of ROS.67 Haemolytic anaemia is characterised by the 
production of Heinz bodies in erythrocytes which follows from the oxidative degradation 
of Hb.107 Munday et al. offered a mechanism for the oxidative degradation of Hb by garlic 
disulfides which is shown below (Figure 57). Here a one-electron oxidation of a thiolate 
(R-S-) at the iron(II) centre of haemoglobin is proposed to generate H2O2 (a ROS), Met-
haemoglobin (MetHb – iron(III)) and a thiyl radical. The resulting formation of oxidative 
species (H2O2 and thiyl radicals) then leads to depletion of GSH which may lead to 
oxidative damage of Hb and possible formation of Heinz bodies. 
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Figure 57: Mechanism whereby an eliminated thiolate is oxidised at the iron(II) centre of Hb to 
form ROS and MetHb34 
 
If Munday’s hypothesis holds true, a direct interaction between ajoene and the 
metalloporphryrin (heme) rings in Hb would reveal a change in the redox state of iron 
centre, as Hb is oxidised to MetHb. In UV-Vis experiments this oxidation (from iron(II) to 
iron(III)) results in a characteristic flattening of two diagnostic absorption bands for the 
heme-iron centre at 541 (β-band) and 577 nm (α-band).108 Figure 58 shows the shift in 
the spectra that would be expected if Hb were oxidised to MetHb.109 
 
 
 
Figure 58: Disappearing α- and β- bands of metalloporphyrin absorption in Hb upon oxidation 
of the iron(II) centre (HbMetHb)109 
 
Hence, to test if ajoene directly interacts with the Hb iron centre and as a result forms 
MetHb, we performed a spectrophotometric analysis by titrating mouse blood with  
Z-ajoene up to 200 µM. The resulting overlaid UV-Vis spectra can be seen in Figure 59: 
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Figure 59: UV-Vis spectra of haemoglobin titrated against bis-PMB  
 
No disappearance of the α- and β-bands (at 577 and 541 nm respectively) was observed 
(red arrow in Figure 59) and this implies that bis-PMB is not oxidising the Hb iron centre 
at the concentrations used in the experiments. Although ajoene did not cause oxidation 
at the iron(II) centre, the spectrum did however show a distinct red shift in the protein 
absorption region (blue arrow in Figure 59). This change in the 250 nm absorption 
region is the protein region of the spectrum and could imply interaction with the protein 
or the formation of a new chemical species. To investigate whether ajoene covalently 
modifies the Hb protein, a proteomics study was conducted.  
 
3.4.4 Proteomic study of ajoene-Hb interactions 
In the first step of the proteomic assay (Step i in Figure 60, two samples of purified 
human haemoglobin protein were prepared by incubation without (control) or with 100 
µM Z-ajoene and sent for proteomics analysis at the Centre for Proteomics and Genomics 
Research (CPGR), Cape Town, South Africa.  
 
 
 
Figure 60: Workflow of sample preparation for proteomic analysis 
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The proteomic analysis is a sensitive analytical technique that allows for the detection of 
modifications on proteins by comparing the mass change of peptide fragments in treated 
and untreated samples. The Cys (C) β-93 residue of the haemoglobin β-subunit has been 
previously identified to be particularly sensitive to oxidation and S-glutathionylation.110 
We wondered whether ajoene, by mimicking GSH/GSSG, may also S-thiolate Hb at this 
cysteine residue. The Cys β-93-containing peptide fragment (GTFATLSELHCDK) was 
obtained by overnight trypsin digestion of the two Hb samples (Step ii in Figure 60). The 
protease, trypsin, site-specifically hydrolyses protein amide bonds at the carboxylic ends 
of lysine (K) and arginine (except if followed by proline) to afford tryptic peptide 
fragments, as shown in Figure 61: 
 
 
 
Figure 61: Site-specific digestion of human haemoglobin β-subunit by trypsin to obtain the Cys β-
93-containing tryptic fragment (GTFATLSELHCDK) 
 
The resulting trypsin-digested samples were run through an LC-ESI-MS system to obtain 
a “three-dimensional” spectrum in which each LC elution time point provided a 
corresponding mass spectrum (Step iii in Figure 60). 
 
According to the Expasy peptide prediction software, the predicted mass to charge ratio 
(m/z) of the haemoglobin fragment containing Cys -93 (GTFATLSELHCDK) was 
1421.6729 for the [M+H]+ ion and 711.3401 for the [M+2H]2+ ion. This fragment was 
detected in both ionic forms as shown in Figure 62: 
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Figure 62: Mass spectra of untreated and Z-ajoene-treated Hb samples. A showing the [M+H]+ 
and B showing the [M+2H]2+ 
 
Both spectra show two distinct differences (highlighted in red). The top spectra of the 
control samples (A and B) shows the expected ion peaks of the GTFATLSELHCDK 
fragment. The treated spectra on the other hand were found to lack the ion peaks at 
1421.67620 (in A) and at 711.34132 (in B), but shows a new peaks at m/z = 1493.67863 
and at m/z = 747.34368, in A and B respectively. If ajoene successfully  
S-thiolated the Cys β-93 residue on GTFATLSELHCDK, the treated fragment mass 
increase would equal that of the added S-allyl group (based on regioselectivity). One must 
take into consideration that the fragment (-SH) loses one proton upon adduct formation 
(-S-S-). The calculations of the exact mass differences between the treated and untreated 
fragments for both the [M+H]+ and [M+2H]2+ ions are as follows: 
 
 
For [M+H]+: 𝑀𝑎𝑠𝑠[𝑎𝑑𝑑𝑢𝑐𝑡] = 𝑀𝑎𝑠𝑠[𝑓𝑟𝑎𝑔𝑚𝑒𝑛𝑡(−𝑆𝐻) − 𝐻+] + 𝑀𝑎𝑠𝑠[𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒] 
𝑀𝑎𝑠𝑠[𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒] = 𝑀𝑎𝑠𝑠[𝑎𝑑𝑑𝑢𝑐𝑡] − 𝑀𝑎𝑠𝑠[𝑓𝑟𝑎𝑔𝑚𝑒𝑛𝑡(−𝑆𝐻) − 𝐻+] 
𝑀𝑎𝑠𝑠[𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒] = 1493.67863 − (1421.67620 − 1.0078) 
𝑀𝑎𝑠𝑠[𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒] = 𝑀𝑎𝑠𝑠[𝑎𝑑𝑑𝑢𝑐𝑡] − 𝑀𝑎𝑠𝑠[𝑓𝑟𝑎𝑔𝑒𝑚𝑒𝑛𝑡(−𝑆−)] 
𝑀𝑎𝑠𝑠[𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒] = 1493.67863 − 1420.6684 = 𝟕𝟑. 𝟎𝟏𝟎𝟐𝟑 
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For [M+2H]+2:  𝑀𝑎𝑠𝑠[𝑎𝑑𝑑𝑢𝑐𝑡] = 𝑀𝑎𝑠𝑠[𝑓𝑟𝑎𝑔𝑚𝑒𝑛𝑡(−𝑆𝐻) − 𝐻+] + 𝑀𝑎𝑠𝑠[𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒] 
𝑤ℎ𝑒𝑟𝑒 𝑀𝑎𝑠𝑠[𝑋] = (𝑝𝑒𝑎𝑘 ×  2) − 2𝐻 
∴ 𝑀𝑎𝑠𝑠[𝑎𝑑𝑑𝑢𝑐𝑡] = (747.34462 ×  2) − 2 × 1.0078 = 1492.67364  
∴ 𝑀𝑎𝑠𝑠[𝑓𝑟𝑎𝑔𝑚𝑒𝑛𝑡(−𝑆−)] = ((711.34132 × 2) − 2 × 1.0078) − 1.0078 = 1419.65924 
∴ 𝑀𝑎𝑠𝑠[𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒] = 𝑀𝑎𝑠𝑠[𝑎𝑑𝑑𝑢𝑐𝑡] − 𝑀𝑎𝑠𝑠[𝑓𝑟𝑎𝑔𝑒𝑚𝑒𝑛𝑡(−𝑆−)] 
𝑀𝑎𝑠𝑠[𝑑𝑖𝑓𝑓𝑒𝑟𝑒𝑛𝑐𝑒] = 1492.67364 − 1419.65924 = 𝟕𝟑. 𝟎𝟏𝟒𝟒𝟎 
 
Table 5 lists the m/z ratios of the predicted and observed ions together with the 
calculated mass differences: 
 
Table 5: Mass/charge ratio of Cys β-93-containing ions and their respective calculated mass 
difference  
  Fragment 
(GTFATLSELHCDK) 
Adduct 
(GTFATLSELHCDK-
S-S-allyl) 
Difference in 
mass 
(-S-allyl) 
predicted [M+H]+ (A) 1421.67290 1493.67632 73.01174 
 [M+2H]2+ (B) 711.34010 747.34257 73.01174 
actual [M+H]+ (A) 1421.67620 1493.67863 73.01023 
 [M+2H]2+ (B) 711.34132 747.34462 73.01440 
 
It was pleasing to see, that the mass difference between the treated and untreated 
fragments for the [M+H]+ and [M+2H]2+ ion corresponded to 73.01023 and 73.01440 Da, 
respectively, In both cases, these masses corresponded to the predicted mass of one S-
allyl- group (73.01174 Da) to two decimal points accuracy. This is highly convincing data 
that Z-ajoene regioselectively S-thiolates Hb at its Cys β-93. 
 
In support of our findings, a study by Beuzard et al. showed that thiol reagents, unrelated 
to alliums, interact directly with Cys β-93.111,112 It was later demonstrated that Cys β-93 
is also targeted by glutathione via S-glutathionylation. The resulting GSS-Hb adduct has 
further been shown to cause a structural change in the protein thereby leading to 
increased affinity for oxygen, termed the alkaline Bohr effect.113,114 Together, the reports 
on garlic induced haemolytic anaemia as well as the alkaline Bohr Effect support a likely 
direct interaction in vivo between Hb and the garlic compound.  
 
These findings provide new evidence into the mechanism of erythrocyte toxicity of garlic 
compounds. It is highly likely that a combination of both GSH and Hb thiolysis may lead 
to the observed oxidative stress and toxic effects (Figure 63). Haemoglobin is the most 
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abundant protein in erythrocytes, and therefore S-thiolation of Hb would lead to an 
effective trapping of ajoene in the erythrocyte, where the expelled enethiolate leaving 
group may lead to further downstream events. These aspects as well as ajoene’s role as a 
glutathione mimic will need to be investigated in the future. 
 
 
 
Figure 63: Proposed governing principle of ajoene cytotoxicity and blood instability 
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3.5 Summary and Outlook 
In this chapter, two divergent synthetic routes were used to produce a small library of 
eight bis-PMB ajoenes with enhanced solubility and variations in the reactivity 
modulating backbone. The previously developed UCT ajoene synthesis allowed access to 
the vinyl-disulfide series (6-9), in which the key S-thiolation step between the vinyl 
thioacetate 2 and the phenolic sulfenylating agent 5 integrated the pharmacophore and 
the handle for polar modifications into the molecule. Synthesis in the dihydroajoene 
series (10-14) also utilised the modified sulfenylating agent and was accomplished via 
the dialkylation of 1,3-propanedithiol. The amide derivatives of both series were 
accessible through alkylation at the phenol moiety.  
 
The subsequent structure-activity relationship study of the analogues demonstrated that 
the more cytotoxic molecules showed decreased blood stability, where it is proposed that 
the observed cytotoxicity and blood instability is directly correlated to ajoene’s 
susceptibility towards thiolysis exchange (better leaving group), which is in agreement 
with our group’s previous findings on garlic-related disulfides. The double bond of the 
vinyl-disulfide group showed to have the most pronounced effect as it greatly increased 
the stability of the resulting leaving group (enethiolate), and hence the dihydroajoenes 
which lack the double bond showed greatly enhanced in vitro blood stability. The 
presence of the sulfoxide group enhanced the activity of the dihydroajoenes, but 
decreased activity in the vinyl-disulfides which implies a long-range inductive electron-
withdrawing effect on the disulfide through the σ-framework of the molecule. The phenol 
and methoxy functionalities had similar effects on cytotoxicity, whereas the amide 
functionality decreased cytotoxicity but enhanced blood stability.  
 
A striking and important observation from this study is that although an inverse 
relationship between cancer cell cytotoxicity and blood stability is observed, it is 
weighted. Although the dihydroajoenes are slightly less cytotoxic than their vinyl-
disulfide counterparts, they are still strongly active with an IC50 of 20 µM. Their 
improvement on blood stability is, however, very acceptable which has increased to 
around 50% remaining at 120 minutes. These findings provide a good lead for future 
therapeutic development of the dihydroajoenes. 
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Furthermore, it was demonstrated that Z-ajoene interacts with Cys β-93 of Hb by both 
proteomics and UV-Vis spectroscopy which provides a possible explanation for the blood 
instability and known cytotoxicity to erythrocytes.  
 
We have previously found that the cytotoxicity of disulfides in cancer cells originates in 
the S-thiolation of protein targets. Strategies to identify these targets will be addressed 
in the upcoming chapter.  
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Chapter Four: Synthesis of a Biotin-labelled Ajoene Probe 
 
4.1 Introduction 
Our group’s recent work on the cytotoxicity mode of action of ajoene in killing cancer cells 
in vitro used laser microscopy to track the movement of a fluorescent dansyl-tagged 
ajoene analogue inside a live cancer cell (MDA breast) (Page 23).115 The study revealed 
that accumulation of the tagged ajoene occurs in the Endoplasmic Reticulum (ER), and a 
western blot of the lysate revealed that many proteins are the S-thiolation targets of 
ajoene. The literature demonstrated that the S-thiolation of proteins using biotinylated 
GSSG116 and isothiocyanates117 had shown to successfully label and identify reactive 
cysteine residues on cellular targets. Based on their mode of action (thiolysis), it is 
expected that ajoene’s targets will overlap with those of GSSG and isothiocyanates. These 
results and analogous studies supported our undertakings to identify the protein targets 
of ajoene in cancer cells using the technique of biotinylation. This required the need to 
synthesise a biotinylated ajoene analogue, which on S-thiolation would result in the 
transfer of the biotin tag to the target. Subsequent isolation of the relevant proteins was 
then envisaged through the use of biotin’s affinity for streptavidin beads, with subsequent 
protein identification by MALDI-TOF mass spectrometry analysis.  
 
4.2 Probe design 
The probe design was based on an important reactivity principle in context established 
in our work,95 which had shown that the site of disulfide exchange in the S-thiolation 
process is at the non-vinyl sulfur of the ajoene disulfide pharmacophore as illustrated in 
Figure 64: 
 
 
 
Figure 64: Regioselectivity of protein S-thiolation by ajoene 
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Therefore a crucial design element as it indicated that the biotin tag needed to be attached 
to the non-vinyl sulfur. Applying this design principle resulted in the structure (on paper) 
of our first prototype, which is shown in Figure 65: 
 
 
 
Figure 65: Envisioned biotinylated ajoene analogue design, highlighting key synthetic aspects 
 
Previous synthetic endeavours directed towards the synthesis of the first prototype by 
Pike indicated that the biotin tag might be too close in proximity to the ajoene 
pharmacophore warhead,118 so a second prototype was designed whose synthesis is 
described in this thesis. This second-generation target probe was designed based on the 
work of Jezowska et al., on the biotinylation of peptides and oligonucleotides98, and its 
structure is shown in Figure 66 together with a convergent retrosynthesis (in red and 
blue) that was translated into a successful synthesis: 
 
 
 
Figure 66: Second-generation biotinylated ajoene probe with its retrosynthesis 
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Hence, the synthesis involved bringing together two separately synthesised pieces, 19 
and 25, using “Click”-technology, in which the two “Click”-synthons were generated from 
a combination of amide couplings and substitution chemistry. A crucial advance from the 
first prototype synthesis was the finding that a much cleaner amide coupling for 
incorporation of the biotin fragment could be achieved using the N-hydroxysuccinimidyl 
biotin ester as coupling partner, which could be readily prepared from the commercially 
available biotin acid using a conventional DCC coupling with N-hydroxysuccinimide 
(NHS). With these insights the synthesis of fragments 19 and 25 could proceed and these 
are now discussed. 
 
4.3 Synthesis of the “Click”-partners 
4.3.1 Synthesis of azide-ajoene, 19 
The retrosynthesis plan for 19 is shown in Figure 67:  
 
 
 
Figure 67: Retrosynthesis of fragment 19 
 
The established UCT synthesis was well suited for obtaining the azide-ajoene fragment, 
19, using azido thiotosylate 17 as the sulfenylating agent, whose synthesis is given in 
Figure 68: 
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Figure 68: Synthesis of azide sulfenylating agent 17 
 
The synthesis of sulfenylating agent 17 conveniently started from the previously 
described iodide 4. In the first step 4 was subjected to an SN2 substitution with sodium 
azide (1.5 eq) in DMF at 100 °C behind a blast shield. The reaction was left to proceed 
over three hours after which TLC indicated the formation of a closely running but distinct 
product. A conventional isolation and chromatography gave 15 as a clear-yellow oil in 
96% yield. 
 
The infrared spectrum of 15 showed a characteristic N=N stretching frequency of the 
azide at 2092 cm-1. The azido methylene protons in the 1H-NMR spectrum revealed the 
anticipated deshielding compared to the signal in the iodide 4, together with a downfield 
shift in the 13C-NMR spectrum from 6.4 ppm in 4 to 52.8 ppm in 15 due to the electron-
withdrawing character of the azido group. Finally, a downfield broad singlet for the 
phenolic proton could also be discerned in the 1H-NMR spectrum.  
 
Incorporation of the bromopropyl side chain made use of a second SN2 reaction by slowly 
adding 15 to a stirring solution of an excess of 1,3-dibromopropane (3 eq) to minimise 
disubstitution, together with caesium carbonate (1.1 eq) as base. The reaction was held 
at 50 °C for six hours to achieve completion. Any remaining base was quenched by 
aqueous ammonium chloride in the work-up, and the bromide, 16, was obtained by silica 
column chromatography in 68% yield.  
 
An important observation in regard to higher reaction temperatures and/or higher 
concentrations of base was made. During chromatography one could observe a faint spot 
that ran very close in Rf to that of the product by TLC and which also showed up as an 
impurity in the NMR spectra of the product. The spot was isolated via a slow silica gel 
column, and the 1H-NMR spectrum revealed it to be the allyl ether as shown in Figure 69, 
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presumably derived via an E2 elimination of HBr in keeping with the high temperature  
(-TΔS as a driver to the ΔG). 
 
 
 
Figure 69: Observed elimination reaction on 16 
 
 
 
Figure 70: 1H-NMR of 16 (blue), its elimination by-product (green) and mixture (red) 
 
The 1H-NMR spectrum (Figure 70) in blue shows the desired ether product, while the 
spectrum in green shows the elimination product, in which the downfield allyl triad can 
be clearly discerned. Finally, the spectrum in red reflects a mixture as isolated from an 
initial purification attempt. An IR spectrum run on pure 16 indicated successful ether 
formation by showing the azide N=N stretching peak at 2091 cm-1 and the disappearance 
of the aromatic O-H stretch, which was observed in compounds 2 and 15 at ~3200 cm-1. 
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For the final step towards obtaining the sulfenylating agent 17, bromide 16 underwent a 
third SN2 reaction, using potassium p-toluenethiosulfonate (potassium thiotosylate; 2 eq) 
as nucleophile by heating the mixture (60 °C) in acetonitrile for eighteen hours to achieve 
a full conversion of starting material by TLC. The reaction proved to be low yielding 
(38%) though, and showed a variety of side products on TLC.  
 
All 14 resonances of the 18 carbon atoms (symmetry) in the molecule were accounted for 
in the 13C-NMR spectrum of 17. The 1H-NMR spectrum of 17 is shown in Figure 71, 
which, compared to 16, showed an additional set of deshielded AA’BB’ doublet of 
doublets at 7.82 ppm (H-2’’) and 7.12 ppm (H-3’’) as well as a new methyl (H-5’’) singlet 
at 2.44 ppm, all consistent with the introduction of the thiotosylate group. The IR 
spectrum showed the retention of the azide functionality by virtue of an azide N=N 
stretch at 2090 cm-1. Lastly, the high-resolution mass spectrometry (HRMS) data showed 
a correct molecular mass as an M+H peak: (ES) m/z: Found 392.1103, C18H22O3N3S2 
(M+H)+  requires 392.1108, which confirmed product formation. 
 
 
 
Figure 71: 1H-NMR spectrum of azide sulfenylating agent, 17 
 
With the sulfenylating agent 17 in hand the coupling to vinyl thioacetate 5 previously 
described (Page 17) proceeded according to the previously established methodology to 
give vinyl-disulfide 18, shown in Figure 72: 
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Figure 72: Synthesis of 18 
 
Here, the low temperature base hydrolysis of 2 afforded the enethiolate in situ which was 
subsequently sulfenylated by 17 to afford 18. Purification via silica gel column 
chromatography gave the vinyl-disulfide 18 in 85% yield as a 2:3 mixture of E/Z-isomers. 
 
Proof of retention of the vinylthio moiety in the product was given by the presence of four 
vinyl signals in the 1H-NMR spectrum of 18 for the two vinyl hydrogens of each 
geometrical isomer, as seen in Figure 73. These provided the characteristic pattern going 
from lowfield to highfield of Z, E, E, Z, here at 6.25 ppm (H-9Z), 6.09 ppm (H-9E), 5.89 
ppm (H-8E) and 5.71 ppm (H-8Z) respectively, in which typical coupling constants could 
be discerned of ~15 Hz for trans and ~10 Hz for cis. The propyl tether featured as three 
separate signals at 2.91 ppm (H-10), 2.91 ppm (H-11) and 4.07-.4.02 ppm (H-12), 
integrating for 2:2:2 protons respectively. Collectively the analysis of 13C-NMR and HSQC 
data identified all 18 carbon resonances of which some showed a splitting due to their 
proximity to the stereogenic axis. The infrared spectrum of 18 showed the presence of 
the azide moiety in the product through an N=N stretch at 2086 cm-1. Conclusive evidence 
of success was given by the HRMS, where the molecular ion (M+H)+ was found at 
462.1344, in which C22H28N3O2S3 requires 462.1349. 
 
 
 
Figure 73: 1H-NMR spectrum of 18 
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The final step towards obtaining the ajoene analogue involved the chemoselective 
oxidation of the sulfide 18 to its sulfoxide 19 using m-CPBA as an oxidant at low 
temperature (-78 °C). Analogous to previously described oxidations (towards 7,9,12 and 
14), the reaction proceeded over one hour and the product was observed as a more polar 
spot on TLC. Subsequent chromatographic purification afforded the azide-ajoene 
analogue 19 as a 2:3 mixture of E/Z-isomers, in 62% yield. 
In its role as an advanced intermediate, the microanalysis of 19 was diligently performed. 
The newly formed chiral sulfoxide resulted in diastereotopicity in the adjacent (vicinal) 
methylene hydrogens that was observed in the geminal couplings of H-6 and H-7. All 14 
proton signals and 18 carbon signals were successfully assigned via 1H-NMR, COSY, 13C-
NMR and HSQC spectra are shown in Figures 74 and 75, with nuclei distal to the 
stereogenic double bond axis, as with previous ajoene derivatives, showing up as a single 
resonance. 
 
 
 
Figure 74: 1H-NMR spectrum of azide-ajoene,19 
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Figure 75: 13C-NMR spectrum of azide-ajoene, 19 
 
The S=O stretch at 1031 cm-1 and the N=N stretch at 2094 cm-1 in the IR spectrum 
highlighted the formation of the sulfoxide and the retention of the crucial azide moiety 
respectively. Lastly, the HRMS data, displayed in Figure 76, revealed the correct 
molecular ion (M+H)+ at 478.1303, where C22H28N3O3S3 requires 478.1293, thus 
consolidating a successful formation of 19. 
 
 
 
Figure 76: High-resolution mass spectrum of 19 
 
With the successful synthesis azide-ajoene coupling partner completed, the following 
section will describe the route towards the alkyne-biotin “Click”-coupling partner, 25. 
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4.3.2 Synthesis of alkyne-biotin linker, 25 
The retrosynthesis plan for 25 is shown in Figure 77. The key design element was to 
insert a water-soluble tether between the biotin tag and the alkyne functionality for 
“Click” coupling to the ajoene pharmacophore. The cheaply available diamine tether was 
suitable in that it could be mono-protected, coupled to the alkyne source 21, deprotected 
and then coupled with the biotin tag in the last step. Due to its polar nature biotin is 
notoriously difficult to work and was thus placed at the end of the sequence. 
 
 
 
Figure 77: Retrosynthesis of fragment 25 
 
 
Figure 78: Synthesis of 20 
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The synthesis of the alkyne fragment proceeded via the mono-Boc-protection of 
commercially available 4,7,10-trioxatridecane-1,13-diamine. To this end, the diamine 
(1.5 eq) and Boc anhydride (1 eq) were reacted in DCM at room temperature, as 
presented in Figure 78. The appearance of an additional spot above the suspected mono-
substituted product run on TLC at two hours, as seen in Figure 79, led to the termination 
of the reaction. Subsequent purification of the “middle” spot gave the mono-Boc-
protected diamine linker 20 in 46% yield. Due to the affordability of the starting material 
we could get away with this low yield, but future optimisations would include increasing 
its equivalence to three or more to reduce di-substitution.  
 
 
 
Figure 79: TLC reaction profile of the protection of the diamine 
 
The integration ratio of 9:2 between the tert-butyl and deshielded α-methylene quartet 
to the carbamate in the 1H-NMR spectrum suggested the successful mono-substitution in 
the product. Further evidence was given in the 13C-NMR spectrum in terms of the 
observation of a single carbamate carbonyl carbon signal as well as a quaternary carbon 
for the tert-butyl moiety at 156.2 and 77.9 ppm, respectively. 
 
 
 
Figure 80: Synthesis of 21 
 
The crucial choice of alkyne source was made according to the strategy used by Jezowska 
previously referred to.98 Here, propiolic acid was used, not only because of its 
commercially availability but also because it provided a more reactive alkynyl partner for 
the “Click”-coupling.119 In addition, rather than couple propiolic acid directly to the amino 
group of mono-boc protected tether 20, in keeping with the strategy of Jezowska, it was 
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decided to use a commercially available amino acid bifunctional synthon as a secondary 
tether. To this end a standard DCC/BtOH coupling of the propiolic acid and the benzylic 
amino group of the bifunctional tether proceeded to completion over two hours to afford 
21 (Figure 80) in 35% yield, following a Celite filtration to remove the DCU by-product 
and followed by silica gel chromatography. The low yield of 21 could be attributed to di-
/poly-merisations reactions occurring on reduced chemoselective grounds (two acids in 
reactants). 
 
An alkyne singlet at 3.60 ppm and the benzylic methylene singlet at 4.46 ppm in the 1H-
NMR spectrum of 21 indicated a successful addition. The 13C-NMR spectrum revealed five 
quaternary carbon signals at 169.7, 154.8, 144.5/131.2, and 78.0 ppm which, in order, 
represented the carboxylic and amide carbonyls, the ring’s ipso and para positions, and 
the alkyne internal carbon.  
 
 
 
Figure 81: Synthesis of 22 
 
20 and 21 were also conveniently coupled using DCC/BtOH, as depicted in Figure 81, to 
afford 22 in 84% yield after purification via silica gel column chromatography.  
 
The diagnostic alkyne and tert-butyl singlets respectively at 3.64 ppm and 1.42 ppm, with 
an integration ratio of 1:9, in the 1H-NMR spectrum signified a positive result. The 
analysis of the 13C-NMR spectrum revealed all 22 distinct carbon signal and the HRMS 
data showed the (M+H)+ molecular at 506.2866, while C26H40N3O7 required 506.2872, 
which together combined to give full confidence in the formation of 22. 
 
The subsequent low temperature (0 °C) Boc deprotection using TFA (10 eq) in DCM was 
carefully monitored via TLC. The consumption of 22 resulted in the appearance of a more 
polar spot that could be visualised with ninhydrin spray. At the three hour mark, the 
reaction mixture was concentrated under low-pressure to remove solvent and excess 
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TFA. Silica column chromatographic purification using MeOH:DCM (1:9) as eluent 
afforded the free base 23 in 88% yield by an unknown deprotonation mechanism. 
 
The loss of the protecting group was supported by the absence of both the Boc tert-butyl 
singlet in the 1H-NMR spectrum of 23 (Figure 82) as well as the t-butyl quaternary 
carbon signal in the 13C-NMR spectrum. The alkyne terminal hydrogen (singlet) could not 
be discerned as it was masked by the six methylene signals adjacent to the ether oxygen 
atoms in the linker chain; nevertheless, the integration of the peak as 13H (6x 2 
methylene + 1 alkyne protons) suggested its presence around 3.50 ppm. Additionally, the 
13C-NMR spectrum correctly showed all 19 carbon signals for 23. Lastly, the molecular 
ion (M+H)+ of 406.2342 in the HRMS spectrum, for which C21H32N3O5 required 406.2347, 
ratified our success.  
 
 
 
Figure 82: 1H-NMR spectrum of 23 
 
The final part of the synthesis to obtain “Click”-coupling partner 25 is shown in Figure 
83: 
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Figure 83: Synthesis of alkyne-biotin linker, 25 
 
Initially, incorporation of the biotin moiety was envisioned as proceeding via a 
carbodiimde coupling between biotin and the amine partner but this was unsuccessful. A 
more extensive literature search then highlighted the use of biotin-N-
hydroxysuccinimide ester as electrophilic partner in amide couplings and this proved to 
be very efficient.120 
 
Hence, the required succinimide ester 24 was produced by reacting biotin with NHS (1.2 
eq), DCC (1.2 eq) and DMAP (0.2 eq) in DMF at 0 °C for 24 hours. The resulting reaction 
mixture was filtered through Celite (removal of DCU), then gently heated under reduced 
pressure to remove the bulk of DMF and lastly triturated with diethyl ether to afford 24 
as a solid in 65% yield. 
 
The broad singlet integrating for four protons at 2.81 ppm representing the two NHS 
methylene proton signals in the 1H-NMR spectrum and a melting point of 205-208 °C, 
where literature reported 206-207 °C,120 was taken as sufficient evidence to continue on 
to the next step. 
 
The final target 25 was reached when the amine 23 and the NHS-ester 24 were combined 
in DMF at -78 °C using DIPEA as a base. The full consumption of 23, after two hours, gave 
a new UV-active less polar spot on TLC. After careful removal of DMF, the remaining 
residue was lyophilised and purified by silica gel column chromatography to afford 25 in 
57% yield.  
 
As before with 19, this advanced intermediate was meticulously characterised by  
1H-NMR, 13C-NMR, HSQC, IR and HRMS data. In addition to the previously described 
signals of 23 the spectrum featured biotin signals. The 1H-NMR spectrum (Figure 84) 
showed biotin’s characteristic cis ring junction protons (H-26 and H-27) with a vicinal 
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coupling constant of 7.9 Hz at 4.50 and 4.31 ppm, respectively. H-28 showed the strong 
diastereotopic splitting with a germinal J-value of 12.8 Hz, at 2.94 and 2.72 ppm for H-
28a and H-28b. The highfield region of the spectrum contains the protons of the valeric 
acid chain (H-21 to H-24), where the proximity to the chiral H-25, increased observed 
diastereotopic splitting. The 13C-NMR spectrum showed 29 distinct carbon signals, of 
which the strongly deshielded ureido carbonyl (C-29) at 175.9 ppm and an additional 
amide carbonyl (C-20) at 169.7 ppm implied successful coupling to biotin. Figure 85 
shows the molecular ion (M+H)+ at 632.3143 (M+H)+ in the HRMS spectrum, where 
C31H46N5O7S requires 632.3113, to give conclusive evidence for the formation of 23. 
 
 
Figure 84: 1H-NMR spectrum of 25 
 
 
 
Figure 85: HRMS spectrum of 25 
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4.4 “Click”-coupling of fragments 19 and 25 
The use of benign “Click”-technology in aqueous medium as the last step had sidestepped 
potential synthetic problems. Namely, chemoselectivity during sulfoxide oxidation 
(additional sulfide on biotin), difficulties in working with polar biotin and suspected 
sulfide/vinyl-disulfide reactivity between biotin and ajoene. Furthermore this 
methodology would enable to pre-treatment of cell lines with azide-ajoene 19 and then 
performing the “Click” on cell lysate with the biotin-alkyne 25 afterwards, as to counter 
the probe’s potential in vivo size limitations. Figure 86 shows the synthetic route to 
afford the probe 26: 
 
 
 
Figure 86: Synthesis of biotin-ajoene, 26 
 
To a stirring aqueous solution of CuSO4 and sodium ascorbate the azide 19 and alkyne 
25, both in DMF, were added and heated to 30 °C. The reaction was left to proceed 
overnight and resulted in the formation of a white precipitate. The solvents were 
removed via lyophilisation and the resulting residue was subject to silica gel column 
chromatography to afford the biotin-ajoene 26 as a 7:10 mixture of E/Z-isomer in 56% 
yield.  
 
 81  
 
The probe was found to be insoluble in most conventional NMR solvents and had shown 
a high degree of instability in d6-DMSO, the 1H-NMR spectrum was thus run in 1:9 
MeOD:CDCl3 to mimic the solvent system that had been used in the column (1:9 
MeOH:DCM). The resulting 1H-NMR spectrum, shown in Figure 87, showed 
corresponding peaks attributed to both coupling partners, 19 and 25. The correct 
integration ratio of all six aromatic doublets (2:2:2:2:2:2) gave the first indication of a 
successful reaction. The retention of the pharmacophore was seen as four vinylic signals 
characteristic of ajoene at 6.51, 6.29, 5.82 and 5.66 ppm which presented themselves in 
the usual Z-E-E-Z splitting pattern for H-9Z, H-9E, H-8E, and H-8Z, respectively. They 
showed J-values of 14.7 (trans) and 9.5 Hz (cis) for the E- and Z-isomer and their relative 
ratio of 7:10 (E:Z), compared to 2:3 in 19, suggest that no isomerisation had occurred. 
The signals 4.37 and 4.17 ppm represent the two vicinal protons (H-45 and H-44) at the 
ring junction of the biotin coupling partner. As with 25, the magnetically non-equivalent 
proton pair of H-26 was observed at 2.60 and within the multiplet at 2.84-2.76 ppm 
(overlap with H-10). Biotin’s characteristic valeric acid chain is seen highfield at 1.29 and 
2.09-2.00 for H-41 and H-40/-42, respectively. The triazole (H-19) singlet showed up at 
7.91 ppm and is the most diagnostic proton signal for the successful coupling. Using 13C-
NMR and HSQC data, all 47 carbon signals could be correctly assigned. Lastly, the HRMS 
data in Figure 88 shows the molecular mass peak (M+H)+ at 1109.4332 (M+H)+, where 
C53H73N8O10S4 requires 1109.4338, which corroborated the synthesis of our ajoene-
biotin target 26. 
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Figure 87: 1H-NMR spectrum of 26 
 
Figure 88: HRMS spectrum of 26 
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4.5 Biological evaluation of biotin-probe 
4.5.1 Anti-proliferative activity 
Ajoene has been shown to be an efficient cytotoxic agent to cancer cells both in vitro and 
in vivo. In this regard it has been shown to trigger events that lead to apoptosis and that 
inhibit cell proliferation. Although some of these pathways are known, only a handful of 
the specific ajoene drug targets have been identified. Previous studies in our lab have 
found that ajoene targets and S-thiolates multiple proteins in cancer cells. We aimed to 
identify these proteins using our newly synthesised probe.  
 
It was important to first ascertain that the synthesised biotinylated ajoene still retains its 
activity in cancer cells. The probe’s activity was therefore first validated in a MTT assay 
against WHCO1 cancer-cells. The azide ajoene 19 and alkyne biotin 25 were also tested 
as we anticipated their use for in situ “Click”-biotinylation experiments. The ajoene 
analogues could not be separated into E- and Z- isomers and were thus tested as E/Z-
mixtures. The IC50 value obtained are shown in Table 6: 
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Table 6: Activity of biotin-ajoene and its two “Click”-fragments against WHCO1 cell proliferation 
 
No. Name Structure 
 
WHCO1 
IC50  SD / 
M 
19 Azide-
ajoene 
 
0.1 µM 
25  Biotin-
alkyne 
 
>200 µM 
26 Biotin- 
ajoene 
 
0.43 µM 
 
 
Both the biotin-ajoene 26 and its azide-ajoene precursor 19 were found to be highly 
active. The biotin-alkyne 25 showed no activity above the maximum tested dose of 200 
µM. This was expected, as it lacks the ajoene disulfide pharmacophore. Interestingly, 19 
which contains an azide functional group is the most active ajoene analogue which we 
have synthesised to date.  
 
When the fully assembled biotin probe 26 was solubilised in DMSO, it was found that 
degradation occurred. This was initially observed when the probe was solubilised in 
DMSO for NMR characterisation. An apparent degradation was observed by colour 
change, the forming of a gel and broadening of the 1H-NMR signals in DMSO solvent. 
Subsequent methanol and chloroform were used as NMR solvents however these two 
solvents are not suitable for biological studies as they are toxic to cells. The aggregates 
which are formed in DMSO can be observed in the snapshot taken of the cancer cells 
following 48 hour incubation with 26 (Figure 89). Therefore the apparent cytotoxicity 
of 26 cannot be attributed to biotin-ajoene as this compound had degraded and formed a 
gel in the MTT assay. 
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Figure 89: Magnified image of treated WHCO1 cells showing aggregates of insoluble degraded 
biotin-ajoene following DMSO delivery 
 
We therefore developed a detergent-based solvent system to solubilize biotin-ajoene. We 
used a DMSO:H2O:PEG400 solubilisation mixture in a 2:9:9 ratio which did not result in 
aggregation and the compound appeared stable when monitored by TLC. 
 
5.4.2 Immunoblotting 
After showing that our novel ajoene analogues 19 and 26 had retained their anti-
proliferative activity, it was important to validate that the probe was able to undergo a 
disulfide exchange with reactive cysteine residues on proteins involving transfer of the 
biotin tag. In light of our findings that ajoene formed a disulfide bond with the Cys-93 
residue on the β-subunits of human haemoglobin, we decided to perform a model 
reaction between biotin-ajoene and haemoglobin. Therefore, Hb in buffer (10 µM, PBS, 
pH 7.4) was incubated with 100 M of either biotin-ajoene or azide-ajoene (in 
DMSO/H2O/PEG400). After one hour at 37 °C, an in situ "Click”-reaction was performed 
on the samples pretreated with azide-ajoene. It involved the addition of biotin-alkyne 25 
and its Cu(I) catalyst (aq. CuSO4/sodium ascorbate), followed by another hour of 
incubation at 37 °C. All Hb samples were then subjected to either reducing (DTT, 100 mM) 
or non-reducing conditions (without DTT) and loaded onto a polyacrylamide gel to 
perform electrophoresis. The resulting gel was washed to remove unbound ajoene, 
probed with an anti-biotin antibody and visualised using a secondary antibody 
conjugated to horseradish peroxidase. Chemiluminescence detection of the secondary 
antibody was visualised in a bioimager and the blot is shown in Figure 90: 
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Figure 90: Western blot showing biotinylated Hb 
 
The untreated Hb sample (Lanes 1 and 2 in Figure 90) did not show any 
chemiluminescence bands. This was expected as it did not contain any of the biotinylation 
reagent. Distinct chemiluminescence bands were observed for the Hb sample that had 
been treated with biotin-ajoene 26 (Lanes 3 and 4) which demonstrates that the Hb 
protein was successfully labelled with biotin. It was significant to see that two fluorescent 
bands were observed on the gel. The molecular weight approximations (via the protein 
ladder) gave 35 kDa for the bottom and 20 kDa for the top band, as shown in Figure 90. 
These bands represent the β-subunit monomer (top) or the αβ-dimer (bottom) of the 64 
kDa Hb tetramer. Lanes 5 and 6 which had been treated with the biotin probe 26 and 
then incubated with DTT failed to show a band which implies the biotin label had been 
cleaved off (ie reduced) supporting attachment via a disulfide linkage. The alternative in 
situ “Click”-strategy for biotinylation using 19 and 25 (Lanes 7 and 8) proved to be 
successful with the appearance of chemiluminescence bands identical to those when 
using the intact probe 26. This implies that both strategies transfer biotin to the same 
position and that the label has the same final structure (Protein-S-S-linker-biotin). We 
had already previously demonstrated by proteomics that Hb is one of the targets of 
ajoene. Therefore in this model study, we have now demonstrated that both biotin-ajoene 
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26 and azide-ajoene 19, followed by in vitro “Click” with biotin-alkyne 25, are able to 
successfully attach ajoene to the protein via a disulfide bond. With the successful 
synthesis and biological efficacy experiments of the biotin-ajoene probe, it can now be 
used to tag the binding partners of ajoene in cancer cells. After isolation of these tagged 
proteins via streptavidin beads, these proteins may be identified by proteomics.  
 
4.6 Summary and outlook 
In this chapter, we presented the convergent synthesis of biotin-ajoene 26 from two 
“Click”-able synthons (19 and 25). The azide-functionalised ajoene 19 was accessed via 
the UCT ajoene synthesis. In this synthesis, a novel sulfenylating agent 17 inserted the 
azide moiety at the non-vinyl sulfur of ajoene. The regioselectivity of the proposed 
thiolysis exchange at this position was crucial to ensure the successful transfer of the 
biotin label onto the protein target. Strategic amide coupling and substitution 
methodology afforded biotin-alkyne linker, where it was found that the NHS-ester 24 was 
most suited for the biotin coupling in the final step.  
 
We were able to demonstrate that biotin-ajoene 26 is able to S-thiolate Hb in vitro by SDS-
PAGE using an anti-biotin antibody. Attachment of the large biotin probe at the terminus 
of ajoene still rendered ajoene able to S-thiolate Hb via its sulfoxide vinyl-disulfide 
pharmacophore. The azide-ajoene 19 was the most cytotoxic ajoene analogue 
synthesised to date. With its antiproliferative activity in the nanomolar range and its use 
in the in situ “Click”-methodology, the azide-ajoene 19 has four main advantages over the 
fully assembled probe 26. (1) It is easier to synthesize than biotin-ajoene making it more 
accessible; (2) the azide-ajoene analogue is a close structural relative to bis-PMB and 
ajoene, which means that it may have similar target specificity especially at residues that 
might be sterically restricted; (3) the “Click”-ligation can be easily performed on the 
treated cell lysate, and lastly, (4) biotin-ajoene does not meet three of the five parameters 
for reasonable drug absorption as popularised by Lipinski, where it has a molecular 
weight above 500 Da, has more than ten hydrogen bond acceptors and more than five 
hydrogen bond donors.101,102 In future, the biotin-ajoene probe can be used on cancer 
cells to identify the protein targets of ajoene.  
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Chapter Five: Conclusion and Future Work 
 
In this thesis we aimed to synthesise a bis-PMB ajoene analogue with improved blood 
stability with retained cancer cell cytotoxicity. A small library of eight analogues with 
improved aqueous solubility and variations in the sulfoxide/vinyl-disulfide 
pharmacophore were synthesised. The vinyl-disulfide series was synthesised via the UCT 
ajoene synthesis where the solubility modification was introduced via the phenol 
sulfenylating agent in the key S-thiolation step. A dialkylation strategy of 1,3-
propanedithiol involving the sulfenylating agent successfully afforded the dihydroajoene 
series. The phenolic hydroxyl enabled direct access to the amide series via alkylation with 
iodoacetamide. 
 
The compounds were tested against WHCO1 oesophageal cancer cell proliferation and 
their stability was evaluated in vitro in mouse blood. All the structural variations on the 
ajoene molecule produced strongly cytotoxic analogues with IC50’s below 20 M. 
Importantly, cytotoxicity and blood stability were established as being inversely related. 
It was found that the presence of the double bond (as the vinyl group) was important for 
strong cancer cell cytotoxicity (low blood stability). The analogues with amide 
functionalization were slightly less cytotoxic but also more stable in blood compared than 
those with a hydroxyl group. The role of the sulfoxide is not as clear but it appears to 
decrease activity of the vinyl-disulfides while increasing activity of the dihydroajoenes. 
This is presumably due to inhibition of disulfide activation in the vinyl-disulfides versus 
enhanced disulfide activation in the dihydroajoenes, the latter by a long range inductive 
electron-withdrawal via the sigma-framework. 
 
It is proposed that thiolysis exchange with a cysteine thiolate or GSH constitutes the 
underlying mechanism of ajoene and that activation of the disulfide towards thiolysis 
exchange renders the compound more cytotoxic to cancer cells and less stable in blood. 
Owing to literature reports on the toxicity of garlic disulfides towards erythrocytes as 
well as the observed adverse effects of bis-PMB in animal studies from our group, we 
suspected that ajoene may interact with haemoglobin. We found from UV-Vis and MS 
studies, that ajoene can covalently modify human haemoglobin via thiolysis exchange at 
cysteine-93 in the β-subunit. Therefore the cytotoxicity of ajoene to erythrocytes may 
arise from reaction with GSH and Hb. Within the parameters of our aim, the 
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dihydroajoenes (11-14) present an improved lead structure for future in vivo 
experiments, where the removal of the double bonds resulted in acceptable blood half-
lives of approximately 60 minutes (compared to about 5 minutes in bis-PMB), and the 
retention of strong in vitro cancer cell cytotoxicity (IC50<25 µM for the weakest of the 
series).  
 
We have previously shown that a synthetic fluorescent synthetic-derived dansyl-labelled 
ajoene regioselectively S-thiolates multiple protein targets within cancer cells via a thiol-
disulfide exchange. In this thesis, we synthesised a novel biotin-labelled ajoene probe 26 
via a “Click”-reaction in the final step between alkyne-biotin 25 and azidated ajoene 19. 
The alkyne-biotin was afforded via a series of substitution and amide coupling reactions. 
In line with our design considerations, the sulfenylating agent 17 successfully placed of 
the azide functionality at the non-vinyl sulfur position, of the vinyl-disulfide 
pharmacophore, which directs the regioselective transfer of the biotin label onto protein 
targets.  
 
The above-mentioned biotin-labelled ajoenes have been applied in biotin-streptavidin 
technology, aimed at the isolation and characterisation of ajoene’s protein targets within 
cancer cells. In a model experiment, we showed that protein biotinylation via thiolysis 
could be achieved via two strategies, which were both successful and in agreement. In the 
first strategy the whole probe was used to directly label the cancer cell proteins, while in 
the second, the probe was assembled in situ via “Click”-chemistry after cancer cell pre-
treatment with azide-ajoene. The successful transfer of the (biotin) label was 
demonstrated onto Hb protein by western blot using an anti-biotin antibody. This 
chemical biology tool will be used in my upcoming doctoral studies to investigate and 
identify ajoene’s protein targets, and to explore their involvement in apoptotic and 
antiproliferative anticancer signalling pathways of ajoene. 
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Chapter Six: Experimental section  
 
6.1 Synthetic Method 
6.1.1 General 
All solvents were freshly distilled. Dichloromethane was distilled over phosphorus 
pentoxide under nitrogen. Tetrahydrofuran was distilled under nitrogen and dried over 
sodium wire benzophenone. Acetonitrile was distilled from calcium hydride under 
nitrogen. Other reagents were purified according to standard procedures. All reagents 
were purchased from Sigma-Aldrich (South Africa) or Merck (Darmstadt, Germany) and 
were used without further purification. Room temperature refers to ambient 
temperature. Low temperature reactions were carried out using liquid nitrogen in 
acetone (-78 °C)/CH3CN (-40 °C)/BnOH (-20 °C) or a slurry of water and ice (0 °C). Thin 
layer chromatography (TLC) was used to monitor reactions using aluminium backed 
Merck silica-gel 60 F254 plates. Compounds on TLC were visualised by a combination of 
ultra-violet light (Vmax = 254nm), iodine vapour, by spraying with a 2.5% solution of 
anisaldehyde in a mixture of sulfuric acid and ethanol (1:10 v/v), ninhydrin (300 mg in 
97 mL ethanol and 3 mL acetic acid) or KMnO4 (1.5 g with 10g K2CO3 and 1.25 mL 10% 
NaOH in 200 mL H2O) and then heating at 150°C. Column chromatography was 
performed using silica-gel 60 mesh (Merck 7734). All chromatography was carried out 
using petroleum ether (b.p. 40-60 °C), ethyl acetate, dichloromethane or methanol as 
eluents, or a combination of these. NMR spectra were recorded on either a Varian 
Mercury 300 MHz (75.5 MHz for 13C-NMR) or a Bruker 400 MHz (101 MHz for 13C-NMR) 
instrument and were carried out in chloroform-d, acetone-d6, dmso-d6,  methanol-d4 with 
the following references respectively in ppm: chloroform (δ 7.26 in 1H-NMR and δ 77.16 
in 13C-NMR), acetone ( = 2.05 in 1H-NMR δ = 206.26 in 13C-NMR), dimethylsulfoxide ( = 
2.50 in 1H-NMR and  = 39.52 in 13C-NMR) or methanol ( = 3.31 in 1H-NMR δ = 49.00 in 
13C-NMR).121 All Chemical shifts (δ) are reported in ppm and J values are quoted in Hz. 
Melting points were measured on a Reichert-Jung Thermovar hot-stage microscope and 
are uncorrected. Infrared spectra were recorded on a Perkin Elmer Spectrum 100 FT-IR 
Spectrometer. High-resolution mass spectrometry was performed at the Central 
Analytical Facilities, School of Chemistry, University of Stellenbosch on a Waters Synapt 
G2 machine in ESI mode.  
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6.1.2 bis-PMB analogues 
 
(4-Methoxybenzyl)(prop-2-yn-1-yl)sulfane, (1)66 
 
To a stirring solution of PMBCl (1.73 mL, 12.8 mmol, 1 eq) in acetonitrile (40 mL) under 
N2 was added thiourea (1.17 g, 15.4 mmol, 1.2 eq) and the reaction heated to 85°C after 
which it was refluxed for 14 hours. The mixture was cooled in an ice bath and the 
resulting white precipitate was filtered, washed with ice-cooled acetonitrile (2 x 10 mL) 
and dried under reduced pressure to afford the isothiouronium salt as a white solid (2.80 
g, 94%). 
 
νmax/ cm-1 (ATR): 2974, 2950 (N-H stretch x 2); Mp (CH3CN): 161-162 °C. 
 
The isothiouronium salt (2.80 g, 12.0 mmol, 1 eq) was added to a solution of KOH (1.35 
g, 24.1 mmol, 2 eq), in anhydrous MeOH (24 mL) under N2 at -20°C (benzyl alcohol/liquid 
nitrogen) and left stirring for two hours. Propargyl bromide (2 mL, 18.05 mmol, 1.5 eq) 
was then added and the reaction stirred at 0°C for 30 minutes upon which the reaction 
was quenched with saturated aqueous NH4Cl (10 mL). The product was extracted with 
EtOAc (3 x 20 mL) and the combined fractions were washed with water (2 x 20 mL) and 
brine (1 x 15 mL). The solvent was removed under reduced pressure and the residue was 
purified via silica column chromatography (EtOAc:Hexane = 5:95) to afford propargyl 
sulfide 1 as a clear light-yellow oil (1.98 g, 85%). 
 
Rf = 0.9 (EtOAc:Hexane, = 10:90); IR νmax/ cm-1 (ATR): 3286 (alkyne C-H stretch); δH (300 
MHz, CDCl3) 7.26 (3H, d, J = 8.7 Hz, H-3), 6.86 (2H, d, J = 8.7 Hz, H-4), 3.83 (2H, s, H-6), 
3.80 (3H, s, H-1), 3.07 (2H, d, J = 2.6 Hz, H-7), 2.28 (1H, t, J = 2.6 Hz, H-9); δC (101 MHz, 
CDCl3) 158.9 (C-2), 130.2 (C-4), 129.5 (C-5), 114.1 (C-3), 80.1 (C-8), 71.3 (C-9), 55.4 (C-
1), 34.8 (C-6), 18.4 (C-7). 
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S-(3-((4-Methoxybenzyl)thio)prop-1-en-1-yl) ethanethioate, (2)66 
 
The propargyl sulfide 1 (1.4 g, 7.3 mmol, 1 eq) was suspended in toluene (35 mL) under 
N2 and ACCN (0.18 g, 0.73 mmol, 0.1 eq) was added. The mixture was brought to reflux 
(85°C), at which point thiolacetic acid (0.62 mL, 8.7 mmol, 1.2 eq) was added drop-wise. 
The reaction was held at 85°C and was allowed to progress for three hours. The reaction 
was brought down to room temperature and quenched with saturated aqueous sodium 
bicarbonate (5 mL). The toluene was removed under reduced pressure and the product 
was extracted with EtOAc (3 x 20 mL). The combined fractions were washed with water 
(2 x 15mL) and brine (1 x 10 mL), then dried over MgSO4 and concentrated. The silica 
column chromatography (EtOAc:Hexane = 10:90) afforded thioacetate 2 as a 1:2 mixture 
of E/Z-isomers and as an odiferous clear colourless oil (0.98 g, 45%). 
 
E/Z mixture: Rf = 0.7 (EtOAc:Hexane, = 20:80); IR νmax/ cm-1 (ATR): 1700 (C=O); 
 
E-isomer: δH (300 MHz,CDCl3): 7.22 (2H, d, J = 8.7 Hz, H-4), 6.85 (2H, d, J = 8.7 Hz, H-3), 
6.50 (1H, dt, J = 15.6, 1.2 Hz, H-9), 5.82 (1 H, m, H-8), 3.80 (3H, s, H-1), 3.63 (2H, s, H-6), 
3.12 (3H, dd, J = 7.4, 1.2 Hz H-7), 2.39 (3H, s, H-11); δC (75 MHz, CDCl3): 193.1 (C-10), 
158.9 (C-2), 130.3 (C-8), 130.2 (C-4), 129.9 (C-5), 119.5 (C-9), 114.1 (C-3), 55.4 (C-1), 34.5 
(C-6), 33.3 (C-7), 30.5 (C-11). 
 
Z-isomer: δH (300 MHz, CDCl3): 7.22 (2H, d, J = 8.6 Hz, H-4), 6.85 (2H, d, J = 8.6 Hz, H-3), 
6.67 (1H, dt, J = 9.6 Hz, 1.1, H-9), 5.86 (1 H, m, H-8), 3.80 (3H, s, H-1), 3.64 (2H, s, H-6), 
3.13 (2H, dd, J = 7.6, 1.1 Hz, H-7) 2.40 (3H, s, H-11); δC (75 MHz, CDCl3): 191.4 (C-10), 
158.9 (C-2), 130.0 (C-4), 129.9 (C-5), 128.7 (C-8), 119.7 (C-9), 114.1 (C-3), 55.4 (C-1), 35.3 
(C-6), 31.0 (C-7), 30.8 (C-11). 
 
4-(2-Hydroxyethyl)-phenol, (3)103 
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LiAlH4 (2.00 g, 53.0 mmol, 2.2 eq) was added to THF (80 mL) at 0°C under N2 and ethyl 2-
(4-hydroxyphenyl)ethanoate (4.00 g, 24.1 mmol, 1 eq) in THF (20 mL) added drop-wise. 
After two hours the reaction was quenched with 1M HCl (80 mL). Upon filtration through 
Celite the filtrate was extracted using EtOAc (3 x 100 mL), washed with saturated 
aqueous sodium bicarbonate (50mL) and then brine (50mL). The combined organic 
fractions were dried over MgSO4 and concentrated under reduced pressure. Purification 
via column chromatography (EtOAc:  Hexane) yielded alcohol 3 as a white crystalline 
solid (3.26g, 98%), which was crystallised from EtOAc/Hexane. 
 
Rf = 0.35 (EtOAc: Hexane = 50:50); Mp (EtOAc/Hexane): 91-93 °C, lit103 Mp: 90 °C; IR νmax/ 
cm-1 (ATR): 3384 (O-H), 3130 (aromatic O-H); δH (300 MHz, d6 acetone): 8.10 (1H, brs, 
OH), 7.05 (2H, d, J = 8.7 Hz, H-3), 6.73 (2H, d, J = 8.7 Hz, H-2), 3.67 (2H, t, J = 7.2 Hz, H-6), 
2.94 (1H, brs, OH’) 2.70 (2H, t, J = 7.2 Hz, H-5); δC (101 MHz, d6-acetone): 156.3 (C-1), 
130.8 (C-4), 130.5 (C-3), 115.7 (C-2), 64.1 (C-6), 39.2 (C-5). 
 
4-(2-Iodoethyl)-phenol, (4)122 
 
The alcohol 3 (3.26 g, 23.6mmol, 1 eq) dissolved in THF (45 mL) at 0° C under N2 and 
imidazole (3.21 g, 47.2 mmol, 2 eq), triphenylphosphine (12.4 g, 47.2 mmol, 2 eq)  and 
iodine (12.0 g, 47.2 mmol, 2 eq) were sequentially added to the reaction vessel. The 
mixture was allowed to warm to room temperature and after two hours the reaction was 
quenched with aqueous saturated sodium thiosulfate (30 mL). The organic products 
were extracted into EtOAc (3 x 40 mL), which was then washed with HCl (1 M, 20 mL), 
aqueous saturated sodium bicarbonate (30 mL) and brine (20 mL). The solvent was dried 
(MgSO4) and removed under reduced pressure. The residue was purified by column 
chromatography (EtOAc:Hexane) to afford iodide 4 as a yellow crystalline solid (5.66 g, 
97%). 
 
Rf = 0.7 (EtOAc:Hexane = 30:70); Mp (EtOAc/Hexane): 109-113°C, lit122 Mp: 111-112°C; 
IR νmax/ cm-1 (ATR): 3198 (aromatic O-H); δH (400 MHz, CDCl3): 7.06 (2H, d, J= 8.6 Hz, H-
3), 6.78 (2H, d, J = 8.6 Hz, H-2), 4.80 (1H, brs, OH), 3.31 (2H, t, J = 7.8 Hz, H-6), 3.10 (2H, t, 
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J = 7.8 Hz, H-5); δC (101 MHz, CDCl3) δ 154.5 (C1), 133.2 (C4), 129.7 (C-3), 115.6 (C-2), 
39.6 (C-5), 6.4 (C-6). 
 
S-4-Hydroxyphenethyl 4-methylbenzenesulfonothioate, (5) 
 
The Iodide 3 (1.20 g, 4.84 mmol, 1 eq) was dissolved in DMF (10 mL) under N2 and 
potassium thiotosylate (2.19 g, 9.68 mmol, 2 eq) was added over 15 minutes. The reaction 
was allowed to proceed at room temperature overnight. The reaction mixture was diluted 
with EtOAc (15 mL) and water was added (10 mL). The product was extracted with EtOAc 
(3 x 15 mL). The combined organic fractions were washed copiously with water (4 x 15 
mL) and brine (10 mL). The solvent was removed under reduced pressure and silica 
column chromatography (Hexane:EtOAc) afforded thiosulfonate 5 as a yellow clear oil 
(1.44 g, 97%). 
 
Rf = 0.3 (EtOAc:Hexane, = 30:70); IR νmax/ cm-1 (ATR): 3436 (phenolic O-H), 1136 
(O=S=O), 521 (S-S); δH (300 Mhz,CDCl3): 7.82 (2H, d, J = 8.3 Hz, H-8); 7.34 (2H, d, J = 8.3 
Hz, H-9), 6.96 (2H, d, J = 8.7 Hz, H-3),  6.74 (2H, d, J = 8.7 Hz, H-2), 3.18 (2H, t, J = 7.5 Hz, 
H-5), 2.83 (2H, t, J = 7.7  Hz, H-6), 2.45 (3H, s, H-11); δC (101 MHz, CDCl3): 154.7 (C-1), 
145.0 (C-10), 142.2 (C-7), 130.9 (C-4), 130.0 (C-9), 129.9 (C-8), 127.2 (C-3), 115.7 (C-2), 
37.6 (C-6), 34.4 (C-5), 21.8 (C-11). 
 
4-(2-((3-((4-Methoxybenzyl)thio)prop-1-en-1-yl)disulfanyl)ethyl)phenol, (6) 
 
The vinyl thioacetate 2 (586 mg, 2.19 mmol, 1 eq) in anhydrous MeOH (1.95 mL, 1 M) was 
cooled to -40°C (Acetonitrile/liq. N2) under N2 and potassium hydroxide (129 mg, 2.30 
mmol, 1.05 eq) in MeOH (2.05 mL, 1 M) was added. The reaction was stirred for 30 
minutes upon which the reaction was cooled to -78°C and thiotosylate 5 (743 mg, 2.41 
mmol, 1.1 eq) in MeOH (2.43 mL, 1 M) was added. The reaction was allowed to proceed 
for three hours and was quenched at room temperature with saturated aqueous 
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ammonium chloride (4 mL). The product was extracted with EtOAc (3 x 15 mL) and the 
combined organic fractions were washed with water (2 x 10 mL) followed by brine (1 x 
10 mL). The solvent was removed under reduced pressure and the residue purified using 
silica column chromatography (EtOAc:Hexane = 15:85) to afford disulfide 6 as a clear 
colourless oil and as a 3:5 mixture of E/Z isomers (594 mg, 72%). 
 
E/Z mixture: Rf = 0.35 (EtOAc:Hexane, = 20:80); IR νmax/ cm-1 (ATR): 3382 (phenolic OH); 
HRMS (ES): m/z 379.0849 [M+ H] +, C19H23O2S3 requires 379.0860;123 
 
E-isomer: δH (300 MHz, CDCl3): 7.21 (2H, d, J = 8.7 Hz, H-4), 7.07 (2H, d, J = 8.5 Hz, H-13), 
6.84 (2H, d, J = 8.7 Hz, H-14), 6.76 (2H, d, J = 8.5 Hz, H-3), 6.07 (1H, dt, J = 14.6, 1.0 Hz, H-
9), 5.88 (1H, dt, J = 14.6, 7.3 Hz, H-8), 3.80 (3H, s, H-1), 3.62 (2H, s, H-6), 3.08 (2H, dd, J = 
7.1, 0.7 Hz, H-7), 2.92 (4H, s, H-10/-11); δC (101 MHz, CDCl3): 158.8 (C-2), 154.3 (C-15), 
130.7 (C-12), 132.2 or 132.1 (C-5), 130.2 (C-4), 130.0 (C-14), 128.2 (C-9), 128.0 (C-8), 
115.6 (C-3), 114.2 (C-13), 55.5 (C-1), 39.9 (C-10), 34.8 (C-6), 34.8 (C-11), 32.9 (C-7). 
 
Z-isomer: δH (300 MHz, CDCl3): 7.24 (2H, d, J = 8.7 Hz, H-4), 7.05 (2H, d, J = 8.5 Hz, H-13), 
6.90 (2H, d, J = 8.5 Hz, H-14), 6.75 (2H, d, J  = 8.7 Hz, H-3), 6.24 (1H, dt, J = 9.3, 1.0 Hz, H-
9), 5.70 (1H, dt, J = 9.3, 7.3 Hz, H-8), 3.80 (3H, s, H-1), 3.69 (2H, s, H-6), 3.23 (2H, dd, J = 
7.6, 0.8 Hz, H-7), 2.92 (4H, s, H10/-11); δC (101 MHz, CDCl3): 158.8 (C-2), 154.3 (C-15), 
132.4 (C-9), 132.2 or 132.1 (C-5), 130.7 (C-12) 130.2 (C-4), 130.0 (C-14), 128.3 (C-8), 
115.6 (C-3), 114.2 (C-13), 55.5 (C-1), 40.6 (C-10), 35.6 (C-6), 34.8 (C-11), 29.5 (C-7). 
 
4-(2-((3-((4-Methoxybenzyl)sulfinyl)prop-1-en-1-yl)disulfanyl)ethyl)phenol, (7) 
 
The sulfide 6 (250 mg, 0.66 mmol, 1 eq) was dissolved in DCM (10 mL) under N2 and 
cooled to -78°C.  m-CPBA (142 mg, 0.83 mmol, 1.25 eq) was added in portions and the 
reaction allowed to warm to room temperature over three hours before being quenched 
with saturated aqueous sodium bicarbonate (5 mL). The product was extracted with DCM 
(3 x 10 mL) and the combined fractions were washed with water (2 x 10 mL) followed by 
brine (5 mL). The solvent was removed under reduced pressure and the residue purified 
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via silica column chromatography (EtOAc:Hexane = 80:20) to afford ajoene analogue 7 as 
a pale-yellow oil and as a 2:1 mixture of Z/E isomers, (155 mg, 60%).  
 
E/Z mixture: Rf = 0.45 (EtOAc:Hexane, = 70:30); IR νmax/ cm-1 (ATR): 3171 (phenolic OH); 
HRMS (ES): m/z 393.0646 (M-H+), C19H21O3S3 requires 393.0658; 
 
E-isomer: δH (400 MHz, CDCl3): 7.23 (2H, d, J = 8.6 Hz, H-4), 7.03 (2H, d, J = 8.6 Hz, H-13), 
6.90 (2H, d, J = 8.6 Hz, H-3), 6.77 (2H, d, J = 8.6 Hz, H-14), 6.24 (1H, d, J = 14.8 Hz, H-9), 
5.86 (1H, dt, J = 14.7, 7.6 Hz, H-8), 3.91 (2H, m, H-6), 3.81 (3H, s, H-1), 3.51-3.42 (1H, m, 
H-7a), 3.33 (1H, ddd, J = 13.2, 8.0, 0.9 Hz, H-7b), 2.87-2.67 (4H, m, H-10/-11); δC (101 
MHz, CDCl3): 160.0 (C-2), 155.0 (C-15), 135.1 (C-9), 131.4 (C-4), 131.3 (C-12), 129.9 (C-
13), 121.4 (C-5), 116.4 (C-8), 115.8 (C-14), 114.7 (C-3), 56.4 (C-6), 55.5 (C-1), 52.9 (C-7), 
40.4 (C-10), 34.8 (C-11). 
 
Z-isomer: δH (400 MHz, CDCl3): 7.23 (2H, d, J = 8.6 Hz, H-4), 7.02 (2H, d, J = 8.6 Hz, H-13), 
6.90 (2H, d, J = 8.6 Hz, H-3), 6.76 (2H, d, J = 8.6 Hz, H-14), 6.57 (1H, d, J = 9.4 Hz, H-9), 5.76 
(1H, dt, J = 9.5, 7.9 Hz, H-8), 3.96 (2H, m, H-6), 3.80 (3H, s, H-1), 3.55 (1H, ddd, J = 13.4, 
7.7, 0.9 Hz, H-7a), 3.51-3.42 (1H, m, H-7b), 2.87-2.67 (4H, m, H-10/-11); δC (101 MHz, 
CDCl3): 160.0 (C-2), 155.0 (C-15), 139.0 (C-9), 131.4 (C-4), 131.2 (C-12), 129.9 (C-13), 
121.5 (C-5), 118.1 (C-8), 115.8 (C-14), 114.7 (C-3), 57.0 (C-6), 55.5 (C-1), 49.6 (C-7), 40.9 
(C-10), 34.8 (C-11). 
 
2-(4-(2-((3-((4-Methoxybenzyl)thio)prop-1-en-1-
yl)disulfanyl)ethyl)phenoxy)acetamide (8) 
 
Phenol 6 (150 mg, 0.40 mmol, 1 eq) was suspended in acetonitrile (5 mL) under N2 with 
potassium carbonate (111 mg, 0.80 mmol, 2 eq), 2-chloroacetamide (74 mg, 0.80 mmol, 
2 eq) and tert-butylammonium iodide (15 mg, 0.04 mmol, 0.1 eq) and the mixture heated 
at 40°C. The reaction was allowed to proceed for 12 hours and was then quenched with 
saturated aqueous ammonium chloride (2 mL). The product was extracted into EtOAc (3 
x 10 mL) and washed with water (2 x 5 mL) followed by brine (1 x 5 mL). The solvent was 
dried (MgSO4), removed under reduced pressure and silica column chromatography 
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(MeOH:DCM = 2:98) afforded amide 8 as a clear light-yellow oil as a 3:4 mixture of E/Z 
isomers (70 mg, 40%).  
 
E/Z mixture: Rf = 0.3 (MeOH:DCM = 5:95), IR νmax/ cm-1 (APCI): 3438 (amide N-H), 1685 
(amide C=O); HRMS (ES): m/z 436.1068 (M+H)+, C21H26NO3S3 requires 436.1080; 
 
E-isomer: δH (400 MHz, CDCl3): 7.24 (2H, d, J = 8.7 Hz, H-4), 7.15 (2H, d, J = 8.5 Hz, H-13), 
6.89-6.82 (4H, m, H-3/-14), 6.54 (1H, brs, NH), 6.08 (1H, dt, J = 14.7, 1.0 Hz, H-9), 5.89 
(1H, brs, NH), 5.88 (1H, dt, J = 14.6, 7.3 Hz, H-8), 4.47 (2H, s, H-16), 3.79 (3H, s, H-1), 3.62 
(2H, s, H-6), 3.08 (2H, dd, J = 7.2, 0.7 Hz, H-7), 2.94 (4H, s, H-10/-11); δC (101 MHz, CDCl3): 
171.2 (C-17), 158.9 (C-2), 156.0 (C-15), 133.7 (C-5), 130.2 (C-4), 130.1 (C-13), 130.0 (C-
12), 128.5 (C-8), 128.0 (C-9), 114.9 (C-14), 114.1 (C-3), 67.5 (C-16), 55.4 (C-1), 39.6 (C-
10), 34.8 (C-6), 34.7 (C-11), 32.9 (C-7). 
 
Z-isomer: δH (400 MHz, CDCl3): 7.20 (2H, d, J = 8.7 Hz, H-4), 7.13 (2H, d, J = 8.5 Hz, H-13), 
6.89-6.82 (4H, m, H-3/-14), 6.54 (1H, brs, NH), 6.24 (1H, dt, J = 9.3, 1.0 Hz, H-9), 5.89 (1H, 
brs, NH), 5.71 (1H, dt, J = 9.3, 7.7 Hz, H-8), 4.47 (2H, s, H-16), 3.79 (3H, s, H-1), 3.68 (2H, 
s, H-6), 3.28 (2H, dd, J = 7.7, 0.8 Hz, H-7), 2.94 (4H, s, H-10/-11); δC (101 MHz, CDCl3): 
171.2 (C-17), 158.9 (C-2), 156.0 (C-15), 133.7 (C-5), 132.2 (C-9), 130.2 (C-4), 130.1 (C-
13), 130.0 (C-12), 128.2 (C-8), 114.9 (C-14), 114.1 (C-3), 67.5 (C-16), 55.4 (C-1), 40.4 (C-
10), 35.6 (C-6), 34.7 (C-11), 29.5 (C-7). 
 
2-(4-(2-((3-((4-Methoxybenzyl)sulfinyl)prop-1-en-1-
yl)disulfanyl)ethyl)phenoxy)acetamide, (9) 
 
Sulfoxide 7 (107 mg, 0.27 mmol, 1 eq) was suspended in acetonitrile (2 mL) under N2. 
Potassium carbonate (75 mg, 0.54 mmol, 2 eq) and 2-iodoacetamide (100 mg, 0.54 mmol, 
2 eq) were added and the mixture was heated to 40°C. The reaction was left for 12 hours 
before being quenched with saturated aqueous ammonium chloride (5 mL). The product 
was extracted with EtOAc (3 x 5 mL) and washed with water (2 x 2 mL) followed by brine 
(2 mL). The combined organic fractions were dried over MgSO4 and concentrated under 
reduced pressure. The residue was purified via silica column chromatography 
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(MeOH:DCM = 5:95), which afforded ajoene analogue 9 as a clear colourless oil (58 mg, 
48%) and as a 3:2 mixture of E/Z isomers. 
 
E/Z mixture: Rf = 0.65 (MeOH:DCM = 5:95), IR νmax/ cm-1 (APCI): 3418 (amide N-H), 1716 
(amide C=O); HRMS (ES): m/z 452.1026 [M+H] +, C21H26NO4S3 requires 452.1024;123 
 
E-isomer: δH (600 MHz, CDCl3): 7.19 (2H, d, J = 8.7 Hz, H-4), 7.13 (2H, d, J = 8.6 Hz, H-13), 
6.89 (2H, d, J = 8.7 Hz, H-3), 6.85 (2H, d, J = 8.6 Hz, H-14), 6.56 (1H, brs, NH), 6.34 (1H, dt, 
J = 14.8, 0.9 Hz, H-9), 5.92 (1H, dt, J = 14.8, 7.5 Hz, H-8), 5.86 (1H, brs, NH), 4.46 (2H, s, H-
16), 3.91 (2H, s, H-6), 3.80 (3H, s, H-1), 3.48-3.42 (1H, m, H-7a), 3.30 (1H, ddd, J = 13.2, 
8.1, 0.9 Hz, H-7b), 2.94 (4H, s, H-10/-11); δC (151 MHz, CDCl3): 171.1 (C-17), 159.9 (C-2), 
156.1 (C-15), 134.4 (C-9), 133.5 (C-5), 131.3 (C-4), 130.1 (C-13), 121.7 (C-12), 117.2 (C-
8), 114.9 (C-14), 114.7 (C-3), 67.4 (C-16), 56.5 (C-6), 55.5 (C-1), 52.9 (C-7), 39.7 (C-10), 
34.6 (C-11). 
 
Z-isomer: δH (600 MHz, CDCl3): 7.22 (2H, d, J = 8.7 Hz, H-4), 7.13 (2H, d, J = 8.6 Hz, H-13), 
6.89 (2H, d, J = 8.7 Hz, H-3), 6.85 (2H, d, J = 8.6 Hz, H-14), 6.57 (1H, dt, J = 9.4, 0.9 Hz, H-
9), 6.56 (1H, brs, NH), 5.86 (1H, brs, NH), 5.78 (1H, dt, J = 9.4, 7.9 Hz, H-8), 4.46 (2H, s, H-
16), 3.92 (2H, s, H-6), 3.80 (3H, s, H-1), 3.54 (1H, ddd, J = 13.4, 7.7, 1.0 Hz, H-7a), 3.48-3.42 
(1H, m, H-7b), 2.94 (4H, s, H-10/-11); δC (151 MHz, CDCl3): 171.1 (C-17), 160.0 (C-2), 
156.1 (C-15), 138.5 (C-9), 133.4 (C-5), 131.4 (C-4), 130.1 (C-13), 121.6 (C-12), 118.7 (C-
8), 114.9 (C-14), 114.6 (C-3), 67.4 (C-16), 57.0 (C-6), 55.5 (C-1), 49.7 (C-7), 40.5 (C-10), 
34.6 (C-11). 
 
3-((4-Methoxybenzyl)thio)propane-1-thiol, (10) 
 
Propane-1,3-dithiol (0.93 mL, 9.2 mmol, 1.2 eq) was suspended in MeOH (30 mL) under 
N2, and potassium hydroxide (0.73 g, 13 mmol, 1.4 eq) was added and the mixture left to 
stir at room temperature for 30 minutes. The reaction was then cooled to 0°C, PMBCl (1.2 
g, 7.7 mmol, 1 eq) was added drop-wise and the reaction allowed to proceed for two 
hours. The reaction was quenched using aqueous HCl (20 mL, 1 M) and then neutralised 
to pH 7 using saturated aqueous sodium bicarbonate. The product was extracted using 
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EtOAc (3 x 30 mL). The combined fractions were washed with H2O (2 x 30 mL) followed 
by brine (20 mL), dried over MgSO4 and concentrated under reduced pressure. The 
resulting residue was purified via silica column chromatography (EtOAc:Hexane = 2:98) 
to afford thiol 10 as a clear, light-green oil (1.33 g, 88%). 
 
Rf = 0.25 (EtOAc:Hexane = 2:98); δH (300 MHz, CDCl3): 7.23 (2H, d, J = 8.8 Hz, H-4), 6.85 
(2H, d, J = 8.8 Hz, H-3), 3.80 (3H, s, H-1), 3.66 (2H, s, H-6), 2.52 (2H, t, J = 7.1 Hz, H-9), 1.84  
(2H, t, J = 7.1 Hz, H-7), 1.33 (1H, t, J = 8.0 Hz, SH), 1.31 (2H, p, H-8). 
 
4-(2-((3-((4-Methoxybenzyl)thio)propyl)disulfanyl)ethyl)phenol, (11) 
 
The thiol 10 (765 mg, 3.38 mmol, 1 eq) was taken up in MeOH (20 mL) under N2 and 
cooled to -78°C. Triethylamine (0.68 mL, 4.9 mmol, 1.5 mmol) was added and after 20 
minutes the thiotosylate 5 (1.44 g, 4.67 mmol, 1.4 eq) in MeOH (5 mL) was added. The 
mixture was allowed to warm to room temperature over one hour. The reaction was 
immediately quenched with saturated aqueous ammonium chloride (10 mL). The 
product was extracted with EtOAc (3 x 40 mL) and the combined fractions were washed 
with water (2 x 20 mL) followed by brine (10 mL). The organic solvent was dried with 
MgSO4 and removed under reduced pressure. The resulting residue was purified via silica 
column chromatography (EtOAc:Hexane = 20:90) to afford disulfide 11 as a colourless 
waxy solid (992 mg, 77%). 
 
Rf = 0.5 (EtOAc: Hexane = 20:80); Mp (EtOAc/Hexane): 84-86 °C; IR νmax/ cm-1 (ATR): 
3433 (phenolic OH), 550 (S-S); δH (400 Mhz, CDCl3): 7.23 (2H ,d , J = 8.8 Hz, H-4), 7.06 (2H, 
d, J = 8.6 Hz, H-13), 6.85 (2H, d, J = 8.8 Hz, H-3), 6.76 (2H, d, J = 8.6 Hz, H-14), 3.80 (3H, s, 
H-1), 3.67 (2H, s, H-6), 2.89 (4H, brs, H10/-H11), 2.73 (2H, t, J = 7.1 Hz, H-9), 2.51 (2H, t, J 
= 7.1 Hz, H-7), 1.93 (2H, p, H-8); δC (101 MHz, CDCl3): 158.8 (C-2), 154.3 (C-15), 132.3 (C-
12), 130.5 (C-5), 130.0 (C-4), 129.9 (C-13), 115.5 (C-14), 114.1 (C-3), 55.4 (C-1), 40.7 (C-
10), 37.6 (C-9), 35.8 (C-6), 34.9 (C-11), 29.9 (C-7), 28.6 (C-8); HRMS (ES): m/z 379.0860 
[M-H]+, C19H23O2S3 requires 379.0866.124 
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4-(2-((3-((4-Methoxybenzyl)sulfinyl)propyl)disulfanyl)ethyl)phenol, (12) 
 
The sulfide 11 (200 mg, 0.53 mmol, 1 eq) was suspended in DCM (4 mL) under N2 and 
cooled to -78°C. m-CPBA (178 mg, 0.8 mmol, 1.5 eq) was then added in portions and the 
reaction was allowed to warm up to room temperature over one hour. The reaction was 
quenched with saturated aqueous sodium bicarbonate (5 mL) and extracted with DCM (3 
x 10 mL). The combined organic fractions were washed with water (2 x 10 mL) followed 
by brine (5 mL). The solvent was dried using MgSO4 and the product was concentrated 
under reduced pressure. Purification via silica column chromatography (MeOH:DCM = 
5:95) afforded sulfoxide 12 as a clear colourless oil (148 mg, 70%). 
 
Rf = 0.25 (MeOH:DCM = 5:95); IR νmax/ cm-1 (ATR): 3161 (S=O); δH (400 MHz, CDCl3): 7.20 
(2H, d, J = 8.6 Hz, H-4), 7.02 (2H, d, J = 8.4 Hz, H-13), 6.89 (2H, d, J = 8.6 Hz, H-3), 6.76 (2H, 
d, J = 8.4 Hz, H-14), 3.99 (1H, d, J = 13.0 Hz, H-6a), 3.95 (2H, d, J = 13.0 Hz, H-6b), 3.80 (3H, 
s, H-1), 2.92 – 2.82 (4 H, m, H-10/-11), 2.77-2.58 (4 H, m, H-7/-9), 2.19-2.07 (2H, m, H-8); 
δC (101 MHz, CDCl3): 160.0 (C-2), 155.0 (C-15), 131.5 (C-5), 131.4 (C-4), 129.8 (C-13), 
121.3 (C-12), 115.8 (C-3), 114.7 (C-14), 57.7 (C-6), 55.5 (C-1), 49.0 (C-7), 41.0 (C-11), 37.2 
(C-9), 34.9 (C-10), 22.3 (C-8); HRMS (ES): m/z 397.0966 (C19H25O3S3 requires 
397.0960.M+H)+. 
 
2-(4-(2-((3-((4-Methoxybenzyl)thio)propyl)disulfanyl)ethyl)phenoxy)acetamide, (13) 
 
The sulfide 10 (222 mg, 0.58 mmol, 1 eq) was dissolved in acetonitrile (5 mL) under N2. 
Cesium carbonate (286 mg, 0.88 mmol, 1.5 eq), tert-butylammonium iodide (22 mg, 0.58 
mmol, 0.1 eq) and 2-chloroacetamide (81 mg, 0.87 mmol, 1.5 eq) were added and the 
reaction was left to stir at room temperature for 18 hours. The reaction was quenched 
with saturated aqueous ammonium chloride (5 mL) and the product extracted into DCM 
(3 x 15 mL). The combined organic fractions were washed with water (2 x 10 mL) 
followed by brine (5 mL). The dried (MgSO4) solvent was removed under reduced 
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pressure. The resulting residue was purified via silica column chromatography 
(EtOAc:Hexane = 30:70) to afford sulfide 13 as a clear milky oil (195 mg, 77%). 
 
Rf = 0.35 (EtOAc:Hexane = 20:80); IR νmax/ cm-1 (ATR): 3380 (amide N-H) 3160 cm-1 
(amide N-H) , 1659 cm-1 (amide C=O); δH (400 MHz, CDCl3): 7.22 (2H, d, J = 8.8 Hz, H-4), 
7.15 (2H, d, J = 8.8 Hz, H-13), 6.86 (2H, d, J = 8.5 Hz, H-3), 6.84 (2H, d, J = 8.5 Hz, H-14), 
6.53 (1H, brs, NH), 5.71 (1H, brs, NH), 4.48 (2H, s, H-16), 3.79 (3H, s, H-1), 3.67 (2H, s, H-
6), 2.97-2.85 (4H, m, H10/-11), 2.74 (2H, t, J = 7.0 Hz, H-9), 2.51 (2H, t, J = 7.1 Hz, H-7), 
1.93 (2H, p, H-8); δC (101 MHz, CDCl3): 171.1 (C-17), 158.8 (C-2), 156.0 (C-15), 134.0 (C-
5), 130.4 (C-12), 130.1 (C-4), 130.0 (C-13), 114.9 (C-3), 114.1 (C-14), 67.5 (C-16), 55.4 (C-
1), 40.4 (C-10), 37.7 (C-9), 35.8 (C-6), 34.8 (C-11), 29.9 (C-7), 28.6 (C-8); HRMS (ES): m/z 
460.1046 [M+ Na]+, C21H27NNaO3S3 requires 460.1051.124 
 
2-(4-(2-((3-((4-Methoxybenzyl)sulfinyl)propyl)disulfanyl)ethyl)phenoxy)acetamide, 
(14) 
 
The sulfide 13 (104 mg, 0.24 mmol, 1 eq) was dissolved in DCM (3 mL) under N2 and 
cooled to 78°C. m-CPBA (81 mg, 0.4 mmol, 1.5 eq) was added and the reaction allowed to 
warm to room temperature over two hours. The reaction was quenched with saturated 
aqueous sodium bicarbonate (4 mL) and the product extracted into DCM (3 x 10 mL). The 
combined organic fractions were washed with water (2 x 10 mL) and brine (5 mL). The 
solvent was dried with MgSO4 and removed under reduced pressure. Silica column 
chromatography (MeOH:DCM = 5:95) afforded sulfoxide 14 as a clear light-yellow oil (78 
mg, 72%). 
 
Rf = 0.3 (MeOH:DCM = 5:95); IR νmax/ cm-1 (ATR): 3413 (amide N-H), 3177 (S=O?) 1634 
(amide C=O); δH (400 MHz, CDCl3): 7.20 (2H, d, J = 8.7 Hz, H-4), 7.13 (2H, d, J = 8.7 Hz, H-
13), 6.89 (2H, d, J = 8.7 Hz, H-3), 6.85 (2H, d, J = 8.7 Hz, H-14), 6.56 (1H, brs, NH), 6.06 (1H, 
brs, NH), 4.47 (2H, s, H-16), 3.96 (1H, t, J = 13.1 Hz, H-6a), 3.93 (1H, t, J = 13.1 Hz, H-6b), 
3.79 (3H, s, H-1), 2.90 (4H, m, H-10/-11), 2.75 (2H, t, J = 6.9 Hz, H-9a), 2.74 (2H, t, J = 6.9 
Hz, H-9b), 2.72-2.57 (2H, m, H-7) 2.22-2.08 (2H, m, H-8); δC (101 MHz, CDCl3): 170.3 (C-
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17), 158.9 (C-2), 155.0 (C-15), 132.7 (C-5), 130.3 (C-4), 129.1 (C-13), 120.6 (C-12), 113.9 
(C14), 113.6 (C-3), 66.5 (C-16), 56.8 (C-6), 54.4 (C-1), 47.9 (C-7), 39.4 (C-11), 36.3 (C-9), 
33.7 (C-10), 21.2 (C-8); HRMS (ES): m/z 454.1187 (M+H)+, C21H28NO4S3 requires 
454.1186. 
 
6.1.3 Biotin-labelled ajoene 
 
4-(2-Azidoethyl)-phenol, (15)125 
 
The Iodide 4 (560 mg, 2.26 mmol, 1eq) was suspended in DMF (3 mL) under N2 and 
sodium azide (220 mg, 3.39 mmol, 1.5 eq) in DMF (1 mL) was added. The reaction was 
heated to 100°C and stirred for three hours. The reaction was cooled, diluted with 50 mL 
of diethyl ether, which was then washed copiously with H2O (4 x 20 mL). The organic 
layer was dried over MgSO4 and the solvent removed under reduced pressure. Column 
chromatography (EtOAc:Hexane) afforded azide 15 as a clear yellow oil (354 mg, 96%). 
 
Rf = 0.3 (EtOAc:Hexane, = 10:90); IR νmax/ cm-1 (ATR): 3342 (aromatic O-H), 2092 
(N=N=N); δH (400 MHz, CDCl3): 7.09 (2H, d, J = 8.5 Hz, H-3), 6.79 (2H, d, J = 8.5 Hz, H-2), 
5.19 (1H, brs, OH), 3.46 (2H, t, J = 7.2 Hz, H-6), 2.83 (2H, t, J = 7.2 Hz, H-5); δC (75 MHz, 
CDCl3): 154.5 (C-1), 130.3 (C-4), 130.1 (C-3), 115.7 (C-2), 52.8 (C-6), 34.6 (C-5). 
 
1-(2-Azidoethyl)-4-(3-bromopropoxy)benzene, (16) 
 
To a stirring solution of 1,3-dibromopropane (0.82 mL, 8.1 mmol, 3 eq) and Cs2CO3 (962 
mg, 2.95 mmol, 1.1 eq) in acetonitrile (25 mL) was added the azide (15) (438 mg, 2.68 
mmol, 1 eq) in acetonitrile (2 mL) slowly. The reaction was heated to 50°C and left stirring 
for six hours. It was then was quenched with saturated aqueous ammonium chloride (5 
mL) and the product extracted with EtOAc (3 x 20 mL). The combined fractions were 
washed with brine (20 mL) and the solvent removed under reduced pressure. Column 
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chromatography (EtOAc:Hexane) afforded bromide 16 as a clear colourless oil (518 mg, 
68 %). 
 
Rf = 0.78 (EtOAc:Hexane, = 30:70); IR νmax/ cm-1 (ATR): 2092 (N=N=N), 1240 (aryl alkyl 
C-O-C); δH (400 MHz, CDCl3): 7.14 (2H, d, J = 8.6 Hz, H-3), 6.87 (2H, d, J = 8.6 Hz, H-2), 4.09 
(2H, t, J = 5.8 Hz, H-1’), 3.60 (2H, t, J = 6.5 Hz, H-3’), 3.47 (2H, t, J = 7.2 Hz, H-6), 2.84 (2H, 
t, J = 7.2 Hz, H-5), 2.31 (2H, p, H-2’); δC (101 MHz, CDCl3) 157.8 (C-1), 130.6 (C-4), 129.9 
(C-3), 114.9 (C-2), 65.6 (C-1’), 52.8 (C-6), 34.7 (C-5), 32.9 (C-3’), 30.1 (C-2’). 
 
S-(3-(4-(2-Azidoethyl)phenoxy)propyl) 4-methylbenzenesulfonothioate, (17) 
 
To a solution of potassium thiotosylate (639 mg, 2.83 mmol, 2 eq) in acetonitrile (10 mL) 
was added bromide 16 (400 mg, 1.41 mmol, 1 eq) in acetonitrile (5 mL) under N2 and the 
reaction was heated to 60°C. The reaction was allowed to proceed over-night for 18 
hours. The mixture was diluted with 25 mL EtOAc and washed with H2O (3 x 20 mL). The 
organic layer was dried over MgSO4 and the solvents removed under reduced pressure. 
Silica gel column chromatography (EtOAc:Hexane) afforded sulfonothioate ether 17 as a 
clear colourless oil (209 mg, 38%). 
 
Rf = 0.3 (EtOAc:Hexane, = 20:80); IR νmax/ cm-1 (ATR): 2090 (N=N=N); δH (300 MHz, 
CDCl3): 7.82 (2H, d, J = 8.6 Hz, H-2’’), 7.32 (2H, d, J = 8.4 Hz, H-3), 7.12 (2H, d, J = 8.6 Hz, H-
3’’), 6.78 (2H, d, J = 8.4 Hz, H-2), 3.95 (2H, t, J = 5.8 Hz, H-1’), 3.46 (2H, t, J = 7.1 Hz, H-6), 
3.18 (2H, t, J = 7.2 Hz, H-3’), 2.83 (2H, J = 7.2 Hz, H-5), 2.44 (3H, s, H-5’’), 2.12 (2H, p, H-
2’); δC (101 MHz, CDCl3): 157.6 (C-1), 144.9 (C-4’’), 142.0 (C-1’’), 130.6 (C-4), 130.0 (C-
3’’), 129.9 (C-3), 127.2 (C-2’’), 114.8 (C-2), 65.7 (C-1’), 52.8 (C-6), 34.6 (C-5), 32.9 (C-3’), 
28.9 (C-2’), 21.8 (C-5’’); HRMS (ES): m/z 392.1103 (M+H)+, C18H22O3N3S2 requires 
392.1108. 
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1-(3-(4-(2-Azidoethyl)phenoxy)propyl)-2-(3-((4-methoxybenzyl)thio)prop-1-en-1-
yl)disulfane, (18) 
 
To stirred solution of thioacetate 2 (119 mg, 0.44 mmol, 1 eq) in MeOH (1 mL) at -40°C 
under N2, was added potassium hydroxide (26 mg, 0.47 mmol, 1.05 eq) in MeOH (1.5 mL). 
The mixture was left for 20 minutes, upon which the temperature was lowered to -78°C 
and the azidothiotosylate 17 (191 mg, 0.49 mmol, 1.1 eq) in MeOH (0.49 mL, 1 M) was 
added drop-wise. The reaction was allowed to proceed to room temperature over two 
hours before being quenched with saturated aqueous ammonium chloride (1 mL). The 
product was extracted into EtOAc (3 x 10 mL) and the combined fractions were 
sequentially washed (2 x 5 mL water, 5 mL brine), dried over MgSO4 and concentrated 
under reduced pressure. Silica gel column chromatography afforded disulfide 18 as a 2:3 
mixture of E/Z-isomers and as a clear colourless oil (172 mg, 85%). 
 
E/Z mixture: Rf = 0.6 (EtOAc:Hexane, = 20:80); IR νmax/ cm-1 (ATR): 2086 (N=N=N); HRMS 
(ES): m/z 462.1344 (M+H)+, C22H28N3O2S3 requires 462.1349. 
 
E-isomer: δH (300 MHz, CDCl3): 7.22 (2H, d, J = 8.7 Hz, H-4), 7.12 (2H, d, J = 8.7 Hz, H-15), 
6.85 (2H, d, J = 8.7, H-14), 6.84 (2H, d, J = 8.7 Hz, H-3), 6.09 (1H, dt, J = 14.7, 1.0 Hz, H-9), 
5.89 (1H, dt, J = 14.6, 7.2 Hz, H-8), 4.07-4.02 (2H, m, H-12), 3.80 (3H, s, H-1), 3.63 (2H, s, 
H-6), 3.46 (2H, t, J = 7.2 Hz, H-18), 3.07 (2H, dd, J = 7.2, 1.0 Hz, H-7), 2.91 (2H, t, H-10), 
2.83 (2H, t, J = 7.1 Hz, H-17), 2.22-2.12 (2H, m, H-11); δC (101 MHz, CDCl3 ): 158.9 (C-2), 
157.8 (C-13), 130.4 (C-5), 130.2 (C-15), 130.0 (C-16) 129.9 (C-4), 128.3 (C-8), 128.0 (C-
9), 114.9 (C-14), 114.1 (C-3), 66.0 (C-12), 55.4 (C-1),  52.8 (C-18), 34.8 (C-6/-10), 34.6 (C-
17), 32.9 (C-7), 29.0 (C-11). 
 
Z-isomer: δH (300 MHz, CDCl3): 7.22 (2H, d, J = 8.7 Hz, H-4)), 7.12 (2H, d, J = 8.7 Hz, H-15), 
6.85 (2H, d, J = 8.7, H-14), 6.84 (2H, d, J = 8.7 Hz, H-3), 6.25 (1H, dt, J = 9.3, 1.0 Hz, H-9), 
5.71 (1H, dt, J = 9.3, 7.6 Hz, H-8), 4.07-4.02 (2H, m, H-12), 3.80 (3H, s, H-1), 3.68 (2H, s, H-
6), 3.46 (2H, t, J = 7.2 Hz, H-18), 3.21 (2H, dd, J = 7.6, 1.1 Hz, H-7), 2.91 (2H, t, H-10), 2.83 
(2H, t, J= 7.2 Hz, H-17), 2.22-2.12 (2H, m, H-11); δC (101 MHz, CDCl3 ): 158.9 (C-2), 157.8 
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(C-13), 132.1 (C-9), 130.4 (C-5), 130.2 (C-15), 130.0 (C-16), 129.9 (C-4), 128.6 (C-8), 
114.9 (C-14), 114.1 (C-3), 66.0 (C-12), 55.4 (C-1),  52.8 (C-18), 35.6 (C-6/-10), 34.6 (C-
17), 29.5 (C-7), 28.9 (C-11). 
 
1-(3-(4-(2-Azidoethyl)phenoxy)propyl)-2-(3-((4-methoxybenzyl)sulfinyl)prop-1-en-1-
yl)disulfane, (19) 
 
The sulfide 18 (50 mg, 0.11 mmol, 1 eq) was dissolved in DCM (0.5 mL) under N2 and 
cooled to -78°C. m-CPBA (21 mg, 0.12 mmol, 1.1 eq) was added and the reaction was kept 
at -78°C, resulting in a more polar spot being observed on TLC (EtOAc:Hexane = 80:20). 
The reaction was allowed to warm to room temperature, and upon full consumption of 
the starting material by TLC the reaction was quenched with saturated aqueous sodium 
bicarbonate (2 mL). The product was extracted into DCM (3 x 3 mL) and the combined 
organic fractions were washed (2 x 2 mL water, 2 mL brine), dried over MgSO4 and 
concentrated under reduced pressure. The purification via silica column chromatography 
afforded the azide-ajoene 19 as a 2:3 mixture of E/Z-isomers as a clear colourless oil (32 
mg, 62%). 
 
E/Z mixture: Rf = 0.4 (EtOAc:Hexane = 80:20); IR νmax/ cm-1 (ATR): 2094 (N=N=N), 1031 
(S=O); HRMS (ES): m/z 478.1303 (M+H)+, C22H28N3O3S3 requires 478.1293; 
 
E-isomer: δH(400 MHz, CDCl3): 7.21 (2H, d, J = 8.7 Hz, H-15), 7.12 (2H, d, J = 8.7  Hz, H-4), 
6.90 (2H, d, J = 8.7 Hz, H-14), 6.83 (2H, d, J = 8.7 Hz, H-3), 6.36 (1H, dt, J = 14.8, 1.0 Hz, H-
9), 5.96 (1H, dt, 14.8, 7.4 Hz, H-8), 4.04 (2H, t, J = 5.9 Hz, H-12), 3.91 (2H, s, H-6), 3.80 (3H, 
s, H-1), 3.48-3.41 (1H, m, H-7a), 3.46 (2H, t, J = 7.3 Hz, H-18), 3.29 (1H, ddd, J = 13.2, 8.0, 
1.1 Hz, H-7b), 2.91 (2H, t, J = 7.0 Hz, H-10), 2.83 (2H, t, J = 7.2 Hz, H-17), 2.16 (2H, m, H-
11); δC (101 MHz, CDCl3): 160.0 (C-2), 157.8 (C-13), 134.4 (C-9), 131.3 (C-15), 130.5 (C-
16), 129.9 (C-4), 121.7 (C-5), 117.5 (C-8), 114.9 (C-3), 114.7 (C-14), 66.0 (C-12), 56.6 (C-
6), 55.5 (C-1), 52.9 (C-7), 52.8 (C-18), 34.9 (C-10), 34.6 (C-17), 29.0 (C-11). 
 
Z-isomer: δH(400 MHz, CDCl3): 7.21 (2H, d, J = 8.7Hz, H-15), 7.12 (2H, d, J = 8.7 Hz, H-4), 
6.90 (2H, d, J = 8.7 Hz, H-14), 6.83 (2H, d, J = 8.7 Hz, H-3), 6.60 (1H, dt, J = 9.4, 1.0 Hz, H-
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9), 5.80 (1H, dt, J = 9.4, 7.9 Hz, H-8), 4.05 (2H, t, J = 6.0 Hz, H-12), 3.92 (2H, s, H-6), 3.80 
(3H, s, H-1), 3.53 (1H, ddd, J = 13.4, 7.6, 1.0 Hz, H-7a), 3.48-3.41 (1H, m, H-7b), 3.46 (2H, 
t, J = 7.3 Hz, H-18), 2.93 (2H, t, J = 7.1 Hz, H-10), 2.83 (2H, t, J = 7.2 Hz, H-17), 2.16 (2H, m, 
H-11); δC (101 MHz, CDCl3): 160.0 (C-2), 157.8 (C-13), 138.3 (C-9), 131.4 (C-15), 130.5 
(C-16), 129.9 (C-4), 121.8 (C-5), 118.9 (C-8), 114.9 (C-3), 114.7 (C-14), 65.9 (C-12), 57.1 
(C-6), 55.5 (C-1), 52.8 (C-18), 49.7 (C-7), 35.7 (C-10), 34.6 (C-17), 28.9 (C-11). 
 
tert-Butyl (3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)carbamate, (20)126 
 
4,7,10-trioxatridecane-1,13-diamine (2.00 mL, 13.3 mmol, 1.5 eq) in DCM was reacted 
with di-tert-butyl dicarbonate (1.93 g, 8.86 mmol, 1 eq) at room temperature over two 
hours. The solvent was removed under reduced pressure and the resulting residue was 
purified via silica column chromatography (20% MeOH in DCM) to afford mono-Boc-
protected diamine linker 20 as an amber oil (1.31 g, 46%). 
 
Rf = 0.15 (MeOH:DCM = 20:80); IR νmax/ cm-1 (ATR): 1694 (C=O); δH (400 MHz, CDCl3): 
5.21 (1H, brs, NH), 3.64-3.50 (12H, m, H-3/-4/-5/-6/-7/-8), 3.40 (2H, m, H-1),  3.19 (2H, 
t, J = 6.0 Hz, H-10), 2.76 (2H, s, NH2), 1.80-1.71 (4H, m, H-2/-9), 1.41 (9H, s, H-3’); δC (101 
MHz, CDCl3): 156.2 (C-1’), 77.9 (C-2’), 70.7 (C-5/-6), 70.6 (C-7), 70.3 (C-4), 70.0 (C-8), 69.6 
(C-3), 39.8 (C-10), 38.5 (C-1), 32.1 (C-9) 29.8 (C-2), 28.6 (C-3’).  
 
4-(Propiolamidomethyl)benzoic acid, (21)119 
 
A solution of propiolic acid (0.49 mL, 7.9 mmol, 1.2 eq), 4-(aminomethyl)benzoic acid 
(1.00 g, 6.62 mmol, 1 eq) and hydroxybenzotriazole (202 mg, 1.32 mmol, 0.2 eq) in 
acetonitrile (40 mL) was cooled to 0°C under N2, to which DCC (1.64 g, 7.94 mmol, 1.2 eq) 
was subsequently added. The reaction was kept at 0°C for one hour and then allowed to 
reach room temperature over one hour. The reaction mixture was filtered through Celite, 
and the solvent was removed under reduced pressure. The resulting oil was taken up in 
EtOAc (50 mL) and washed with H2O (2 x 30 mL). Upon drying over MgSO4 and removal 
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of the solvent, silica gel column chromatography (MeOH:DCM = 10:90) afforded amide 
21 as a colourless crystalline solid (476 mg, 35%). 
 
Rf = 0.5 (MeOH:DCM = 10:90); Mp (MeOH:DCM): 190-193 °C; IR νmax/ cm-1 (ATR): 3268 
(carboxylic O-H), 2110 (alkyne C-H), 1684 (C=O); δH (300 MHz, MeOD): 7.99 (2H, d, J = 
8.1 Hz, H-3), 7.38 (2H, d, J = 8.1 Hz, H-4), 4.46 (2H, s, H-6), 3.60 (1H, s, H-9); δC (101 MHz, 
MeOD): 169.7 (C-1), 154.8 (C-7), 144.5 (C-2), 131.2 (C-5), 131.0 (C-3), 128.5 (C-4), 78.0 
(C-8), 76.2 (C-9), 43.9 (C-6). 
 
tert-Butyl (1-oxo-1-(4-(propiolamidomethyl)phenyl)-6,9,12-trioxa-2-azapentadecan-
15-yl)carbamate, (22) 
 
The acid 21 (250 mg, 1.46 mmol, 1 eq) and HOBt (246 mg, 1.61 mmol, 1.1 eq) were 
suspended in DCM (15 mL) at 0°C under N2. DCC (392 mg, 1.84 mmol, 1.3 eq) and the 
amine 20 (592 mg, 1.85 mmol, 1.3 eq) in DCM (2 mL) were sequentially added, and the 
reaction was left to warm to room temperature. After four hours, the reaction was filtered 
through Celite and the solvent evaporated under reduced pressure. Silica gel column 
chromatography (MeOH:DCM = 10:90) afforded alkyne 22 as a clear-yellow oil. (620 mg, 
84%). 
 
Rf = 0.75 (MeOH:DCM = 10:90); IR νmax/ cm-1 (ATR): 3340 (amide N-H), 2116 (alkyne C-
H), 1696 (C=O); δH (300 MHz, CDCl3): 7.77 (2H, d, J = 8.2 Hz, H-7), 7.32 (2H, d, J = 8.2 Hz, 
H-6), 7.29 (1H, brs, NH), 6.87 (1H, brs, NH), 4.85 (1H, brs, NH), 4.51 (2H, d, J = 6.0 Hz, H-
4), 3.68 – 3.56 (10H, m, H-13/-14/-15/-16/-17), 3.49 – 3.42 (4H, m, H-12/-19), 3.13 (2H, 
q, H-10), 2.82 (1H, s, H-1), 1.93-1.85 (2H, p, H-18), 1.69-1.63 (2H, p, H-11), 1.42 (9H, s, H-
22); δC (101 MHz, CDCl3): 167.0 (C-9), 156.3 (C-20), 152.4 (C-3), 140.7 (Cquat), 134.3 
(Cquat), 127.9 (C-7), 127.6 (C-6), 79.3 (C-21) 77.4 (C-2), 73.9 (C-1), 71.0 (C-17), 70.6 (C-
14/-15), 70.5 (C-13), 70.2 (C-16), 69.5 (C-12),43.5 (C-4), 39.3 (C-19), 38.6 (C-10), 29.8 (C-
18), 28.9 (C-11), 28.6 (C-22); HRMS (ES): m/z 506.2866 (M+H)+, C26H40N3O7 requires 
506.2872. 
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N-(3-(2-(2-(3-aminopropoxy)ethoxy)ethoxy)propyl)-4-
propiolamidomethyl)benzamide, (23) 
 
Carbamate 22 (437 mg, 0.86 mmol, 1 eq) was dissolved in DCM (6.4 mL) at 0°C under N2, 
trifluoroacetic acid (0.66 mL, 8.6 mmol, 10 eq) was added and the mixture was allowed 
to warm to room temperature over three hours. The solvent and remaining acid reactant 
were then removed under reduced pressure. The resulting residue was purified via silica 
gel column chromatography (MeOH:DCM = 10:90) to afford the amine 23 as a clear-
yellow oil (307 mg, 88%).  
 
Rf = 0.65 (MeOH:DCM = 20:80); IR νmax/ cm-1 (ATR): 3244 (N-H), 2106 (alkyne C-H), 1680 
(C=O); δH (300 MHz, d6-DMSO): 9.30 (1H, brs, NH), 8.41 (1H, brs, NH), 7.79 (2H, d, J = 8.2 
Hz, H-7), 7.31 (2H, d, J = 8.2 Hz, H-6), 4.33 (2H, d, J = 6.1 Hz, H-4), 3.54-3.43 (12H, m, H-
12/-13/-14/-15/-16/-17), 3.17 (s, 1H, H-1), 3.30 (2H, q, J = 6.3 Hz, H-10), 2.86  (2H, m, 
H19), 1.82-1.71 (4H, m, H-11/-18); δC (101 MHz, d6-DMSO): 165.9 (C-9), 151.7 (C-3), 
141.5 (Cquat), 133.4 (Cquat), 127.2 (C-7), 127.0 (C-6), 78.1 (C-2), 76.1 (C-1), 69.7 (C-14), 
69.6 (C-15), 69.5 (C-13), 69.4 (C-16), 68.3 (C-17), 67.3 (C-12), 42.0 (C-4), 36.8 (C-19), 36.6 
(C-10), 29.3 (C-18), 27.1 (C-11); HRMS (ES): m/z 406.2342 (M+H)+, C21H32N3O5 requires 
406.2347. 
 
2,5-Dioxopyrrolidin-1-yl 5-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-
yl)pentanoate, (24)120 
 
To a solution of biotin (500 mg, 2.05 mmol, 1eq), DMAP (37.0 mg, 0.31 mmol, 0.15 eq) 
and DCC (550 mg, 2.66 mmol, 1.3 eq) in DMF (10 mL) at 0 °C under N2 was added N-
hydroxysuccinimide (280 mg, 2.46 mmol, 1.2 eq). The reaction was allowed to warm to 
room temperature and stirred for 24 hours. The mixture was filtered through Celite and 
the bulk of the DMF removed by gentle heating in a steaming water bath under reduced 
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pressure on the rotoevaporator. Trituration with diethyl ether afforded a copious 
precipitate, which was filtered and washed with ice-cold diethyl ether (3 x 10 mL) to 
afford succinimide ester 24 (451 mg, 65%). 
 
 
Mp (DMF:Diethyl Ether): 205-208 °C, lit120 Mp: 206-207 °C; IR νmax/ cm-1 (ATR): 3226 (N-
H), 1747, 1728, 1700 (3 x C=O); δH (300 MHz, DMSO): 6.39 (1H, s, NH), 6.34 (1H, s ,NH), 
4.31 (1H, dd, J = 7.6, 5.2 Hz, H-9), 4.15 (1H, m, H-10), 3.11 (1H, m, H-8), 2.83 (1H, dd, J = 
12.4, 5.1 Hz, H-11a), 2.81 (4H, brs, H-1), 2.66 (2H, t, J = 7.3 Hz, H-4), 2.58 (1H, d, J = 12.4 
Hz, H-11b), 1.72-1.36 (6H, m, H-5/-6/-7).  
 
N-(15-Oxo-19-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-4,7,10-
trioxa-14-azanonadecyl)-4-(propiolamidomethyl)benzamide, (25)98 
 
The amine 23 (449 mg, 0.86 mmol, 1.2 eq) and Ester 24 (246 mg, 0.72 mmol, 1 eq) were 
dissolved in DMF (2 mL) under N2 and cooled to -78°C. DIPEA (0.25 mL, 1.4 mmol, 2eq) 
was added and the mixture was left to stir for two hours, while warming to room 
temperature. The bulk of the solvent was then removed under reduced pressure and the 
residue was lyophilised. Silica gel column chromatography (MeOH:DCM = 5:95) afforded 
biotin-alkyne 25 as a clear colourless wax (236 mg, 57%). 
 
Rf = 0.60 (MeOH:DCM = 10:90); IR νmax/ cm-1 (ATR): 3266 (amide N-H), 2106 (alkyne C-
H), 1694 (C=O); δH (400 MHz, MeOD): 7.81 (2H, d, J = 8.4 Hz, H-7), 7.40 (2H, d, J = 8.4 Hz, 
H-6), 4.50 (2H, ddd, J = 7.9, 4.9, 0.6 Hz, H-27), 4.47 (2H, s, H-4), 4.31 (1 H, dd, J = 7.9, 4.5 
Hz, H-26), 3.68-3.62 (8H, m, H-13/-14/-15/-16), 3.57 (2H, t, J = 6.2 Hz, H-10), 3.51 (2H, t, 
H-17), 3.50 (2H, t, H-12), 3.37 (1H, s, H-1) 3.29-3.19 (3H, m, H-19/-25), 2.94 (1H, dd, J = 
12.8, 5.0 Hz, H-28a), 2.72 (1H, d, J = 12.8 Hz, H-28b), 2.21 (2H, t, J = 7.4 Hz, H-21), 1.90 
(2H, p, H-18), 1.76 (2H, p, H-11), 1.70-1.55 (4H, m, H-22/-23), 1.48-1.42 (2H, m, H-24); δC 
(101 MHz, MeOD): 175.9 (C-29), 169.7 (C-20), 166.0 (C-3), 154.7 (C-9), 143.0 (Cquat), 
134.9 (Cquat), 128.7 (C-7), 128.6 (C-6), 78.1 (C-2), 76.2 (C-1),71.5 (C-14 or 15), 71.5 (C-14 
or  15), 71.3 (C-13), 71.2 (C-16), 70.4 (C-12), 70.0 (C-17), 63.4 (C-27), 61.6 (C-26), 57.0 
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(C-25), 43.9 (C-4), 41.0 (C-28), 38.8 (C-19), 37.8 (C-10), 36.9 (C-21), 30.4 (C-11 or 18), 
30.4 (C-11 or 18), 29.8 (C-24), 29.5 (C-23), 26.9 (C-22); HRMS (ES): m/z 632.3143 
(M+H)+, C31H46N5O7S requires 632.3113. 
 
1-(4-(3-((3-((4-Methoxybenzyl)sulfinyl)prop-1-en-1-yl)disulfanyl)propoxy)phenethyl)-
N-(4-((15-oxo-19-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl)-
4,7,10-trioxa-14-azanonadecyl)carbamoyl)benzyl)-1H-1,2,3-triazole-4-carboxamide,  
(26) 
 
The reaction vessel was loaded with CuSO4.5H2O (2.5 mg, 0.01 mmol, 0.1 eq) and sodium 
ascorbate (5.9 mg, 0.03 mmol, 0.3 eq) in H2O (1 mL) under N2. To the rapidly stirring 
solution the azide-ajoene 19 (52 mg, 0.11 mmol, 1 eq) in DMF (1 mL) and biotin-alkyne 
25 (69 mg, 0.11 mmol, 1 eq) in DMF (1 mL) were added. The reaction was heated to 30°C 
and left to stir over-night for 18 hours. The solvents were removed via lyophilisation and 
the off-white solid residue was subjected to silica gel column chromatography 
(MeOH:DCM = 10:90) to afford biotin-ajoene 26 as 7:10 mixture of E/Z-isomers and as a 
white crystalline solid (68 mg, 56%). 
 
E/Z mixture: Rf = 0.7 (MeOH:DCM = 0.2:0.8); IR νmax/ cm-1 (ATR): 3310 (amide N-H), 
1696/1649 (C=O); HRMS (ES): m/z 1109.4332 (M+H)+, C53H73N8O10S4 requires 
1109.4338; 
 
E-isomer: δH (400 MHz, MeOD:CDCl3 = 1:9): 7.91 (1H, s, H-19), 7.66 (2H, d, J = 8.4 Hz, H-
25), 7.30 (2H, d, J = 8.4 Hz, H-24), 7.11 (2H, d, J = 8.7 Hz, H-15), 6.91 (2H, d, J = 8.7 Hz, H-
4), 6.79 (2H, d, J  = 8.7 Hz, H-14), 6.70 (2H, d, J = 8.7 Hz, H-3), 6.29 (1H, dt, J = 14.7, 1.0 Hz, 
H-9), 5.82 (1H, dt, J = 14.8, 7.8 Hz, H-8), 4.53 (2H, s, H-22), 4.50 (2H, t, J = 7.3 Hz, H-18), 
4.37 (1H, ddd, J = 7.8, 5.0, 0.9 Hz, H-45), 4.17 (1H, dd, J = 7.8, 4.6 Hz, H-44), 3.93 (2H, m, 
H-12), 3.85 (2H, d, J = 4.1 Hz, H-6), 3.69 (3H, s, H-1), 3.56 – 3.35 (14H, m, H-7/-30/-31/-
32/-33/-34/-35), 3.27-3.22 (2H, m, H-28), 3.15 (2H, t, J = 6.6 Hz, H-37), 3.08-3.01 (3H, m, 
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H-17/-43),  2.84-2.76 (2H, m, H-10/-46a), 2.60 (1H, d, J = 12.8 Hz, H-46b), 2.09 – 2.00 (4H, 
m, H-11/-39), 1.78 (2H, p, H-29), 1.62 (2H, p, H-36), 1.57 – 1.43 (4H, m, H-40/42), 1.29 
(2H, p, H-41); δC (101 MHz, MeOD:CDCl3 = 1:9): 173.8 (Cquat), 167.7 (Cquat), 164.0 (Cquat), 
160.5 (Cquat), 159.9 (Cquat), 159.6 (Cquat), 157.9 (Cquat), 142.5 (Cquat), 141.5 (Cquat), 134.7 (C-
9), 133.6 (Cquat), 131.2 (C-15), 129.6 (C-4), 128.7 (Cquat), 127.6 (C-25), 127.4 (C-24), 126.1 
(C-19), 116.7 (C-8), 114.9 (C-3), 114.5 (C-14), 70.4 (C-32), 70.3 (C-33), 70.1 (C-28), 69.9 
(C-31), 69.9 (C-34), 69.4 (C-37), 65.8 (C-12), 61.9 (C-45), 60.1 (C-44), 56.1 (C-6), 55.5 (C-
43), 55.2 (C-1), 52.7 (C-7), 52.1 (C-18), 42.6 (C-22), 40.3 (C-46), 38.1 (C-30), 37.2 (C-35), 
35.8 (C-39), 35.5 (C-17), 34.6 (C-10), 28.9 (C-36), 28.9 (C-29), 28.7 (C-11), 28.4(C-41), 
28.1 (C-42), 25.4 (C-40). 
 
Z-isomer: δH (400 MHz, MeOD:CDCl3 = 1:9): 7.91 (1H, s, H-19), 7.66 (2H, d, J = 8.4 Hz, H-
25), 7.30 (2H, d, J = 8.4 Hz, H-24), 7.11 (2H, d, J = 8.7 Hz, H-15), 6.91 (2H, d, J = 8.7 Hz, H-
4), 6.79 (2H, d, J  = 8.7 Hz, H-14), 6.70 (2H, d, J = 8.7 Hz, H-3), 6.51 (1H, dt, J = 9.5, 0.9 Hz, 
H-9), 5.66 (1H, dt, J = 14.8, 7.8 Hz, H-8), 4.53 (2H, s, H-22), 4.50 (2H, t, J = 7.3 Hz, H-18), 
4.37 (1H, ddd, J = 7.8, 5.0, 0.9 Hz, H-45), 4.17 (1H, dd, J = 7.8, 4.6 Hz, H-44), 3.92 (2H, m, 
H-12), 3.85 (2H, d, J = 4.1 Hz, H-6), 3.69 (3H, s, H-1), 3.56 – 3.35 (14H, m, H-7/-30/-31/-
32/-33/-34/-35), 3.27-3.22 (2H, m, H-28), 3.15 (2H, t, J = 6.6 Hz, H-37), 3.08-3.01 (3H, m, 
H-17/-43), 2.84-2.76 (2H, m, H-10/-46a), 2.60 (1H, d, J = 12.8 Hz, H-46b), 2.09 – 2.00 (4H, 
m, H-11/-39), 1.78 (2H, p, H-29), 1.62 (2H, p, H-36), 1.57 – 1.43 (4H, m, H-40/42), 1.29 
(2H, p, H-41); δC (101 MHz, MeOD:CDCl3 = 1:9): 173.8 (Cquat), 167.7 (Cquat), 164.0 (Cquat), 
160.5 (Cquat), 159.9 (Cquat), 159.6 (Cquat), 157.9 (Cquat), 142.5 (Cquat), 141.5(Cquat), 138.6 (C-
9), 133.6 (Cquat), 131.3 (C-15), 129.6 (C-4), 128.7 (Cquat), 127.6 (C-25), 127.4 (C-24), 126.1 
(C-19), 118.2 (C-8), 114.9 (C-3), 114.5 (C-14), 70.4 (C-32), 70.3 (C-33), 70.1 (C-28), 69.9 
(C-31), 69.9 (C-34), 69.4 (C-37), 65.7 (C-12), 61.9 (C-45), 60.1 (C-44), 56.6 (C-6), 55.5 (C-
43), 55.2 (C-1), 52.1 (C-18), 49.4 (C-7), 42.6 (C-22), 40.3 (C-46), 38.1 (C-30), 37.2 (C-35), 
35.8 (C-39), 35.5 (C-17), 35.5 (C-10), 28.9 (C-36), 28.9 (C-29), 28.6 (C-11), 28.4(C-41), 
28.1 (C-42), 25.4 (C-40). 
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6.2 Biological method 
6.2.1 General 
The oesophageal cancer cell-line WHCO1 was derived from biopsy of primary 
oesophageal squamous cell carcinoma of South African origin.127 Cells were all incubated 
at 37 °C under 5% CO2 and cultured with antibiotics in DMEM (Dulbecco’s Modified Eagle 
Medium) containing 10% heat-inactivated FBS (Fetal Bovine Serum, Gibco, Life 
Technologies, South Africa). The cells were cultured in 100 mm petri dishes and allowed 
to reach 80-95% confluence prior to being split. The splitting procedure that was done 
under a sterile hood and involved removal of the growth media and a quick wash to 
remove excess media with phosphate buffer (PBS) (3-4 mL) at pH 7.4, followed directly 
by incubating the cells in 0.05% trypsin-EDTA (2 mL) for three minutes at 37 °C. The 
trypsin was used to detach the cells from the surface of the dish, and it was then 
deactivated with the growth media (3 mL). The cells were then pelleted by centrifugation 
for four minutes at 40000 rpm using a Hettich EBA 20 centrifuge. The pellet was then 
resuspended into growth media (1 mL) and using 10% of the cells to propagate further. 
 
6.2.2 Cell proliferation analysis 
The anti-proliferative effects of the analogues on tumour cells was measured by the 3-
(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, Sigma Aldrich, South 
Africa) cellular viability assay Each experiment was performed in quadruplet in a  96-
well-plate (Costar, Corning Inc., USA). The cells were plated in 90 µL of growth media at 
a cell density of 2500 WHCO1 cells per well. After plating, the cells were allowed to settle 
in an incubator overnight.  
 
On day two, a stock dilution series ranging from 200 – 0 mM of drug was prepared in 
DMSO. Each solution was further diluted 100 fold into media, after which 10 µL was 
added to the cells to give a final drug concentration of 200 – 0 M of the original solutions 
and 0.1% DMSO. The cells were then incubated with the drugs at 37°C, 5% CO2 for 24 
hours. 
 
On day three, 10 µL of the MTT reagent (5 mg/mL) was added to each well and the cells 
were incubated for a further four hours; followed by the addition of 100 µL 10% SLS in 
0.01 M HCl (Merck, Darmstadt Germany) to solubilise the formazan crystals. 
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On day five, the plates were read at 595 nm on a Multiscan FC plate reader (Thermo 
Fischer Scientific, Life Technologies, South Africa) and the background absorbance of the 
media, drugs and MTT (without cells) was also recorded at 595 nm. The background 
absorbance (with media only) was then subtracted from each reading and the data was 
analysed using Graphpad Prism 6, using a non-linear regression analysis fitted to 
sigmoidal dose-response curve with A595nm-baseline versus Log C to obtain the IC50 at 
95% confidence interval. 
 
6.2.3 Blood stability 
Blood was collected from 10 mice in K2EDTA coated tubes. A concentration of 0.4 mg/mL 
compound was added to the whole blood and incubated at 37 °C. At the indicated time 
points, aliquots of 10 µL were removed and extracted on ice into 100 µL CH3CN by vortex, 
sonication and then centrifugation. The CH3CN phase was then removed and diluted into 
mobile phase (1:1) and analysed by LC-MS/MS on an API 2000 MS/MS (AB Sciex) using 
Luna PFP 5 µm, 50 x 2.0 mm (Phenomenex) column. Mobile phase: CH3CN and 10 mM 
ammonium acetate using a gradient from 60% CH3CN to 100% CH3CN in six minutes, then 
100% CH3CN for one minute followed by a three minute equilibration time at 60% CH3CN 
with a flow rate of 300 µL/minute with a total run time of ten minutes. Peak areas were 
quantitated relative to a calibration curve. 
 
6.2.4 UV-Vis spectroscopy 
Stock solutions of 200 mM Z-ajoene were prepared in DMSO. Fresh blood was collected 
from one Balb/C mouse and placed on ice in a heparin coated tube. A 10 µL aliquot of the 
blood was diluted into 2 mL of PBS buffer, pH 7.4 in a 2 mL quartz cuvette. The 
background spectrum was recorded from 700-230 nm in a Shimadzu UV1800 UV–visible 
spectrophotometer against a blank containing PBS alone. To both test sample and the 
blank was added increasing concentrations (0 – 200 µM) of Z-ajoene to reach a maximum 
concentration of 0.1% DMSO. 
 
6.2.5 Proteomics  
A stock solutions of 500 µM human Hb (Sigma) was were prepared in 0.02 M HEPES 
buffer (pH 7.4). After 25-fold dilution to 20 µM, to one Hb aliquot Z-ajoene in DMSO (10 
mM) was added to give a final concentration of 100 µM. The other (untreated) sample 
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was prepared by adding the same volume of only vehicle (DMSO). The samples were 
incubated for two hours and stored overnight at 3 °C before being delivered to the CPGR. 
 
Approximately 6g of Hb protein was aliquoted into a 1.5 mL centrifuge tube to a final 
volume of 20 L. Trypsin (Promega) was resuspended in Millipore Water and added to 
each sample to give a final trypsin:protein ratio of 1:20. The volume was then corrected 
to 50 L with 50 mM triethylammonium bicarbonate (Sigma). Samples were digested for 
18 hours at 37 °C. Peptide samples were dried by vacuum centrifugation and 
resuspended in 0.1% formic acid (Sigma), 2.5% acetonitrile (Anatech) to a final 
concentration of 500 ng/L. Samples were then stored at -80°C and analysed using LCMS.  
 
Nano-RPLC chromatography was performed on a Dionex Ultimate 3000 nano-HPLC 
system. LC−MS/MS analysis was conducted with a Q-Exactive quadrupole-Orbitrap mass 
spectrometer (Thermo Fisher Scientific, USA) coupled with a Dionex Ultimate 3000 nano-
HPLC system. The mobile phases consisted of solvent A (0.1% formic acid in water) and 
solvent B (100% CH3CN, and 0.1% formic acid). The HPLC fractionated peptides were 
dissolved in sample loading buffer (2.5% CH3CN, 0.1% formic acid, water) and loaded on 
a C18 trap column (100 µm×20 mm×5 µm). Chromatographic separation was performed 
with a C18 column (75 µm×250 mm×3.6 µm). The mass spectrometer was operated in 
positive ion mode with a capillary temperature of 250 °C. The applied electrospray 
voltage was 1.95 kV. 
 
6.2.6 Immunoblotting 
The gels were prepared using standard protocols: The separating gel was made using 
acrylamide concentration of 10%, with the pH of 8.8 in Tris buffer. The Stacking gel was 
made using 3% acrylamide in Tris buffer, pH of 6.8. The 10 M Hb stock solution was 
made in PBS. A 10 mM stock solution of ajoene in DMSO:PEG400:PBS (10:50:40) was 
made. The individual samples were prepared, as follows:  
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Untreated Whole probe Whole probe + DTT in situ “Click” 
10 µM Hb  10 µM Hb 10 µM Hb 10 µM Hb  
+1% vehicle +100µM biotin-ajoene  
+1% vehicle 
+100 µM biotin-ajoene  
+1% vehicle  
+100 µM azide-ajoene  
+1% vehicle 
Incubate: 30 minutes at 37 °C 
  +100 mM DTT +100 µM biotin-alkyne 
+1 mM aq. sodium ascorbate  
+1 mM aq. CuSO4 
Incubate: 60 minutes at 37 °C 
 
Protein in 3 µL sample buffer (0.25M Tris (pH 6.8), 4% SDS, 20% glycerol, Bromophenol 
Blue) was loaded onto the stacking gel to obtain a final protein mass of 0.5 µg or 1.0 µg in 
each lane, respectively. The gel tank (Bio-Rad Mini-Protean 3 Cell Assembly) was filled 
with running buffer (3% Tris, 14% Glycine, 1% SDS) and the gels were run at 100 V while 
the protein moved through the stacking gel. Once the dye front reached the running gel, 
the voltage was increased to 200 V for the remainder of the experiment. The protein was 
then transferred to a nitrocellulose membrane, followed by blocking overnight at 4 °C 
with 5% non-fat milk in PBS containing Tween-20; followed by an overnight incubation 
with the anti-biotin primary antibody (1:10000) (Santa Cruz, Whitehead Scientific) at 4 
°C. The specific biotinylated protein was detected using a horseradish peroxidase-
conjugated secondary anti-body (1:5000) and the LumiGLO chemiluminescent reagent 
(KPL, Bicom Biotech, South Africa). A protein ladder (Thermo Fischer Scientific, Life 
Technologies) was used to estimate the molecular weight of proteins. 
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